Engineered Polypeptides
Engineered TfR constructs address the BBB's barrier to therapeutic delivery by binding to BBB receptors, enhancing brain uptake of therapeutic agents up to 20-fold, overcoming the limitations of the BBB for targeted brain therapy.
Patent Information
- Application Number
- JP2019545353
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-11-08
- Filing Date
- 2018-02-15
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2038-02-15
AI Technical Summary
The blood-brain barrier (BBB) restricts the delivery of therapeutic macromolecules to the brain, limiting their therapeutic potential due to the lack of effective receptors for targeted delivery across this barrier.
Development of recombinant transferrin receptor (TfR) constructs, comprising a monomeric TfR apical domain without the protease-like or helical domain, which are engineered to retain the native TfR's three-dimensional structure and include specific epitopes, allowing them to bind to BBB receptors for targeted delivery of therapeutic agents.
The engineered TfR constructs enhance the delivery of therapeutic agents across the BBB, increasing their uptake into the brain by up to 20-fold compared to agents without the polypeptide, facilitating effective treatment of brain disorders.
Smart Images

Figure 0007577447000089 
Figure 0007577447000090 
Figure 0007577447000091
Abstract
Description
[Background technology]
[0001] background The blood-brain barrier (BBB) blocks the passage of most macromolecules from the periphery into the brain, thereby limiting the therapeutic use of these macromolecules. Receptors expressed on the endothelium, including the endothelium of the blood-brain barrier, can mediate the delivery of ligands that bind to the receptors across the blood-brain barrier. Summary of the Invention
[0002] overview In one aspect, the present disclosure provides an isolated recombinant transferrin receptor (TfR) construct comprising a monomeric TfR apical domain, the construct not comprising a protease-like domain or a helical domain of TfR. In one embodiment, the construct presents a conserved epitope or antigen and / or retains the approximate three-dimensional structure of the apical domain of native human TfR or has a root mean square deviation (RMSD) of less than about 2. In one embodiment, the three-dimensional structure is determined by X-ray crystallography. In one embodiment, the construct comprises a human TfR apical domain. In one embodiment, the RMSD between the TfR apical domain construct described herein and the apical domain of native full-length TfR is less than about 4, less than about 3, or less than about 2, and is between the range of about 1 to about 2. In one embodiment, the RMSD between any one of the TfR apical domain constructs having the sequence of any one of SEQ ID NOs:109, 110, 301, 468, and 469 (e.g., 109, 110, and 301) and the apical domain of a native full-length TfR is about 1.2.
[0003] In another aspect, the disclosure features a TfR construct comprising: (a) a first polypeptide comprising a sequence of a first portion of a TfR apical domain; (b) an optional linker; and (c) a second polypeptide comprising a sequence of a second portion of a TfR apical domain, wherein the sequence of the first portion of the TfR apical domain is C-terminal to the sequence of the second portion of the TfR apical domain relative to the full-length TfR sequence, and wherein the first polypeptide, the optional linker, and the second polypeptide are fused in tandem.
[0004] In some embodiments, the last amino acid of the second portion is fused to the first amino acid of the first portion. In some embodiments, the first amino acid of the second polypeptide is fused to the last amino acid of the first polypeptide. In some embodiments, the first polypeptide comprises a C-terminal fragment of a full-length TfR apical domain and the second polypeptide comprises an N-terminal fragment of a full-length TfR apical domain.
[0005] In some embodiments, the first portion of the TfR apical domain comprises 25-55 amino acids (e.g., 30-55, 35-55, 40-55, 45-55, 50-55, 25-50, 25-45, 25-40, 25-35, or 25-30 amino acids). In some embodiments, the second portion of the TfR apical domain comprises 75-120 amino acids (e.g., 80-120, 85-120, 90-120, 95-120, 100-120, 105-110, 115-120, 75-115, 75-110, 75-105, 75-100, 75-95, 75-90, 75-85, or 75-80 amino acids).
[0006] In some embodiments, the first polypeptide comprises: In some embodiments, the first polypeptide comprises a sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) to the sequence of SEQ ID NO:427. In some embodiments, the first polypeptide comprises a sequence having up to seven amino acid changes (e.g., one, two, three, four, five, six, or seven amino acid insertions, deletions, and / or substitutions) to the sequence of SEQ ID NO:427. In some embodiments, the second polypeptide comprises a sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) to the sequence of SEQ ID NO:427. In some embodiments, the second polypeptide comprises a sequence having at least seven amino acid changes (e.g., one, two, three, four, five, six, or seven amino acid insertions, deletions, and / or substitutions) to the sequence of SEQ ID NO:427. In some embodiments, the first polypeptide comprises a sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) to the sequence of SEQ ID NO:428. In some embodiments, the first polypeptide comprises a sequence having up to 16 amino acid changes (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 amino acid insertions, deletions, and / or substitutions) to the sequence of SEQ ID NO:428.
[0007] In some embodiments, the TfR apical domain comprises the sequence of SEQ ID NO:107 or 108.
[0008] In some embodiments, the TfR construct binds to an arenavirus (eg, Machupo virus).
[0009] In some embodiments, the TfR construct comprises: (a) a first polypeptide comprising a sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) to the sequence of SEQ ID NO:427; (b) an optional linker; and (c) a second polypeptide comprising a sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) to the sequence of SEQ ID NO:428.
[0010] In some embodiments, the TfR construct comprises: (a) a first polypeptide comprising a sequence having up to 7 amino acid changes (e.g., 1, 2, 3, 4, 5, 6, or 7 amino acid insertions, deletions, and / or substitutions) relative to the sequence of SEQ ID NO:427; (b) an optional linker; and (c) a second polypeptide comprising a sequence having up to 16 amino acid changes (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 amino acid insertions, deletions, and / or substitutions) relative to the sequence of SEQ ID NO:428.
[0011] In some embodiments, the first polypeptide comprises at the C-terminus the sequence In some embodiments, the second polypeptide further comprises a sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) or up to 5 amino acid changes (e.g., insertion, deletion and / or substitution of 1, 2, 3, 4, or 5 amino acids) to TIFF0007577447000003.tif4128, or a fragment thereof. In some embodiments, the first polypeptide further comprises a sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) or up to 5 amino acid changes (e.g., insertion, deletion and / or substitution of 1, 2, 3, 4, or 5 amino acids) to TIFF0007577447000004.tif5128, or a fragment thereof. In some embodiments, the second polypeptide further comprises a sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) or up to 5 amino acid changes (e.g., 1, 2, 3, 4, or 5 amino acid insertions, deletions, and / or substitutions) to TIFF0007577447000005.tif5128, or a fragment thereof. Further included are sequences having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) or up to 5 amino acid changes (e.g., insertion, deletion and / or substitution of 1, 2, 3, 4, or 5 amino acids) to TIFF0007577447000006.tif4128, or a fragment thereof.
[0012] In certain embodiments, the first polypeptide has the sequence In certain embodiments, the second polypeptide comprises a sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) or up to 10 amino acid changes (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid insertions, deletions, and / or substitutions) to TIFF0007577447000007.tif12150. TIFF0007577447000008.tif12159.
[0013] In some embodiments, the first polypeptide is fused directly in tandem with the second polypeptide. In certain embodiments, the TfR construct comprises a first polypeptide having the sequence of SEQ ID NO:449 and a second polypeptide having the sequence of SEQ ID NO:450, wherein the C-terminus of the first polypeptide is fused to the N-terminus of the second polypeptide. In certain embodiments, the TfR construct comprises A first polypeptide having a sequence of TIFF0007577447000009.tif12150; and a second polypeptide having a sequence of TIFF0007577447000010.tif12159, wherein the C-terminus of the first polypeptide is fused to the N-terminus of the second polypeptide.
[0014] In some embodiments, the linker comprises or consists of 1 to 10 amino acids (e.g., 1 to 8, 1 to 6, 1 to 4, or 1 or 2 amino acids, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids). In certain embodiments, the linker is G, GG, GGG, or GGGG (SEQ ID NO:453). In certain embodiments, the linker comprises a protein loop domain. In certain embodiments, the distance between the N-terminus and C-terminus of the protein loop domain is less than 5 Å.
[0015] In some embodiments, the TfR construct further comprises a purification peptide. For example, the purification peptide can be fused to the N-terminus or C-terminus of the TfR construct.
[0016] In some embodiments, the TfR construct further comprises a truncation peptide, for example, the truncation peptide can be fused to the N-terminus or C-terminus of the TfR construct.
[0017] In another aspect, the disclosure features an isolated polynucleotide comprising a nucleotide sequence encoding a TfR construct described herein. In another aspect, the disclosure also features a vector comprising the polynucleotide described above. In a further aspect, the disclosure also features a host cell comprising the polynucleotide described above or the vector described above.
[0018] In another aspect, the disclosure features a method for identifying an agent that binds to the apical domain of TfR, the method including (a) contacting a TfR construct described herein with the agent, and (b) determining whether the agent binds to the TfR construct.
[0019] In some embodiments, the agent is a polypeptide or protein. In some embodiments, the agent is a modified Fc polypeptide or a modified Fc polypeptide dimer. In yet other embodiments, the agent is an antibody.
[0020] In some embodiments, said determining step (b) is performed by ELISA or surface plasmon resonance.
[0021] In yet another aspect, the disclosure features a method of making a recombinant TfR apical domain construct, the method including expressing a gene including a first polynucleotide and a second polynucleotide fused in tandem, where the first polynucleotide encodes a C-terminal fragment of the full-length TfR apical domain and the second polynucleotide encodes an N-terminal fragment of the full-length TfR apical domain.
[0022] In some embodiments, the first and second polynucleotides are fused in tandem such that, upon expression, the first amino acid of the N-terminal fragment of the domain is linked in primary sequence to the last amino acid of the C-terminal fragment of the domain.
[0023] In some embodiments, the gene further comprises an optional linker polynucleotide encoding an optional protein linker, which, when expressed, is linked in primary sequence to the first amino acid of the N-terminal fragment of the domain with the last amino acid of the linker, and the first amino acid of the linker is linked in primary sequence to the last amino acid of the C-terminal fragment of the domain.
[0024] In some embodiments, the gene encodes a first polynucleotide, an optional linker polynucleotide, and a second polynucleotide in tandem such that, upon expression, the expressed protein is in the form of a circular structure, hi some embodiments, the method further comprises purifying the expressed protein to obtain an isolated recombinant TfR apical domain construct.
[0025] One embodiment of the present disclosure also includes an isolated recombinant human TfR apical domain construct produced according to the above method.
[0026] Another embodiment includes an isolated recombinant TfR apical domain construct comprising the amino acid sequence of any one of SEQ ID NOs: 109, 110, 301, 468, and 469 (e.g., 109, 110, and 301).
[0027] Another embodiment includes an isolated recombinant TfR apical domain construct comprising an amino acid sequence having at least about 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) to any one of SEQ ID NOs: 109, 110, 301, 468, and 469 (e.g., 109, 110, and 301).
[0028] In another aspect, provided herein is a polypeptide capable of being actively transported across the blood-brain barrier (BBB), comprising: (a) a modified Fc polypeptide, or a fragment thereof; (b) a first site within the modified Fc polypeptide or fragment that specifically binds to a BBB receptor; and (c) a second site that binds to a neonatal Fc receptor (FcRN). In some embodiments, the second site is a native FcRn binding site. In some embodiments, the FcRn binding site is within the modified Fc polypeptide. In some embodiments, the FcRn binding site comprises amino acid changes relative to the native Fc sequence that increase serum half-life. In certain embodiments, the amino acid changes comprise substitutions of Tyr at position 25, Thr at position 27, and Glu at position 29, with each residue position determined relative to SEQ ID NO:1. Alternatively, in other embodiments, the amino acid changes comprise substitutions of Leu at position 201, and Ser at position 207, with each residue position determined relative to SEQ ID NO:1. Alternatively, in a further embodiment, the amino acid change comprises a substitution of Ser or Ala at position 207, where each residue position is determined with reference to SEQ ID NO:1.
[0029] In some embodiments, the modified Fc polypeptide or fragment thereof comprises at least 50 amino acids (e.g., at least 60, 75, 90, or 95 amino acids) corresponding to the amino acid sequence of a native Fc polypeptide (e.g., at least 50 contiguous amino acids). In certain embodiments, the modified Fc polypeptide or fragment comprises at least 100 amino acids (e.g., at least 125, 140, 150, 160, 175, or 180 amino acids) corresponding to the amino acid sequence of a native Fc polypeptide.
[0030] In some embodiments, the first site in the modified Fc polypeptide or fragment has at least one modified amino acid in a beta sheet of the Fc polypeptide. In certain embodiments, the beta sheet is in the CH2 domain. In certain embodiments, the beta sheet is in the CH3 domain. In some embodiments, the first site comprises a substitution of at least one solvent-exposed amino acid. In some embodiments, the first site comprises a substitution of at least two solvent-exposed amino acids, and two solvent-exposed residues in a loop region or beta sheet are not in the same loop region or beta sheet.
[0031] In some embodiments, the modified Fc polypeptide or fragment sequence comprises a modified CH2 domain sequence, which may be derived from a CH2 domain sequence of human IgG1, IgG2, IgG3, or IgG4. In some embodiments, the modification of the CH2 domain comprises substitution of at least two amino acids within a set of amino acids selected from the group consisting of: (a) residues 47, 49, 56, 58, 59, 60, 61, 62, and 63, (b) residues 39, 40, 41, 42, 43, 44, 68, 70, 71, and 72, (c) residues 41, 42, 43, 44, 45, 65, 66, 67, 69, and 73, and (d) residues 45, 47, 49, 95, 97, 99, 102, 103, and 104, wherein each residue position is determined with reference to SEQ ID NO:1.
[0032] In some embodiments, the modified Fc polypeptide or fragment sequence comprises a modified CH3 domain sequence, which may be derived from a CH3 domain sequence of human IgG1, IgG2, IgG3, or IgG4. In some embodiments, the modification to the CH3 domain comprises substitution of at least two amino acids within the set of amino acids selected from the group consisting of: (a) residues 157, 159, 160, 161, 162, 163, 186, 189, and 194, and (b) residues 118, 119, 120, 122, 210, 211, 212, and 213, wherein each residue position is determined with reference to SEQ ID NO:1.
[0033] In some embodiments, the modified Fc polypeptide or fragment has at least 75% amino acid sequence identity compared to the corresponding wild-type Fc polypeptide or fragment, hi further embodiments, the identity is at least 80%, 90%, 92%, or 95%.
[0034] The modified Fc polypeptide or fragment may have effector function, or in alternative embodiments, no effector function. In certain embodiments, the modified Fc polypeptide or fragment comprises a modification that reduces effector function. In some embodiments, the modification that reduces effector function comprises a substitution of Leu at position 7 and Leu at position 8, the position of each residue being determined relative to SEQ ID NO:1. In some embodiments, the modification that reduces effector function further comprises a substitution of Pro at position 102, the position of the residue being determined relative to SEQ ID NO:1.
[0035] In a further aspect, provided herein is a dimeric protein comprising the polypeptide or fragment described in the above paragraph. In some embodiments, the dimeric protein is a heterodimer comprising a first and a second polypeptide chain, the first polypeptide chain comprising a first site that specifically binds to a BBB receptor. In certain embodiments, the second polypeptide chain does not comprise a site that specifically binds to a BBB receptor. In some embodiments, the dimeric protein is a homodimer comprising a first and a second polypeptide chain, the first and the second polypeptide chain each comprising a site that specifically binds to a BBB receptor.
[0036] In some embodiments, the BBB receptor is selected from the group consisting of transferrin receptor (TfR), insulin receptor, insulin-like growth factor receptor (IGF-R), low density lipoprotein receptor (LDLR), low density lipoprotein receptor-related protein 1 (LRP1), low density lipoprotein receptor-related protein 2 (LRP2), low density lipoprotein receptor-related protein 8 (LRP8), GLUT1, basigin, diphtheria toxin receptor, membrane-bound precursor of heparin-binding epidermal growth factor-like growth factor (HB-EGF), melanotransferrin, and vasopressin receptor. In certain embodiments, the BBB receptor is TfR. In still other embodiments, the BBB receptor is IGF-R.
[0037] In some embodiments, the polypeptide specifically binds to a BBB receptor without competing for binding with the receptor's endogenous ligand, hi certain embodiments, the BBB receptor is a transferrin receptor and the endogenous ligand is transferrin.
[0038] In some embodiments, the polypeptide described in the above paragraph further comprises a polypeptide having biological activity. In certain embodiments, the polypeptide having biological activity is a polypeptide having therapeutic activity. In some embodiments, the uptake of the polypeptide having biological activity into the brain is at least 10 times greater than the uptake of the polypeptide having biological activity in the absence of the modified Fc polypeptide or fragment. In some embodiments, the uptake of the polypeptide having biological activity into the brain is at least about 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, or more than the uptake of the polypeptide having biological activity in the absence of the modified Fc polypeptide or fragment.
[0039] In a further aspect, provided herein is a protein capable of being actively transported across the BBB, comprising: (a) an antibody variable region sequence, or an antigen-binding fragment thereof, capable of binding to an antigen; and (b) a polypeptide, or a fragment thereof, comprising a modified Fc polypeptide, wherein the modified Fc polypeptide or fragment has a first binding site that specifically binds to a BBB receptor and a second binding site that binds to a neonatal Fc receptor (FcRn). In some embodiments, the antibody variable region sequence comprises a Fab domain. In some embodiments, the Fab domain binds to a tau protein (e.g., a human tau protein) or a fragment thereof. The tau protein may be a phosphorylated tau protein, a non-phosphorylated tau protein, a splice isoform of a tau protein, an N-terminally truncated tau protein, a C-terminally truncated tau protein, and / or a fragment thereof. In some embodiments, the Fab domain binds to a beta-secretase 1 (BACE1) protein (e.g., a human BACE1 protein) or a fragment thereof. The BACE1 protein may be a splice isoform of a BACE1 protein or a fragment thereof. In some embodiments, the Fab domain binds to a triggering receptor expressed on myeloid cells 2 (TREM2) protein (e.g., human TREM2 protein) or a fragment thereof. In other embodiments, the Fab domain binds to an α-synuclein protein (e.g., human α-synuclein protein) or a fragment thereof. The α-synuclein protein can be monomeric α-synuclein, oligomeric α-synuclein, α-synuclein fibrils, soluble α-synuclein, and / or fragments thereof. In some embodiments, the antibody variable region sequence comprises two antibody variable region heavy chains and two antibody variable region light chains, or their respective fragments.
[0040] In some embodiments, the variable region can bind to a tau protein (e.g., human tau protein) or a fragment thereof. In some embodiments, the variable region can bind to a phosphorylated tau protein, a non-phosphorylated tau protein, a splice isoform of a tau protein, an N-terminally truncated tau protein, and / or a C-terminally truncated tau protein, or a fragment thereof. In some embodiments, the variable region can bind to a beta-secretase 1 (BACE1) protein (e.g., human BACE1 protein) or a fragment thereof. In some embodiments, the variable region can bind to one or more splice isoforms of a BACE1 protein or a fragment thereof. In some embodiments, the variable region can bind to a triggering receptor expressed on human myeloid cells 2 (TREM2) protein, or a fragment thereof. In some embodiments, the variable region can bind to a human alpha-synuclein protein, or a fragment thereof. In some embodiments, the variable region is capable of binding to monomeric human alpha-synuclein, oligomeric human alpha-synuclein, human alpha-synuclein fibrils, and / or soluble human alpha-synuclein, or fragments thereof.
[0041] In some embodiments, the protein comprises one modified Fc polypeptide or fragment that binds to a BBB receptor, hi other embodiments, the protein comprises two modified Fc polypeptides or fragments that bind to a BBB receptor.
[0042] In some embodiments, uptake of the protein into the brain is at least 10-fold greater compared to (a) the same protein in the absence of a polypeptide comprising a modified Fc polypeptide or fragment, or (b) the same protein in the presence of a polypeptide comprising an Fc polypeptide or an Fc polypeptide fragment that does not have a modification that results in binding to a BBB receptor.
[0043] In a further aspect, provided herein is a conjugate comprising (a) a polypeptide as described in the paragraph above, and (b) a therapeutic or diagnostic agent, the conjugate capable of being transported across the blood-brain barrier, in some embodiments, brain uptake of the therapeutic or diagnostic agent is increased by at least 10-fold, 20-fold, 30-fold, 40-fold, or 50-fold relative to uptake of the therapeutic or diagnostic agent in the absence of the polypeptide. [The present invention 1001] 1. An isolated recombinant transferrin receptor (TfR) construct comprising a monomeric TfR apical domain, said TfR construct not comprising a protease-like domain or a helical domain of said TfR. [The present invention 1002] A TfR construct of the present invention 1001 that displays a conserved epitope or antigen and / or retains the approximate three-dimensional structure of the apical domain of native human TfR or has a root mean square deviation (RMSD) of less than about 2. [The present invention 1003] The TfR construct of claim 1001 or 1002, wherein the three-dimensional structure is determined by X-ray crystallography. [The present invention 1004] (a) a first polypeptide comprising the sequence of a first portion of a TfR apical domain; (b) an optional linker; and (c) a second polypeptide comprising the sequence of a second portion of the TfR apical domain; Including, the sequence of the first portion of the TfR apical domain is C-terminal to the sequence of the second portion of the TfR apical domain relative to a full-length TfR sequence; the first polypeptide, the optional linker, and the second polypeptide are fused in tandem; TfR constructs. [The present invention 1005] 1004. The TfR construct of the present invention, wherein the last amino acid of said second portion is fused to the first amino acid of said first portion. [The present invention 1006] The TfR construct of claim 1004 or 1005, wherein the first polypeptide comprises a C-terminal fragment of a full-length TfR apical domain and the second polypeptide comprises an N-terminal fragment of the full-length TfR apical domain. [The present invention 1007] The first polypeptide comprises: TIFF0007577447000011.tif5128 The TfR construct of any of claims 1004 to 1006, comprising a sequence having at least 90% sequence identity to the sequence of [The present invention 1008] The TfR construct of any of claims 1004 to 1006, wherein the first polypeptide comprises a sequence having up to 7 amino acid changes relative to the sequence of SEQ ID NO:427. [The present invention 1009] The second polypeptide comprises: TIFF0007577447000012.tif12159 The TfR construct of any of claims 1004 to 1008, comprising a sequence having at least 90% sequence identity to the sequence of [The present invention 1010] The TfR construct of any of claims 1004 to 1008, wherein the second polypeptide comprises a sequence having up to 16 amino acid changes relative to the sequence of SEQ ID NO:428. [The present invention 1011] The TfR construct of any one of claims 1001 to 1010, wherein the TfR apical domain comprises the sequence of SEQ ID NO: 107 or 108. [The present invention 1012] A TfR construct according to any one of claims 1001 to 1011, which binds to an arenavirus. [The present invention 1013] (a) a first polypeptide comprising a sequence having at least 90% sequence identity to the sequence of SEQ ID NO:427; (b) the optional linker; and (c) a second polypeptide comprising a sequence having at least 90% sequence identity to the sequence of SEQ ID NO:428; and The TfR construct of any one of claims 1004 to 1012, [The present invention 1014] (a) the first polypeptide comprising a sequence having up to seven amino acid changes relative to the sequence of SEQ ID NO:427; (b) the optional linker; and (c) said second polypeptide comprising a sequence having up to 16 amino acid changes relative to the sequence of SEQ ID NO:428; The TfR construct of any one of claims 1004 to 1012, [The present invention 1015] the first polypeptide having at its C-terminus the sequence TIFF0007577447000013.tif5128 The TfR construct of any of claims 1004 to 1014, further comprising a sequence having at least 90% sequence identity or up to 5 amino acid changes to said TfR construct, or a fragment thereof. [The present invention 1016] the second polypeptide having at its C-terminus the sequence TIFF0007577447000014.tif5128 The TfR construct of any of claims 1004 to 1015, further comprising a sequence having at least 90% sequence identity or up to 5 amino acid changes to said TfR construct, or a fragment thereof. [The present invention 1017] the first polypeptide having at its N-terminus the sequence TIFF0007577447000015.tif5128 The TfR construct of any of claims 1004 to 1016, further comprising a sequence having at least 90% sequence identity or up to 5 amino acid changes to said TfR construct, or a fragment thereof. [The present invention 1018] the second polypeptide having at its N-terminus the sequence TIFF0007577447000016.tif5128 The TfR construct of any of claims 1004 to 1017, further comprising a sequence having at least 90% sequence identity or up to 5 amino acid changes to said TfR construct, or a fragment thereof. [The present invention 1019] the first polypeptide having the sequence TIFF0007577447000017.tif12150 The TfR construct of any of claims 1004 to 1018, comprising a sequence having at least 90% sequence identity or up to 10 amino acid changes to said TfR construct. [The present invention 1020] said second polypeptide having the sequence TIFF0007577447000018.tif12159 The TfR construct of any of claims 1004 to 1019, comprising a sequence having at least 90% sequence identity or up to 20 amino acid changes to said TfR construct. [The present invention 1021] The TfR construct of any of claims 1004 to 1020, wherein the first polypeptide is directly fused in tandem with the second polypeptide. [The present invention 1022] A TfR construct according to any one of claims 1004 to 1021, comprising a first polypeptide having the sequence of SEQ ID NO:449 and a second polypeptide having the sequence of SEQ ID NO:450, wherein the C-terminus of the first polypeptide is fused to the N-terminus of the second polypeptide. [The present invention 1023] TIFF0007577447000019.tif12150 and the first polypeptide having a sequence of TIFF0007577447000020.tif12159 and the second polypeptide having the sequence The TfR construct of any of claims 1004 to 1021, wherein the C-terminus of the first polypeptide is fused to the N-terminus of the second polypeptide. [The present invention 1024] The TfR construct of any one of claims 1004 to 1020, 1022, and 1023, wherein the linker is 1 to 10 amino acids in length. [The present invention 1025] The TfR construct of the present invention, wherein the linker is G, GG, GGG, or GGGG (SEQ ID NO:453). [The present invention 1026] The TfR construct of any one of claims 1004 to 1020, 1022, and 1023, wherein the linker comprises a protein loop domain. [The present invention 1027] 1026. The TfR construct of the present invention, wherein the distance between the N-terminus and C-terminus of the loop domain of the protein is less than 5 Å. [The present invention 1028] The TfR construct of any one of claims 1001 to 1027, further comprising a purified peptide. [The present invention 1029] The TfR construct of the present invention, wherein the purified peptide is fused to the N-terminus or C-terminus of the TfR construct. [The present invention 1030] The TfR construct of any one of claims 1001 to 1029, further comprising a truncation peptide. [The present invention 1031] The TfR construct of the present invention 1030, wherein the truncated peptide is fused to the N-terminus or C-terminus of the TfR construct. [The present invention 1032] An isolated polynucleotide comprising a nucleotide sequence encoding any one of the TfR constructs of the present inventions 1001 to 1031. [The present invention 1033] A vector comprising a polynucleotide of the present invention. [The present invention 1034] A host cell comprising a polynucleotide of the invention 1032 or a vector of the invention 1033. [The present invention 1035] 1. A method for identifying a substance that binds to the apical domain of TfR, comprising: (a) contacting any one of the TfR constructs according to claims 1001 to 1031 with the substance; (b) determining whether the agent binds to the TfR construct; The method comprising: [The present invention 1036] The method of claim 1035, wherein the substance is a polypeptide or a protein. [The present invention 1037] The method of any one of claims 1035 to 1036, wherein said agent is a modified Fc polypeptide or a modified Fc polypeptide dimer. [The present invention 1038] 1037. The method of claim 1035 or 1036, wherein said substance is an antibody. [The present invention 1039] The method according to any one of claims 1035 to 1038, wherein said determining step (b) is carried out by ELISA or surface plasmon resonance. [The present invention 1040] A method for producing a recombinant TfR apical domain construct, comprising expressing a gene comprising a first polynucleotide and a second polynucleotide fused in tandem, wherein the first polynucleotide encodes a C-terminal fragment of a full-length TfR apical domain and the second polynucleotide encodes an N-terminal fragment of the full-length TfR apical domain. [The present invention 1041] The method of claim 1040, wherein the first polynucleotide and the second polynucleotide are fused in tandem such that, upon expression, the first amino acid of the N-terminal fragment of the domain is linked in primary sequence to the last amino acid of the C-terminal fragment of the domain. [The present invention 1042] The method of claim 1040 or 1041, wherein the gene further comprises an optional linker polynucleotide encoding an optional protein linker, which, when expressed, is linked in primary sequence to the first amino acid of the N-terminal fragment of the domain with the last amino acid of the linker, and to the last amino acid of the C-terminal fragment of the domain with the first amino acid of the linker. [The present invention 1043] 3. The method of any of claims 1040 to 1042, wherein said gene encodes said first polynucleotide, said optional linker polynucleotide, and said second polynucleotide in tandem such that, upon expression, the expressed protein is in the form of a circular structure. [The present invention 1044] The method of any of claims 1040 to 1043, further comprising purifying the expressed protein to obtain the isolated recombinant TfR apical domain construct. [The present invention 1045] An isolated recombinant human TfR apical domain construct produced according to any one of the methods of the present inventions 1040 to 1044. [The present invention 1046] An isolated recombinant TfR apical domain construct comprising any one of the amino acid sequences of SEQ ID NOs:109, 110, and 301. [The present invention 1047] An isolated recombinant TfR apical domain construct comprising an amino acid sequence having at least about 90% identity to any one of SEQ ID NOs:109, 110, and 301. [Brief description of the drawings]
[0044] [Figure 1] Figures 1A-1D show the results of phage ELISA of four CH2A2 clones. CH2A2 Fc variants were expressed on the surface of phage and tested for binding to anti-c-Myc antibody 9E10 (expression control), negative control, human transferrin receptor (TfR), and cynomolgus monkey (cyno) TfR coated on plates. The x-axis shows the OD268 of the phage solution, which is a measure of phage concentration. (Figure 1A) shows the results of ELISA for clone CH2A2.5. (Figure 1B) shows the results of ELISA for clone CH2A2.1. (Figure 1C) shows the results of ELISA for clone CH2A2.4. (Figure 1D) shows the results of ELISA for clone CH2A2.16. [Diagram 2]Figures 2A and 2B show the results of a phage ELISA of the CH2A2 clone binding to human TfR. Phages were added to ELISA plates coated with TfR at approximately the binding EC50, and soluble holo-Tf or soluble TfR was added at different concentrations. The data show that the CH2A2 clone competed with soluble TfR, but not with holo-Tf, for binding to the TfR coated on the plate. (Figure 2A) Results of the experiment with soluble holo-Tf added. (Figure 2B) Results of the experiment with soluble TfR added. [Diagram 3] Figures 3A-3D show binding of CH2C clones to TfR in the presence or absence of holo-Tf. (Figure 3A) shows the results of a phage ELISA in which TfR was coated onto an ELISA plate and phage-displayed clone CH2C.23 was added in the presence or absence of a large excess of holo-Tf (5 μM). (Figure 3B) shows binding of CH2C clones in Fc-Fab fusion format to ELISA plates coated with human or cynomolgus TfR. (Figure 3C) shows the results of a phage ELISA in which human TfR, cynomolgus TfR, holo-Tf, anti-Myc, or streptavidin were coated onto an ELISA plate and phage-displayed clones CH2C.17 and CH2C.22 were added at different dilutions in the presence or absence of holo-Tf. These data show that these clones did not compete with holo-Tf for binding to TfR. (Figure 3D) Octet® (i.e., Biolayer Interferometry) kinetic trace of the binding of clone CH2C.7 to TfR-biotin coated onto an anti-streptavidin sensor in the presence of 5 μM holo-Tf, with background subtracted for binding of holo-Tf alone, showing no competition for binding with Tf. [Figure 4]Figures 4A and 4B show binding of CH3B clones to TfR in the presence or absence of holo-Tf. (Figure 4A) Shows the results of a phage ELISA in which human TfR, cynomolgus TfR, holo-Tf, anti-Myc, or streptavidin were coated onto ELISA plates and phage-displayed clones CH3B.11 and CH3B.12 were added at different dilutions in the presence or absence of holo-Tf. These data show that these clones did not compete with holo-Tf for binding to TfR. (Figure 4B) Shows binding of CH3B clones to ELISA plates coated with human or cynomolgus TfR. Fc regions containing CH3B clone sequences were fused to Fab fragments and assayed in a dimer format. [Diagram 5] NNK patch library for maturation of CH3B clones. Ribbons show the skeleton of the CH3 domain, the dark surface represents the original CH3B register, and the light surface patches represent the expanded repertoire. [Figure 6] Figure 1 shows FACS plots of CH3C clone selection in yeast showing enrichment of binding populations after three sorting rounds. In sorting rounds 1 and 2, biotinylated TfR was preloaded with streptavidin-Alexa Fluor® 647 before incubation with yeast. In sorting round 3, biotinylated TfR was first incubated with yeast and streptavidin-Alexa Fluor® 647 was added for secondary detection. In all sorting rounds, expression was monitored using a chicken anti-c-Myc antibody (obtained from Thermo Fisher) against the C-terminal Myc tag on the yeast display construct. [Figure 7]Figures 7A-7C show binding of CH3C clones to TfR in the presence or absence of holo-Tf. Clones were assayed in Fc-Fab fusion format. Ab204, a standard antibody with a variable region that binds to TfR, was used as a positive control for this assay. (Figure 7A) Binding of CH3C mutants to human TfR coated on ELISA plates. (Figure 7B) Binding of CH3C mutants to human TfR coated on ELISA plates in the presence of 5 μM holo-Tf. (Figure 7C) Binding of CH3C mutants to cynomolgus monkey TfR coated on ELISA plates. [Figure 8] Binding of CH3C clones to 293F cells that endogenously express human TfR is shown. Cells were distributed into 96-well V-bottom plates and different concentrations of CH3C clones formatted as Fc-Fab fusion binding proteins were added. After 1 hour incubation at 4° C., each plate was centrifuged, washed, and then incubated with goat anti-human IgG-Alexa Fluor® 647 secondary antibody for 30 minutes at 4° C. After further washing of the cells, each plate was read on a FACSCanto™ II flow cytometer and the median fluorescence in the APC (647 nm) channel was determined using FlowJo® software. [Figure 9] Figures 9A and 9B show the internalization of CH3C.3 into HEK293 cells that endogenously express the human TfR. After addition of 1 μM of CH3C.3 or control for 30 minutes at 37°C and 8% CO2, cells were washed, permeabilized, and stained with anti-human IgG-Alexa Fluor® 488 secondary antibody. After further washing, cells were imaged by fluorescence microscopy and the number of puncta was quantified. (Figure 9A) Microscopy data is shown. (Figure 9B) A graph of the number of puncta per well is shown. [Figure 10]Selection scheme of CH3C soft library is shown. Initial libraries were sorted by MACS against human (H) or cynomolgus (C) TfR. The resulting yeast pool was then split and each was sorted against human or cynomolgus TfR as in the first FAS sorting round. Each resulting pool was split again for another sorting round. Finally, HHH and CCC pools were kept separate and other pools in which both target species were found were finally pooled. [Figure 11] Figures 11A and 11B show binding of CH3C clones identified from the initial soft randomized library to human and cynomolgus monkey TfR. Positive controls were high affinity anti-TfR antibody Ab204 and low affinity anti-TfR antibody Ab084. (Figure 11A) Binding to human TfR. (Figure 11B) Binding to cynomolgus monkey TfR. [Figure 12] Figures 12A and 12B show binding of CH3C clones identified from the initial soft randomized library to human TfR in the presence or absence of holo-Tf. Clones were in Fc-Fab fusion format. A high affinity anti-TfR antibody, Ab204, was used as a positive control for this assay. (Figure 12A) Binding of CH3C mutants to human TfR coated onto ELISA plates. (Figure 12B) Binding of CH3C mutants to human TfR coated onto ELISA plates in the presence of 5 μM holo-Tf. [Figure 13] Figure 1 shows the binding of CH3C clones identified from the initial soft randomized library to 293F cells. Cells were distributed into 96-well V-bottom plates and different concentrations of CH3C clones formatted as Fc-Fab fusion proteins were added. After 1 hour incubation at 4°C, each plate was centrifuged, washed, and then incubated with goat anti-human IgG-Alexa Fluor® 647 secondary antibody for 30 minutes at 4°C. After further washing of the cells, each plate was read on a FACSCanto™ II flow cytometer and the median fluorescence in the APC (647 nm) channel was determined using FlowJo® software. [Figure 14] Figures 14A-14C show the binding of CH3C clones identified from the initial soft randomized library to CHO-K1 cells. Cells were distributed into 96-well V-bottom plates and different concentrations of CH3C clones formatted as Fc-Fab fusions were added. After 1 hour of incubation at 4°C, each plate was centrifuged, washed, and then incubated with goat anti-human IgG-Alexa Fluor® 647 secondary antibody at 4°C for 30 minutes. After further washing of the cells, each plate was read on a FACSCanto™ II flow cytometer and the median fluorescence of the APC (647 nm) channel was determined using FlowJo® software. (Figure 14A) CHO-K1 cells overexpressing human TfR. (Figure 14B) CHO-K1 cells overexpressing cynomolgus TfR. (Figure 14C) CHO-K1 parental cells not expressing human TfR. [Figure 15] Figures 15A and 15B show the apical domain of the TfR. (Figure 15A) The location of the apical domain of the human TfR protein is shown. The inset shows a close-up of the seven residues that differ between the human TfR and the cynomolgus TfR. (Figure 15B) A sequence alignment including the seven residues that differ between the human TfR (SEQ ID NO:107) and the cynomolgus TfR (SEQ ID NO:108). The consensus sequence is SEQ ID NO:422. [Figure 16]Figures 16A-16E show binding of CH3C clones to apical domains displayed on phage. (Figure 16A) Myc expression of different TfR apical domain mutants, showing that expression levels of each mutant were similar and normalized. (Figure 16B) Binding of CH3C.18 to wild-type and mutant human TfR apical domains, showing low binding to the R208G mutant. (Figure 16C) Binding of CH3C.35 to wild-type and mutant human TfR apical domains, showing low binding to the R208G mutant. (Figure 16D) Binding of CH3C.18 to wild-type human and cynomolgus TfR apical domains, and the G208R mutant cynomolgus apical domain, showing restoration of binding to the mutants. (FIG. 16E) Binding of CH3C.35 to wild-type human and cynomolgus TfR apical domains, and the G208R mutant cynomolgus apical domain, demonstrating restoration of binding to the mutants. [Figure 17] Figures 17A-17D show paratope mapping of CH3C mutants by reverting the mutated positions back to wild type residues. (Figure 17A) Paratope mapping of CH3C.35 by ELISA binding to human TfR for revertants. (Figure 17B) Paratope mapping of CH3C.35 by ELISA binding to cynomolgus TfR for revertants. (Figure 17C) Paratope mapping of CH3C.18 by ELISA binding to human TfR for revertants. (Figure 17D) Paratope mapping of CH3C.18 by ELISA binding to cynomolgus TfR for revertants. [Figure 18] Figures 18A-18D show the design of consensus mutation libraries for CH3C. (Figure 18A) shows a consensus library based on a CH3C.35-like sequence. (Figure 18B) shows a consensus library based on a CH3C.18-like sequence. (Figure 18C) shows a gap library based on CH3C.18 and CH3C.35. (Figure 18D) shows an aromatic library based on CH3C.18. [Figure 19]Figures 19A-19E show binding ELISA of CH3C variants from the consensus mutation library to human or cynomolgus TfR. The new variants (i.e., CH3C.3.2-1, CH3C.3.2-5, and CH3C.3.2-19) had similar binding EC50 values to cynomolgus and human TfR, whereas the parent clones CH3C.18 and CH3C.35 had significantly higher EC50 values to human TfR versus cynomolgus TfR. (Figure 19A) Data for CH3C.3.2-1 are shown. (Figure 19B) Data for CH3C.3.2-19 are shown. (Figure 19C) Data for CH3C.3.2-5 are shown. (Figure 19D) Data for CH3C.18 are shown. (Figure 19E) Data for CH3C.35 are shown. [Figure 20] Figure 1 shows internalization of CH3C variants from the consensus maturation library in human (HEK293) and monkey (LLC-MK2) cells. Clones CH3C.3.2-5 and CH3C3.2-19, which have similar affinity for human and cynomolgus TfR, showed significantly higher uptake into monkey cells compared to clone CH3C.35, which bound better to human TfR. Anti-BACE1 antibody, Ab107, was used as a negative control. (BACE1 is not expressed in either HEK293 or MK2 cells). Anti-TfR antibody, Ab204, was used as a positive control. [Figure 21] A map of the NNK walk residues shown on the CH3 structure is shown (source PDB 4W4O). The black surface shows the original CH3C register, the grey surface shows the 44 residues incorporated into the NNK walk structure, and the ribbon shows the wild-type backbone. [Figure 22] Enriched yeast populations after three rounds of sorting of the NNK-walk library are shown. Yeast were stained with anti-c-Myc and monitored for expression (x-axis) and binding (y-axis) to the TfR apical domain (200 nM cynomolgus monkey or 200 nM human). The data shown here clearly demonstrate high binding to both orthologues of the TfR apical domain. [Figure 23]Figures 23A and 23B show FACS data for CH3C.35.21 mutants. Yeast were stained with anti-c-Myc and monitored for expression (x-axis) and binding (y-axis) to the human TfR apical domain (200 nM). Figure 23A shows FACS data for clone CH3C.35.21. Figure 23B shows FACS data for mutants in which 11 positions of clone CH3C.35.21 were either reverted to wild type (top row of FACS plots) or expressed as a NNK library of all 20 amino acids (bottom row of FACS plots, prior to sorting). [Figure 24] Figures 24A-24D show a comparison of bivalent and monovalent CH3C polypeptides binding to human and cynomolgus monkey TfR by ELISA. (Figure 24A) A bivalent CH3C polypeptide binding to human TfR. (Figure 24B) A bivalent CH3C polypeptide binding to cynomolgus monkey TfR. (Figure 24C) A monovalent CH3C polypeptide binding to human TfR. (Figure 24D) A monovalent CH3C polypeptide binding to cynomolgus monkey TfR. [Diagram 25] Figures 25A-25E show cell binding of monovalent CH3C polypeptides. (Figure 25A) 293 cells are shown. (Figure 25B) A close-up of binding to 293 cells shown in Figure 25A is shown. (Figure 25C) CHO-K1 cells stably transfected with human TfR is shown. (Figure 25D) A close-up of binding to CHO-K1 cells stably transfected with human TfR is shown in Figure 25C is shown. (Figure 25E) CHO-K1 cells stably transfected with cynomolgus monkey TfR is shown. [Figure 26] 1 shows internalization of monovalent and divalent CH3C polypeptides in HEK293 cells. [Figure 27]Figures 27A-27H show binding kinetics of CH3C polypeptides. (Figure 27A) Data for binding of CH3C.35.N163 to human TfR is shown. (Figure 27B) Data for binding of CHC3.35 to human TfR is shown. (Figure 27C) Data for monovalent binding of CHC3.35.N163 to human TfR is shown. (Figure 27D) Data for monovalent binding of CHC3.35 to human TfR is shown. (Figure 27E) Data for binding of CH3C.35.N163 to cynomolgus TfR is shown. (Figure 27F) Data for monovalent binding of CHC3.35 to cynomolgus TfR is shown. (Figure 27G) Data for monovalent binding of CHC3.35.N163 to cynomolgus TfR is shown. (Figure 27H) Data for monovalent binding of CHC3.35 to cynomolgus TfR is shown. [Figure 28] Figures 28A-28F show the binding kinetics of CH3C polypeptides. (Figure 28A) Data for CH3C.3.2-1 binding to human TfR is shown. (Figure 28B) Data for CH3C.3.2-5 binding to human TfR is shown. (Figure 28C) Data for CH3C.3.2-19 binding to human TfR is shown. (Figure 28D) Data for CH3C.3.2-1 binding to cynomolgus TfR is shown. (Figure 28E) Data for CH3C.3.2-5 binding to cynomolgus TfR is shown. (Figure 28F) Data for CH3C.3.2-19 binding to cynomolgus TfR is shown. [Figure 29] Figures 29A-29E show binding of polypeptide-Fab fusions to FcRn at pH 5.5 in the presence (lower trace) or absence (upper trace) of the human TfR extracellular domain. Figure 29A shows data for clone CH3C.35. Figure 29B shows data for clone CH3C.35.19. Figure 29C shows data for clone CH3C.35.20. Figure 29D shows data for clone CH3C.35.21. Figure 29E shows data for clone CH3C.35.24. [Diagram 30]Pharmacokinetic (PK) analysis of CH3C polypeptides in wild-type mice. All polypeptide-Fab fusions showed comparable clearance to wild-type Fc-Fab fusions (i.e., anti-RSV antibody Ab122 and anti-BACE1 antibody Ab153) except for CH3C.3.2-5, which showed faster clearance. [Diagram 31] Brain pharmacokinetic / pharmacodynamic (PK / PD) data are shown for mouse brain tissue. Chimeric huTfR heterozygous mice (n=4 / group) were administered either Ab153 or monovalent CH3C.35.N163 (denoted as "CH3C.35.N163_monovalent") at 42 mg / kg intravenously, and wild-type mice (n=3) were administered 50 mg / kg intravenously with control human IgG1 (denoted as "huIgG1"). Bar graphs represent the mean ± SD. [Diagram 32] Figures 32A and 32B show the concentration of IgG found in hTfR apical + / + mice 24 hours after treatment with 50 mg / kg of polypeptide. (Figure 32A) The concentration of IgG in plasma is shown. (Figure 32B) The concentration of IgG in brain tissue is shown. [Diagram 33] Figures 33A and 33B show target binding of polypeptides administered to hTfR apical + / + mice after 24 hours, as measured by reduction in amyloid beta protein 50 (Aβ40). (Figure 33A) Aβ40 concentration in plasma. (Figure 33B) Aβ40 concentration in brain tissue. [Diagram 34] Shown is an SDS-PAGE gel of size fractionation of the complex of CH3C.3.18Fc and the TfR apical domain (AD). Lane 1: molecular weight marker, lane 2: reduced CH3C.18Fc-AD complex after size exclusion chromatography. [Diagram 35] Figures 35A and 35B show the binding of a polypeptide of the invention to the transferrin receptor. Figure 35A shows the binding interface between clone CH3C.18 and the apical domain of the transferrin receptor. Figure 35B shows an enlarged view of the binding surface shown in Figure 35A. [Diagram 36]Figures 36A and 36B show the interaction of CH3C.18 with the TfR apical domain. (Figure 36A) The structural architecture of the TfR apical domain and CH3C.18Fc (top) and the binding surface (within 5 Å) of the TfR apical domain and CH3C.18Fc (bottom) are shown. The co-complex structure was resolved at 3.6 Å resolution. In this structure, the epitope of the TfR apical domain bound to CH3C.18 can be seen. In particular, the N-terminal region of the apical domain is involved in CH3C Fc binding, and the structure is consistent with the mutagenesis data of CH3C.18Fc and the TfR apical domain. Also, all side chains of the CH3C.18 library are in contact with TfR (within 5 Å). CH3C.18 library residues: L157, H159, V160, W161, A162, V163, P186, T189, and W194. Non-library residues: F196 and S156. (FIG. 36B) The main interactions of CH3C.18Fc with the TfR apical domain are shown. The cation-π interaction between W161 on CH3C.18Fc and R208 on the apical domain is the central binding interaction. Mutation of W388 of CH3C.18 or R208 in the apical domain prevents binding of CH3C.18Fc with the apical domain. Consistent with this, the F208G mutation from human to cynomolgus monkeys explains the low affinity of cynomolgus monkeys. Furthermore, there are nearby residues that are not conserved in the human apical domain (N292 and E294 (K292 and D294 in cynomolgus monkeys)), so mutating Q192 in CH3C.18Fc can selectively enhance cynomolgus monkey binding relative to human binding. [Figure 37] Figures 37A and 37B show binding of a polypeptide of the invention to the transferrin receptor. Figure 37A shows hydrogen bond and non-bond contacts between residues of clone CH3C.18 (A strand) and residues of the apical domain of the transferrin receptor (D strand). Figure 37B shows binding of a polypeptide of the invention to the transferrin receptor. Shows hydrogen bond and non-bond contacts between residues of clone CH3C.18 (B strand) and residues of the apical domain of the transferrin receptor (C strand). [Figure 38]1 shows an alignment of the amino acid sequences of human IgG1, IgG2, IgG3, and IgG4 (SEQ ID NOs: 423-426). [Figure 39] Figures 39A-39C show binding of the polypeptides of the invention to the transferrin receptor. (Figure 39A) Structural architecture of the TfR apical domain and CH3C.35Fc (top) and the binding surface (within 5 Å) of the TfR apical domain and CH3C.35Fc (bottom). The co-complex structure was resolved at 3.4 Å resolution. In this structure, the epitope of the TfR apical domain bound to CH3C.35 can be seen. All side chains of the CH3C.35 library are in contact with TfR (within 5 Å). CH3C.35 library residues: Y157, T159, E160, W161, S162, T186, E189, and W194. Non-library residues: F196, S156, Q192. (FIGS. 39B and 39C) Zoomed-in views of the binding interaction between clone CH3C.35 shown in FIG. 39A and the apical domain of the transferrin receptor. [Diagram 40] Figure 40A shows a superposition structure of a complex of CH3C.35Fc and TfR-AD and a complex of CH3C.18Fc and TfR-AD, and Figure 40B shows an enlarged view of the superposition structure of Figure 40A. [Figure 41A] 1 shows the binding of a polypeptide of the invention to the transferrin receptor, with hydrogen bond and non-bond contacts between residues of clone CH3C.35 (A chain) and residues of the apical domain of the transferrin receptor (D chain). [Figure 41B] 1 shows the binding of a polypeptide of the invention to the transferrin receptor, with hydrogen bond and non-bond contacts between residues of clone CH3C.35 (B strand) and residues of the apical domain of the transferrin receptor (C strand). [Diagram 42]Figures 42A and 42B show plasma PK and Aβ40 reduction of Fc-Fab fusion polypeptides comprising CH3C variants fused to the Fab domain of Ab153 in cynomolgus monkeys. (Figure 42A) Ab210 and CH3C.35.9:Ab153 showed faster clearance by TfR-mediated clearance compared to control IgG (Ab122) and Ab153. (Figure 42B) Ab153, Ab210, and CH3C.35.9:Ab153, which all bind and inhibit BACE1, showed significant Aβ40 reduction in plasma. [Diagram 43] Figures 43A and 43B show significant reduction of cerebrospinal fluid (CSF) Aβ and sAPPβ / sAPPα by Fc-Fab fusion polypeptides comprising CH3C variants fused to the Fab domain of Ab153 in cynomolgus monkeys. (Figure 43A) Shows that animals treated with Ab210 and CH3C.35.9:Ab153 showed a 70% reduction in Aβ40 in CSF compared to Ab153 and control IgG (Ab122). (Figure 43B) Shows that animals treated with Ab210 and CH3C.35.9:Ab153 showed a 75% reduction in sAPPβ / sAPPα ratio compared to Ab153 and control IgG (Ab122). n=4 / group. Line graphs represent mean±SEM. [Diagram 44]Figures 44A and 44B show huIgG1 concentrations in plasma (Figure 44A) and brain lysates (Figure 44B) of hTfR apical + / + knock-in (KI) mice after a single 50 mg / kg systemic injection of anti-BACE1_Ab153, CH3C35.21:Ab153, CH3C35.20:Ab153, or CH3C35:Ab153 polypeptide fusions (mean ± SEM, n = 5 / group). Figure 44C shows the concentration of endogenous mouse Aβ in brain lysates of hTfR apical + / + KI mice after a single 50 mg / kg systemic injection of anti-BACE1_Ab153, CH3C35.21:Ab153, CH3C35.20:Ab153, or CH3C35:Ab153 polypeptide fusions (mean ± SEM, n = 5 / group). FIG. 44D shows quantification by Western blot of brain TfR protein normalized to actin in brain lysates of hTfR apical+ / +KI mice following a single 50 mg / kg systemic injection of anti-BACE1_Ab153, CH3C35.21:Ab153, CH3C35.20:Ab153, or CH3C35:Ab153 polypeptide fusions (mean±SEM, n=5 / group). [Diagram 45] Figures 45A and 45B show huIgG1 concentrations in plasma (Figure 45A) and brain lysates (Figure 45B) of hTfR apical + / + KI mice after a single 50 mg / kg systemic injection of anti-BACE1_Ab153, CH3C.35.23:Ab153, or CH3C.35.23.3:Ab153 polypeptide fusions (mean ± SEM, n = 5 / group). Figure 45C shows concentrations of endogenous mouse Aβ in brain lysates of hTfR apical + / + KI mice after a single 50 mg / kg systemic injection of anti-BACE1_Ab153, CH3C.35.23:Ab153, or CH3C.35.23.3:Ab153 polypeptide fusions (mean ± SEM, n = 5 / group). Figure 45D shows quantification by Western blot of brain TfR protein normalized to actin in brain lysates of hTfR apical + / + KI mice following a single 50 mg / kg systemic injection of anti-BACE1_Ab153, CH3C.35.23:Ab153, or CH3C.35.23.3:Ab153 polypeptide fusions (mean ± SEM, n = 4 / group). [Figure 46] Figures 46A-46D show a 28-day PKPD study in cynomolgus monkeys following administration of a single 30 mg / kg dose of the indicated proteins. Figures 46A and 46B show serum huIgG1 and plasma Aβ concentrations in plasma, illustrating the peripheral exposure of administered compounds over time and the resulting effect on plasma Aβ concentrations. Figures 46C and 46D show Aβ and sAPPβ / sAPPα in the CSF of cynomolgus monkeys following administration (mean ± SEM, n=4-5 / group). [Figure 47] Figures 47A-47C show blood reticulocytes (Figure 47A), absolute serum iron concentrations (Figure 47B), and absolute red blood cell counts (Figure 47C) relative to pre-dose concentrations in peripheral blood in cynomolgus monkeys following administration of a single 30 mg / kg dose of each of the indicated proteins (mean ± SEM, n=4-5 / group). [Figure 48] Figures 48A and 48B show peripheral PK analysis (plasma huIgG1 concentrations (Figure 48A) and clearance values (Figure 48B)) of each indicated protein in hFcRn knock-in mice after a single 10 mg / kg intravenous injection over 14 days (mean ± SEM, n=3 / group). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0045] Detailed Description I. Introduction The present invention discloses polypeptides that can be actively transported across the blood-brain barrier (BBB). In one aspect, the present invention is based in part on the discovery that Fc polypeptides capable of binding to blood-brain barrier receptors can be generated by modifying a specific set of amino acids in the Fc region. The Fc polypeptides disclosed herein further bind to the neonatal Fc receptor (FcRn). These polypeptides can be used to transport therapeutic agents (e.g., therapeutic polypeptides, antibody variable regions, and small molecules) to treat disorders and diseases where delivery to the brain is beneficial. Also described herein are transferrin receptor (TfR) constructs that include one or more portions of a monomeric TfR apical domain or a TfR apical domain circularly permuted relative to the full-length TfR sequence. The TfR constructs can be composed of two different portions of the TfR apical domain fused to each other in tandem with an optional linker. The TfR constructs described herein can bind to arenaviruses (e.g., Machupo virus).
[0046] In some embodiments, substitutions in the CH3 or CH2 domain polypeptides can be made to generate polypeptides that bind to BBB receptors, such as the transferrin receptor. Thus, in one aspect, there is provided herein a BBB-binding polypeptide having multiple substitutions in the following amino acid sets: (i) 157, 159, 160, 161, 162, 163, 186, 189, and 194, or (ii) 118, 119, 120, 122, 210, 211, 212, and 213, numbered relative to SEQ ID NO:1. In some embodiments, the BBB-binding polypeptides of the invention have multiple substitutions at amino acid sets (iii) 47, 49, 56, 58, 59, 60, 61, 62, and 63, (iv) 39, 40, 41, 42, 43, 44, 68, 70, 71, and 72, (v) 41, 42, 43, 44, 45, 65, 66, 67, 69, and 73, or (vi) 45, 47, 49, 95, 97, 99, 102, 103, and 104, numbered with reference to SEQ ID NO:1. Anything from four to all of the amino acid positions of a set can be substituted. For the purposes of this disclosure, substitutions are determined with reference to SEQ ID NO:1. Thus, an amino acid is considered a substitution if it differs from the amino acid at the corresponding position in SEQ ID NO:1, even if that amino acid occurs at that position in a naturally occurring Fc polypeptide.
[0047] Also provided herein are methods of producing BBB receptor binding polypeptides by generating mutant polypeptides having substitutions at multiple positions of set (i), (ii), (iii), (iv), (v), or (vi). Such mutants can be analyzed for BBB receptor binding as described herein and further mutated to enhance binding.
[0048] In further aspects, provided herein are therapeutic methods and methods of using BBB receptor binding polypeptides that target compositions to BBB receptor expressing cells (e.g., deliver the composition to the cells or deliver the composition across an endothelium such as the blood-brain barrier).
[0049] II. Definition As used herein, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to a "polypeptide" may include two or more such molecules.
[0050] As used herein, the terms "about" and "approximately," when used to modify a quantity specified in a numerical value or range, indicate that the numerical value and reasonable deviations from that value known to those of ordinary skill in the art, such as, for example, ±20%, ±10%, or ±5%, are within the expected meaning of the stated value.
[0051] "Transferrin receptor" or "TfR" as used in the context of the present invention refers to transferrin receptor protein 1. The polypeptide sequence of human transferrin receptor 1 is set forth in SEQ ID NO:235. Transferrin receptor protein 1 sequences from other species are also known (e.g., chimpanzee (Accession No. XP_003310238.1), rhesus monkey (NP_001244232.1), dog (NP_001003111.1), cow (NP_001193506.1), mouse (NP_035768.1), rat (NP_073203.1), and chicken (NP_990587.1)). The term "transferrin receptor" also encompasses allelic variants of an exemplary reference sequence (e.g., a human sequence) encoded by a gene at the chromosomal locus of transferrin receptor protein 1. The full-length transferrin receptor protein contains a short N-terminal intracellular region, a transmembrane region, and a large extracellular domain. The extracellular domain is characterized by three domains: a protease-like domain, a helical domain, and an apical domain. The apical domain sequence of human transferrin receptor 1 is set forth in SEQ ID NO:107.
[0052] The term "Fc polypeptide" as used herein refers to the C-terminal region of a naturally occurring immunoglobulin heavy chain polypeptide characterized by an Ig fold as a structural domain. An Fc polypeptide comprises a constant region sequence comprising at least a CH2 domain and / or a CH3 domain, and may comprise at least a portion of a hinge region. Generally, an Fc polypeptide comprises a constant region sequence comprising at least a CH2 domain and / or a CH3 domain, and may comprise at least a portion of a hinge region, but does not comprise a variable region.
[0053] "Modified Fc polypeptide" refers to an Fc polypeptide that has at least one mutation, e.g., a substitution, deletion, or insertion, compared to a wild-type immunoglobulin heavy chain Fc polypeptide sequence, but retains the overall Ig fold or structure of a native Fc polypeptide.
[0054] The term "FcRn" refers to the neonatal Fc receptor. Binding of an Fc polypeptide to FcRn decreases the clearance of the Fc polypeptide and increases its serum half-life. The human FcRn protein is a heterodimer consisting of a protein with a size of about 50 kDa that resembles major histocompatibility complex (MHC) class I proteins and β2-microglobulin with a size of about 15 kDa.
[0055] As used herein, "FcRn binding site" refers to a region of an Fc polypeptide that binds to FcRn. In human IgG, the FcRn binding site includes L251, M252, I253, S254, R255, T256, M428, H433, N434, H435, and Y436, when numbered using the EU numbering scheme. These positions correspond to positions 24-29, 201, and 206-209 of SEQ ID NO:1.
[0056] As used herein, a "native FcRn-binding site" refers to a region of an Fc polypeptide that binds to FcRn and has the same amino acid sequence as a region of a naturally occurring Fc polypeptide that binds to FcRn.
[0057] The terms "CH3 domain" and "CH2 domain" as used herein refer to immunoglobulin constant region domain polypeptides. In the context of an IgG antibody, a CH3 domain polypeptide refers to a segment of amino acids from about 341 to about 447 when numbered according to the EU numbering scheme, and a CH2 domain polypeptide refers to a segment of amino acids from about 231 to about 340 when numbered according to the EU numbering scheme. CH2 and CH3 domain polypeptides may also be numbered according to the IMGT (ImMunoGeneTics) numbering scheme, where the CH2 domain is numbered from 1 to 110 and the CH3 domain is numbered from 1 to 107 according to IMGT Scientific chart numbering (IMGT website). The CH2 and CH3 domains are part of the Fc region of an immunoglobulin. In the context of an IgG antibody, an Fc region refers to a segment of amino acids from about 231 to about 447 when numbered according to the EU numbering scheme. As used herein, the term "Fc region" may also include at least a portion of an antibody hinge region. An exemplary hinge region sequence is set forth in SEQ ID NO:234.
[0058] The term "variable region" refers to the domain within an antibody heavy or light chain that is derived from germline variable (V), diversity (D), or joining (J) genes (and not from constant (Cμ and Cδ) gene segments) and confers to the antibody its specificity for binding to antigen. Antibody variable regions generally consist of four conserved "framework" regions sandwiched between three hypervariable "complementarity determining regions".
[0059] The term "linker" as used herein refers to a peptide or protein linking element between two elements, e.g., two polypeptides in a TfR construct. In some embodiments, the linker can comprise 1-10 amino acids (e.g., 1-8, 1-6, 1-4, or 1 or 2 amino acids, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids). In other embodiments, the linker can be a protein loop domain, and the distance between the N-terminus and C-terminus of the protein loop domain is less than 5 Å (e.g., less than 4 Å, 3 Å, 2 Å, or 1 Å). In some embodiments, a protein loop domain may be a globular protein having 800 or less amino acids (e.g., 800, 780, 760, 740, 720, 700, 680, 660, 640, 620, 600, 580, 560, 540, 520, 500, 480, 460, 440, 420, 400, 380, 360, 340, 320, 300, 280, 260, 240, 220, 200, 180, 160, 140, 120, or 100 amino acids).
[0060] As used herein, the term "purification peptide" refers to a peptide of any length that can be used to purify, isolate, or identify a polypeptide. A purification peptide can be fused to a polypeptide for use in purifying the polypeptide and / or isolating the polypeptide from, for example, a cell lysate mixture. In some embodiments, the purification peptide is conjugated to another moiety that has a specific affinity for the purification peptide. In some embodiments, such a moiety that specifically binds to the purification peptide is bound to a solid support, such as a matrix, resin, or agarose beads. Examples of purification peptides that can be used to purify TfR constructs are described in more detail herein.
[0061] As used herein, the term "cleavage peptide" refers to an amino acid sequence that is recognized and cleaved (i.e., by hydrolysis of the peptide backbone) by a specific protease. The specificity of the protease depends in large part on the recognition of the cleavage sequence by the protease.
[0062] As used herein, "tandem" refers to an arrangement of polypeptides in which amino acids of one polypeptide are positioned after amino acids of another polypeptide within a single polypeptide. For example, a TfR construct can include a first polypeptide, an optional linker, and a second polypeptide fused in tandem (i.e., the C-terminus of the first polypeptide is fused to the N-terminus of the optional linker, and the C-terminus of the optional linker is fused to the N-terminus of the second polypeptide).
[0063] The terms "wild-type," "native," and "naturally occurring" with respect to CH3 and CH2 domains are used herein to refer to domains having sequences that occur in nature.
[0064] In the context of the present invention, the term "mutant" is used interchangeably with "variant" in reference to mutant polypeptides or mutant polynucleotides. With respect to a given wild-type CH3 or CH2 domain reference sequence, variants can include naturally occurring allelic variants. A "non-naturally occurring" CH3 or CH2 domain refers to a variant or mutant domain that does not naturally occur in cells and is generated by genetic modification (e.g., using genetic engineering techniques or mutagenesis) of a native CH3 or CH2 domain polynucleotide or polypeptide. A "variant" includes any domain that has at least one amino acid mutation relative to the wild type. Mutations can include substitutions, insertions, and deletions.
[0065] The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids.
[0066] Naturally occurring amino acids are those encoded by the genetic code as well as those that are later modified, such as, for example, hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. "Amino acid analogs" refer to compounds that have the same basic chemical structure as a naturally occurring amino acid (i.e., an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group) (e.g., homoserine, norleucine, methionine sulfoxide, methionine methylsulfonium, etc.). Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. "Amino acid mimetics" refer to compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a similar manner to a naturally occurring amino acid.
[0067] Naturally occurring α-amino acids include, but are not limited to, alanine (Ala), cysteine (Cys), aspartic acid (Asp), glutamic acid (Glu), phenylalanine (Phe), glycine (Gly), histidine (His), isoleucine (Ile), arginine (Arg), lysine (Lys), leucine (Leu), methionine (Met), asparagine (Asn), proline (Pro), glutamine (Gln), serine (Ser), threonine (Thr), valine (Val), tryptophan (Trp), tyrosine (Tyr), and combinations thereof. Naturally occurring stereoisomers of α-amino acids include, but are not limited to, D-alanine (D-Ala), D-cysteine (D-Cys), D-aspartic acid (D-Asp), D-glutamic acid (D-Glu), D-phenylalanine (D-Phe), D-histidine (D-His), D-isoleucine (D-Ile), D-arginine (D-Arg), and D-lysine. (D-Lys), D-leucine (D-Leu), D-methionine (D-Met), D-asparagine (D-Asn), D-proline (D-Pro), D-glutamine (D-Gln), D-serine (D-Ser), D-threonine (D-Thr), D-valine (D-Val), D-tryptophan (D-Trp), D-tyrosine (D-Tyr), and combinations thereof.
[0068] Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission.
[0069] The terms "polypeptide" and "peptide" are used interchangeably herein to refer to a single chain of polymers of amino acid residues. Such terms apply to amino acid polymers in which one or more amino acid residues are artificial chemical mimetics of a corresponding naturally occurring amino acid, as well as to naturally occurring and non-naturally occurring amino acid polymers. An amino acid polymer can be entirely L-amino acids, entirely D-amino acids, or a mixture of L- and D-amino acids.
[0070] As used herein, a "protein" refers to a polypeptide or a dimer (i.e., two) or multimer (i.e., three or more) of single-chain polypeptides. The single-chain polypeptides of a protein can be linked together by covalent bonds, such as disulfide bonds, or by non-covalent interactions.
[0071] The terms "conservative substitution," "conservative variation," or "conservatively modified variant" refer to a change that results in the replacement of an amino acid with another amino acid that can be classified as having similar properties. Examples of categories of conservative amino acid groups defined in this manner include "charged / polar groups" including Glu (glutamic acid or E), Asp (aspartic acid or D), Asn (asparagine or N), Gln (glutamine or Q), Lys (lysine or K), Arg (arginine or R), and His (histidine or H); "aromatic groups" including Phe (phenylalanine or F), Tyr (tyrosine or Y), Trp (tryptophan or W), and (histidine or H); and "aliphatic groups" including Gly (glycine or G), Ala (alanine or A), Val (valine or V), Leu (leucine or L), Ile (isoleucine or I), Met (methionine or M), Ser (serine or S), Thr (threonine or T), and Cys (cysteine or C). Subgroups may also be identified within each group. For example, the group of charged or polar amino acids can be further divided into subgroups including a "positively charged subgroup" including Lys, Arg, and His, a "negatively charged subgroup" including Glu and Asp, and a "polar subgroup" including Asn and Gln. In another example, aromatic or cyclic groups can be further divided into subgroups including a "nitrogen ring subgroup" including Pro, His, and Trp, and a "phenyl subgroup" including Phe and Tyr. In yet another example, aliphatic groups can be further divided into subgroups such as an "aliphatic non-polar subgroup" including Val, Leu, Gly, and Ala, and an "aliphatic weakly polar subgroup" including Met, Ser, Thr, and Cys.Exemplary conservative mutation categories include amino acid substitutions of amino acids within the above subgroups, such as, but not limited to, Lys for Arg or vice versa to maintain a positive charge; Glu for Asp or vice versa to maintain a negative charge; Ser for Thr or vice versa to maintain a free -OH; Gln for Asn or vice versa to maintain a free -NH2. In some embodiments, hydrophobicity is maintained, for example, by substituting a hydrophobic amino acid for a naturally occurring hydrophobic amino acid in the active site.
[0072] The terms "identical" or "identity" in the context of two or more polypeptide sequences refer to two or more sequences or subsequences that are the same over a particular region when compared and aligned for maximum correspondence over a comparison window, or designated region, as determined using a sequence comparison algorithm or by manual alignment and visual inspection, or that have a specified percentage (%) of amino acid residues that are identical, for example, at least 60% identity, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% or more identical.
[0073] In the sequence comparison of polypeptides, generally one amino acid sequence serves as a reference sequence to compare candidate sequences. Alignment can be performed using various methods available to those skilled in the art, such as visual alignment or using publicly available software with known algorithms, to obtain maximum alignment. Such programs include the BLAST program, ALIGN, ALIGN-2 (Genentech, South San Francisco, Calif.), or Megalign (DNASTAR). The parameters used in the alignment to obtain maximum alignment can be determined by those skilled in the art. For the purpose of this application, the sequence comparison of polypeptide sequences uses the standard protein BLAST of the BLASTP algorithm to align two protein sequences using default parameters.
[0074] The terms "corresponding to," "determined with respect to," or "numbered with respect to," when used in the context of identifying a given amino acid residue in a polypeptide sequence, refer to the position of the residue in a particular reference sequence when the given amino acid sequence is compared to the reference sequence for maximum alignment. Thus, for example, an amino acid residue in a polypeptide "corresponds to" an amino acid in the region from amino acid 114 to amino acid 220 of SEQ ID NO:1 when the residue is aligned with that amino acid in SEQ ID NO:1 when optimally aligned with SEQ ID NO:1. A polypeptide that is aligned with a reference sequence need not be the same length as the reference sequence.
[0075] As used herein, "binding affinity" refers to the strength of a non-covalent interaction between two molecules, e.g., between one binding site of a polypeptide and a target to which the polypeptide binds, e.g., the transferrin receptor. Thus, for example, the term may refer to a 1:1 interaction between a polypeptide and its target, unless otherwise indicated or clear from the context. Binding affinity is measured by the dissociation rate constant (k d ,time -1) to the binding rate constant (k a ,time -1 M -1 ) is the equilibrium dissociation constant (K D ) can be quantified by measuring the K D can be determined by measuring the kinetics of complex formation and dissociation using, for example, surface plasmon resonance (SPR) methods, such as the Biacore™ system; kinetic exclusion assays, such as KinExA®; and biolayer interferometry (e.g., using the ForteBio® Octet® platform). As used herein, "binding affinity" includes not only formal binding affinity, such as that reflecting a 1:1 interaction between a polypeptide and its target, but also K, which may reflect strong binding. D Also included are apparent affinities calculated using the formula:
[0076] The phrase "specifically binds" or "selectively binds" to a target, e.g., transferrin receptor, when referring to a polypeptide comprising a modified CH3 and / or modified CH2 domain described herein, refers to a binding reaction in which the polypeptide binds to the target with greater affinity, greater avidity, and / or longer duration than it binds to a structurally different target, e.g., a target that is not of the transferrin receptor family. In typical embodiments, the polypeptide has at least 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 25-fold, 50-fold, or 100-fold or more higher affinity for the transferrin receptor compared to an unrelated target when assayed under the same affinity assay conditions. In some embodiments, the modified CH3 and / or modified CH2 domain polypeptide specifically binds to an epitope on the transferrin receptor that is conserved between species, e.g., between non-human primates and human species. In some embodiments, the polypeptide can bind only to the human transferrin receptor.
[0077] The terms "subject," "individual," and "patient," used interchangeably herein, refer to mammals, including, but not limited to, humans, non-human primates, rodents (e.g., rats, mice, and guinea pigs), rabbits, cows, pigs, horses, and other mammalian species. In one embodiment, the patient is a human.
[0078] The terms "treatment", "treat" and similar terms are used herein generally to mean obtaining a desired pharmacological and / or physiological effect. "Treat" or "treatment" may refer to any indication of success in treating or improving an injury, disease, or condition, including any objective or subjective parameter, such as relief, remission, improved survival rate of a patient, increased duration or survival rate, disappearance of symptoms or making the injury, disease, or condition more tolerable to the patient, slowing the rate of degeneration or decline, or improvement in the patient's physical or mental health. The treatment or improvement of symptoms may be based on objective or subjective parameters. The effect of treatment may be compared to an individual or population of individuals not receiving treatment, or to the same patient at different points in time before or during treatment.
[0079] "Pharmaceutically acceptable excipient" refers to a non-active pharmaceutical ingredient that is biologically or pharmacologically compatible for use in humans or animals, such as, but not limited to, a buffer, carrier, or preservative.
[0080] As used herein, a "therapeutic amount" or "therapeutically effective amount" of a drug is an amount of drug that treats, alleviates, relieves, or reduces the severity of a symptom of a disease in a subject. A "therapeutic amount" or "therapeutically effective amount" of a drug can improve a patient's survival, increase the duration or rate of survival, eliminate symptoms, make an injury, disease, or condition more tolerable, slow the rate of degeneration or decline, or improve the physical or mental well-being of a patient.
[0081] The term "administering" refers to a method of delivering an agent, compound, or composition to the site of desired biological effect. These methods include, but are not limited to, topical, parenteral, intravenous, intradermal, intramuscular, intrathecal, colonic, rectal, or intraperitoneal administration. In one embodiment, the polypeptides described herein are administered intravenously.
[0082] III. Modified Polypeptides Capable of Transport across the BBB In one aspect, provided herein are modified polypeptides capable of binding to blood-brain barrier (BBB) receptors and being transported across the BBB. BBB receptors are expressed on the endothelium of the BBB, as well as other types of cells and tissues. Binding of the modified polypeptide to a BBB receptor initiates internalization of the polypeptide, allowing it to be transported across the BBB. Such receptors include, but are not limited to, transferrin receptor (TfR), insulin receptor, insulin-like growth factor receptor (IGF-R), low-density lipoprotein receptor (LDLR), low-density lipoprotein receptor-related protein 1 (LRP1), low-density lipoprotein receptor-related protein 2 (LRP2), low-density lipoprotein receptor-related protein 8 (LRP8), GLUT1, basigin, diphtheria toxin receptor, membrane-bound precursor of heparin-binding epidermal growth factor-like growth factor (HB-EGF), melanotransferrin, and vasopressin receptor. In some embodiments, the BBB receptor is TfR or IGF-R.
[0083] Modified Fc Polypeptides In certain embodiments, the polypeptides provided herein capable of being transported across the BBB include Fc polypeptides that have been modified (e.g., by one or more amino acid substitutions relative to a native Fc polypeptide) to have a BBB receptor binding site. In certain embodiments, the substitution is of a solvent-exposed amino acid. A solvent-exposed amino acid refers to an amino acid at or near the surface of a polypeptide that is accessible to the aqueous physiological fluid environment in which the polypeptide functions in vivo. Typically, solvent-exposed residues have greater than 50% of their side chains in contact with the solvent, although in some cases less than 50% of the side chains are exposed, e.g., 25%-49%. Solvent-exposed amino acids include those present in beta sheets, alpha helices, and / or loops.
[0084] The solvent-exposed amino acids to be modified according to the present invention are typically those present in a set of amino acids (also referred to herein as a register) that can constitute a continuous surface within a defined three-dimensional region. Solvent-exposed amino acids can be identified based on a model of an IgG, such as anti-HIV IgG B12 (pdb:1HZH). The solvent accessible surface area (Å) of the residue at each position is calculated. 2 ) can be calculated using the program PDBePISA from the European Bioinformatics Institute (EMBL-EBI). This value can be normalized to the maximum possible contact surface area for each corresponding amino acid to obtain a "% exposed" for each residue. Highly solvent exposed residues can then be mapped back to the structure of IgG and visually grouped into sets that give surface area patches (e.g., sets of about 5-15 residues, 6-12 residues, 7-12 residues, or 8-10 residues). In some embodiments, such surface area patches total 600-1500 Å of solvent exposed surface. 2 In an alternative embodiment, the surface area of the patch is between 750 and 1000 Å in total. 2 Optionally, amino acid residues having side chains that are less than 50% exposed may be included such that the surface area patch is continuous or semi-continuous.
[0085] Secondary structures, such as beta sheets, loops, and helices, within immunoglobulins can be determined from the crystal structure using software such as PyMol or SwissPDB Viewer, which visualizes the secondary structure of the polypeptide backbone. For example, analysis of the crystal structure of an Fc polypeptide bound to FcgammaRI (PDB ID number 4W4O) can be used to determine which amino acids fall into different structural regions and to help determine which amino acid side chains may be solvent accessible. Exemplary sets of amino acid residues at positions corresponding to surface region patches include the following six sets, numbered with reference to SEQ ID NO:1: (i) 157, 159, 160, 161, 162, 163, 186, 189, and 194; (ii) 118, 119, 120, 122, 210, 211, 212, and 213; (iii) 47, 49, 56, 58, 59, 60, 61, 62, and 63; (iv) 39, 40, 41, 42, 43, 44, 68, 70, 71, and 72; (v) 41, 42, 43, 44, 45, 65, 66, 67, 69, and 73; and (vi) 45, 47, 49, 95, 97, 99, 102, 103, and 104. Further examples of modifications to such patches, and amino acids that can be modified (eg, substituted) to create BBB receptor binding polypeptides, are detailed herein.
[0086] Amino acid residues, e.g., solvent-exposed surface residues, of an Fc polypeptide that may be modified in accordance with the present invention are numbered herein with reference to SEQ ID NO:1. For example, any Fc polypeptide, such as an IgG1, IgG2, IgG3, or IgG4 Fc polypeptide, can have a modification (e.g., amino acid substitution) at one or more sets of residues (e.g., solvent-exposed residues) that correspond to the residues at the recited positions in SEQ ID NO:1. An alignment of the amino acid sequence of human IgG1 of SEQ ID NO:1 with human IgG2, IgG3, and IgG4 is shown in Figure 38. The respective positions of the IgG2, IgG3, and IgG4 sequences that correspond to any particular position in SEQ ID NO:1 can be readily determined.
[0087] Modified polypeptides of the invention capable of binding to a BBB receptor and being transported across the BBB can have at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to a native Fc region sequence or a fragment thereof, such as a fragment at least 50 amino acids, or at least 100 amino acids in length, or more. In some embodiments, the amino acid sequence of the native Fc is the sequence of the Fc region of SEQ ID NO:1, i.e., amino acids 4-220 of SEQ ID NO:1. In some embodiments, the modified polypeptide has at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to amino acids 4-220 of SEQ ID NO:1, or a fragment thereof, such as a fragment at least 50 amino acids, or at least 100 amino acids in length, or more.
[0088] In some embodiments, the modified Fc polypeptides of the invention comprise at least 50 amino acids, or at least 60, 65, 70, 75, 80, 85, 90, 95 or more, or at least 100 or more amino acids corresponding to the amino acid sequence of a native Fc region. In some embodiments, the invention comprises at least 25 contiguous amino acids, or at least 30, 35, 40, or 45 contiguous amino acids, or 50 contiguous amino acids, or at least 60, 65, 70, 75, 80, 85, 90, or 95 or more contiguous amino acids, or 100 or more contiguous amino acids corresponding to the amino acid sequence of a native Fc region, such as SEQ ID NO:1.
[0089] In some embodiments, modified Fc polypeptides according to the invention comprise at least one substitution, typically 2, 3, 4, 5, 6, 7, 8, 9, or 10 substitutions, at a set of amino acid positions including 39, 40, 41, 42, 43, 44, 68, 70, 71, and 72, each position being determined with reference to SEQ ID NO:1, and the substitution(s) are to the amino acid residue present at the respective position in SEQ ID NO:1.
[0090] In some embodiments, modified Fc polypeptides according to the invention comprise at least one substitution, typically 2, 3, 4, 5, 6, 7, 8, or 9 substitutions, at the set of amino acid positions including 47, 49, 56, 58, 59, 60, 61, 62, and 63, each position being determined with reference to SEQ ID NO:1, and the substitution(s) are to the amino acid residue present at each position in SEQ ID NO:1.
[0091] In some embodiments, modified Fc polypeptides according to the invention comprise at least one substitution, and typically 2, 3, 4, 5, 6, 7, 8, 9, or 10 substitutions, at the set of amino acid positions including 41, 42, 43, 44, 45, 65, 66, 67, 69, and 73, each position being determined with reference to SEQ ID NO:1, and the substitution(s) are to the amino acid residue present at the respective position in SEQ ID NO:1.
[0092] In some embodiments, modified Fc polypeptides according to the invention comprise at least one substitution, typically 2, 3, 4, 5, 6, 7, 8, or 9 substitutions, at a set of amino acid positions including 45, 47, 49, 95, 97, 99, 102, 103, and 104, each position being determined with reference to SEQ ID NO:1, and the substitution(s) are to the amino acid residue present at the respective position in SEQ ID NO:1.
[0093] In some embodiments, modified Fc polypeptides according to the invention comprise at least one substitution, typically two, three, four, five, six or seven substitutions, at the set of amino acid positions including 118, 119, 120, 122, 210, 211, 212, and 213, each position being determined with reference to SEQ ID NO:1, and the substitution(s) are to the amino acid residue present at each position of SEQ ID NO:1.
[0094] In some embodiments, modified Fc polypeptides according to the invention comprise at least one substitution, typically 2, 3, 4, 5, 6, 7, 8, or 9 substitutions, at the set of amino acid positions including 157, 159, 160, 161, 162, 163, 186, 189, and 194, where each position is determined with reference to SEQ ID NO:1 and the substitution(s) are to the amino acid residue present at each position in SEQ ID NO:1.
[0095] FcRn binding site The polypeptides of the invention capable of being transported across the BBB further comprise an FcRn binding site, hi some embodiments, the FcRn binding site is within a modified Fc polypeptide or a fragment thereof.
[0096] In some embodiments, the FcRn binding site comprises a native FcRn binding site. In some embodiments, the FcRn binding site does not comprise an amino acid change to the amino acid sequence of the native FcRn binding site. In some embodiments, the native FcRn binding site is an IgG binding site, for example, a human IgG binding site. In some embodiments, the FcRn binding site comprises a modification that alters binding to FcRn.
[0097] In some embodiments, the FcRn binding site has one or more amino acid residues mutated, e.g., substituted, where such mutation(s) increase serum half-life or do not significantly decrease serum half-life (i.e., decrease serum half-life by 25% or less compared to a corresponding BBB receptor binding protein having a wild-type residue at the mutated position when assayed under the same conditions). In some embodiments, the FcRn binding site has one or more amino acid residues substituted at positions 24-29, 201, and 206-209, where each position is determined with reference to SEQ ID NO:1.
[0098] In some embodiments, the FcRn binding site comprises one or more mutations relative to a native human IgG sequence that increase the serum half-life of the modified polypeptide. In some embodiments, mutations, e.g., substitutions, are introduced at one or more of positions 17-30, 52-57, 80-90, 156-163, and 201-208 relative to SEQ ID NO:1 (which correspond to positions 244-257, 279-284, 307-317, 383-390, and 428-435 using EU numbering). In some embodiments, one or more mutations are introduced at positions 24, 25, 27, 28, 29, 80, 81, 82, 84, 85, 87, 158, 159, 160, 162, 201, 206, 207, or 209 relative to SEQ ID NO:1 (which correspond to positions 251, 252, 254, 255, 256, 307, 308, 309, 311, 312, 314, 385, 386, 387, 389, 428, 433, 434, or 436 using EU numbering). In some embodiments, mutations are introduced at one, two, or three of positions 25, 27, and 29 as determined by SEQ ID NO:1 (these positions correspond to positions 252, 254, and 256 using EU numbering). In some embodiments, the mutations are M25Y, S27T, and T29E as determined by SEQ ID NO:1. In some embodiments, the modified Fc polypeptides of the invention further comprise M25Y, S27T, and T29E. In some embodiments, the modified Fc polypeptides comprise substitutions at one, two, or all three of positions T307, E380, and N434 according to EU numbering (these positions correspond to positions T80, E153, and N207 as determined by SEQ ID NO:1). In some embodiments, the mutations are T307Q and N434A (T80Q and N207A of SEQ ID NO:1). In some embodiments, the modified Fc polypeptide comprises the mutations T307A, E380A, and N434A (T80A, E153A, and N207A of SEQ ID NO:1).In some embodiments, the modified Fc polypeptide comprises substitutions at positions T250 and M428 (these positions correspond to T23 and M201 when numbered with reference to SEQ ID NO:1). In some embodiments, the Fc polypeptide comprises mutations T250Q and / or M428L (T23Q and M201L in SEQ ID NO:1). In some embodiments, the modified Fc polypeptide comprises substitutions at positions M428 and N434 (these positions correspond to M201 and N207 when numbered with reference to SEQ ID NO:1). In some embodiments, the modified Fc polypeptide comprises substitutions M428L and N434S (these positions correspond to M201L and N207S when numbered with reference to SEQ ID NO:1). In some embodiments, the modified Fc polypeptide comprises an N434S or N434A substitution (which corresponds to N207S or N207A when numbered with reference to SEQ ID NO:1).
[0099] IV. Transferrin Receptor Binding Polypeptides This section describes the generation of modified Fc polypeptides in accordance with the invention that are capable of binding to blood-brain barrier (BBB) receptors and being transported across the BBB, using the transferrin receptor as an exemplary BBB receptor.
[0100] CH3 Transferrin Receptor Binding Polypeptide In some embodiments, the domain to be modified is a human Ig CH3 domain, such as an IgG CH3 domain. The CH3 domain may be from any IgG subtype, i.e., IgG1, IgG2, IgG3, or IgG4. In the context of IgG antibodies, the CH3 domain refers to the segment of amino acids from about 341 to about 447 when numbered according to the EU numbering scheme. Positions within the CH3 domain for purposes of identifying a set of corresponding amino acid positions for transferrin receptor binding are referenced to SEQ ID NO:3 or to amino acids 114-220 of SEQ ID NO:1, unless otherwise specified. Substitutions are also referenced to SEQ ID NO:1, i.e., an amino acid is considered to be a substitution for the amino acid at the corresponding position in SEQ ID NO:1. SEQ ID NO:1 includes a partial hinge region sequence, PCP, as amino acids 1-3. The numbering of positions within the CH3 domain relative to SEQ ID NO:1 includes these first three amino acids.
[0101] As noted above, the set of residues in a CH3 domain that may be modified in accordance with the present invention are numbered herein with reference to SEQ ID NO:1. For example, any CH3 domain, such as the CH3 domain of an IgG1, IgG2, IgG3, or IgG4, may have a modification (e.g., an amino acid substitution) at one or more sets of residues that correspond to the residues at the recited positions in SEQ ID NO:1. An alignment of the amino acid sequence of human IgG1 of SEQ ID NO:1 with human IgG2, IgG3, and IgG4 is shown in Figure 38. The respective positions of the IgG2, IgG3, and IgG4 sequences that correspond to any particular position in SEQ ID NO:1 can be readily determined.
[0102] It will be appreciated by those skilled in the art that the CH2 and CH3 domains of other immunoglobulin isotypes, e.g., IgM, IgA, IgE, IgD, etc., can be similarly modified by identifying amino acids within these domains that correspond to sets (i)-(vi) set forth above. Modifications can also be made to corresponding domains from immunoglobulins derived from other species, e.g., non-human primates, monkeys, mice, rats, rabbits, dogs, pigs, chickens, etc.
[0103] In one embodiment, a modified CH3 domain polypeptide that specifically binds to the transferrin receptor binds to the apical domain of the transferrin receptor at an epitope that includes position 208 of the full-length human transferrin receptor sequence (SEQ ID NO:235), which corresponds to position 11 of the apical domain sequence of the human transferrin receptor set forth in SEQ ID NO:107. SEQ ID NO:107 corresponds to amino acids 198-378 of the human transferrin receptor 1 uniprotein sequence P02786 (SEQ ID NO:235). In some embodiments, the modified CH3 domain polypeptide binds to the apical domain of the transferrin receptor at an epitope that includes positions 158, 188, 199, 207, 208, 209, 210, 211, 212, 213, 214, 215, and / or 294 of the full-length human transferrin receptor sequence (SEQ ID NO:235). The modified CH3 domain polypeptide may bind to the transferrin receptor without blocking or otherwise inhibiting the binding of transferrin to the receptor. In some embodiments, the binding of transferrin to the TfR is not substantially inhibited. In some embodiments, the binding of transferrin to the TfR is inhibited by less than about 50% (e.g., less than about 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%). In some embodiments, binding of transferrin to TfR is inhibited by less than about 20% (e.g., less than about 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1%). Exemplary CH3 domain polypeptides that exhibit such binding specificity include polypeptides having amino acid substitutions at positions 157, 159, 160, 161, 162, 163, 186, 189, and 194, as determined from amino acids 114-220 of SEQ ID NO:1.
[0104] Transferrin receptor binding group (i) of CH3: 157, 159, 160, 161, 162, 163, 186, 189, and 194 In some embodiments, modified CH3 domain polypeptides according to the invention contain at least three or at least four, typically five, six, seven, eight, or nine substitutions at a set of amino acid positions including 157, 159, 160, 161, 162, 163, 186, 189, and 194 (set i). Exemplary substitutions that can be introduced at these positions are shown in Table 6. In some embodiments, the amino acid at position 161 and / or 194 is an aromatic amino acid (e.g., Trp, Phe, or Tyr). In some embodiments, the amino acid at position 161 is Trp. In some embodiments, the amino acid at position 161 is Gly. In some embodiments, the aromatic amino acid at position 194 is Trp or Phe.
[0105] In some embodiments, modified CH3 domain polypeptides that specifically bind to the transferrin receptor include at least one position having a substitution relative to SEQ ID NO:1, such as Leu, Tyr, Met, or Val at position 157; Leu, Thr, His, or Pro at position 159; Val, Pro, or an acidic amino acid at position 160; an aromatic amino acid, such as Trp or Gly (e.g., Trp), at position 161; Val, Ser, or Ala at position 162; an acidic amino acid, Ala, Ser, Leu, Thr, or Pro at position 186; Thr or an acidic amino acid at position 189; or Trp, Tyr, His, or Phe at position 194. In some embodiments, modified CH3 domain polypeptides can include conservative substitutions of certain amino acids at one or more of the positions in the above sets, such as amino acids in groups based on the same charge, hydrophobicity, side chain ring structure (e.g., aromatic amino acids), or size, and / or polar or non-polar groups. Thus, for example, Ile may be present at positions 157, 159, and / or 186. In some embodiments, the acidic amino acid at one, two, or each of positions 160, 186, and 189 is Glu. In other embodiments, the acidic amino acid at one, two, or each of positions 160, 186, and 189 is Asp. In some embodiments, two, three, four, five, six, seven, or all eight of positions 157, 159, 160, 161, 162, 186, 189, and 194 have an amino acid substitution as specified in this paragraph.
[0106] In some embodiments, the CH3 domain polypeptide having modifications in set (i) comprises a naturally occurring Asn at position 163. In some embodiments, the modified CH3 domain polypeptide comprises a Gly, His, Gln, Leu, Lys, Val, Phe, Ser, Ala, or Asp at position 163. In some embodiments, the modified CH3 domain polypeptide further comprises one, two, three, or four substitutions at positions including 153, 164, 165, and 188. In some embodiments, Trp, Tyr, Leu, or Gln may be present at position 153. In some embodiments, Ser, Thr, Gln, or Phe may be present at position 164. In some embodiments, Gln, Phe, or His may be present at position 165. In some embodiments, Gln may be present at position 188.
[0107] In certain embodiments, the modified CH3 domain polypeptide comprises 2, 3, 4, 5, 6, 7, 8, 9, or 10 positions selected from the following: Trp, Leu, or Glu at position 153; Tyr or Phe at position 157; Thr at position 159; Glu at position 160; Trp at position 161; Ser, Ala, Val, or Asn at position 162; Ser or Asn at position 163; Thr or Ser at position 186; Glu or Ser at position 188; Glu at position 189; and / or Phe at position 194. In some embodiments, the modified CH3 domain polypeptide contains all of the following eleven positions: Trp, Leu, or Glu at position 153; Tyr or Phe at position 157; Thr at position 159; Glu at position 160; Trp at position 161; Ser, Ala, Val, or Asn at position 162; Ser or Asn at position 163; Thr or Ser at position 186; Glu or Ser at position 188; Glu at position 189; and / or Phe at position 194.
[0108] In certain embodiments, the modified CH3 domain polypeptide comprises Leu or Met at position 157, Leu, His, or Pro at position 159, Val at position 160, Trp at position 161, Val or Ala at position 162, Pro at position 186, Thr at position 189, and / or Trp at position 194. In some embodiments, the modified CH3 domain polypeptide further comprises Ser, Thr, Gln, or Phe at position 164. In some embodiments, the modified CH3 domain polypeptide further comprises Trp, Tyr, Leu, or Gln at position 153, and / or Gln, Phe, or His at position 165. In some embodiments, Trp is present at position 153, and / or Gln is present at position 165. In some embodiments, the modified CH3 domain polypeptide does not have a Trp at position 153.
[0109] In other embodiments, the modified CH3 domain polypeptide comprises a Tyr at position 157, a Thr at position 159, a Glu or Val at position 160, a Trp at position 161, a Ser at position 162, a Ser or Thr at position 186, a Glu at position 189, and / or a Phe at position 194. In some embodiments, the modified CH3 domain polypeptide comprises a native Asn at position 163. In certain embodiments, the modified CH3 domain polypeptide further comprises a Trp, Tyr, Leu, or Gln at position 153 and / or a Glu at position 188. In some embodiments, the modified CH3 domain polypeptide further comprises a Trp at position 153 and / or a Glu at position 188.
[0110] In a further embodiment, the modified CH3 domain further comprises one, two or three positions selected from the following: Lys, Arg, Gly or Pro at position 187; Ser, Thr, Glu or Lys at position 197; and Ser, Trp or Gly at position 199.
[0111] In some embodiments, the modified CH3 domain comprises one or more of the following substitutions: Tyr at position 153, Thr at position 159, Trp at position 161, Val at position 162, Ser or Thr at position 186, Glu at position 188, and / or Phe at position 194.
[0112] In some embodiments, a modified CH3 domain polypeptide that specifically binds to a transferrin receptor has at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to amino acids 114-220 of any one of SEQ ID NOs: 4-29 and 236-299. In some embodiments, such modified CH3 domain polypeptides comprise amino acids 157-163 and / or 186-194 of any one of SEQ ID NOs: 4-29 and 236-299. In some embodiments, such modified CH3 domain polypeptides comprise amino acids 153-163 and / or 186-194 of any one of SEQ ID NOs: 4-29 and 236-299. In some embodiments, the modified CH3 domain polypeptide comprises amino acids 153-163 and / or 186-199 of any one of SEQ ID NOs:4-29 and 236-299.
[0113] In some embodiments, the modified CH3 domain polypeptide has at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to amino acids 114-220 of SEQ ID NO:1, with the proviso that the percent identity does not include the set of positions 157, 159, 160, 161, 162, 163, 186, 189, and 194. In some embodiments, the modified CH3 domain polypeptide comprises amino acids 157-163 and / or amino acids 186-194 set forth in any one of SEQ ID NOs:4-29 and 236-299.
[0114] In some embodiments, the modified CH3 domain polypeptide has at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to any one of SEQ ID NOs: 4-29 and 236-299, provided that at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 of the positions corresponding to positions 153, 157, 159, 160, 161, 162, 163, 164, 165, 186, 187, 188, 189, 194, 197, and 199 of any one of SEQ ID NOs: 4-29 and 236-299 have not been deleted or substituted.
[0115] In some embodiments, the modified CH3 domain polypeptide has at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to any one of SEQ ID NOs: 4-29 and 236-299, and also has the following amino acids at the following positions: Trp, Tyr, Leu, Gln, or Glu at position 153; Leu, Tyr, Met, or Val at position 157; Leu, Thr, His, or Pro at position 159; Val, Pro, or an acidic amino acid at position 160; an aromatic amino acid, such as Trp, at position 161; Val, Ser, or Ala at position 162; and Se at position 163. at position 165; an acidic amino acid, Ala, Ser, Leu, Thr, or Pro at position 186; Lys, Arg, Gly, or Pro at position 187; Glu or Ser at position 188; Thr or an acidic amino acid at position 189; Trp, Tyr, His, or Phe at position 194; Ser, Thr, Glu, or Lys at position 197; and at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 of Ser, Trp, or Gly at position 199.
[0116] In some embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:116-130. In other embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:116-130, but with one or two amino acid substitutions in the sequence. In some embodiments, the polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:116-130, but with three amino acid substitutions in the sequence.
[0117] In some embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:131-139. In other embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:131-130, but with one or two amino acid substitutions in the sequence. In some embodiments, the polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:131-139, but with three or four amino acid substitutions in the sequence.
[0118] In some embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:303-339. In other embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:303-339, but with one or two amino acid substitutions in the sequence. In some embodiments, the polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:303-339, but with three amino acid substitutions in the sequence.
[0119] In some embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 136, 138, and 340-345. In other embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 136, 138, and 340-345, but with one or two amino acid substitutions in the sequence. In some embodiments, the polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 136, 138, and 340-345, but with three or four amino acid substitutions in the sequence.
[0120] In further embodiments, the transferrin receptor binding polypeptide comprises amino acids 157-194, amino acids 153-194, or amino acids 153-199 of any one of SEQ ID NOs: 4-29 and 236-299. In further embodiments, the polypeptide comprises an amino acid sequence having at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to amino acids 157-194 of any one of SEQ ID NOs: 4-29 and 236-299, or to amino acids 153-194 or amino acids 153-199 of any one of SEQ ID NOs: 4-29 and 236-299.
[0121] In some embodiments, the polypeptide comprises any one of SEQ ID NOs: 4-29 and 236-299. In further embodiments, the polypeptide comprises any one of SEQ ID NOs: 4-29 and 236-299 without the first three amino acid residues "PCP" at the amino terminus. In further embodiments, the polypeptide can have at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to any one of SEQ ID NOs: 4-29 and 236-299 determined without the first three amino acid residues "PCP" at the amino terminus.
[0122] Transferrin receptor-binding group (ii) of CH3: 118, 119, 120, 122, 210, 211, 212, and 213 In some embodiments, modified CH3 domain polypeptides according to the invention comprise at least three or at least four, typically five, six, seven, or eight substitutions at the set of amino acid positions comprising: 118, 119, 120, 122, 210, 211, 212, and 213 (set ii). Exemplary substitutions that can be introduced at these positions are shown in Table 5. In some embodiments, modified CH3 domain polypeptides comprise Gly at position 210, Phe at position 211, and / or Asp at position 213. In some embodiments, Glu may be present at position 213. In certain embodiments, modified CH3 domain polypeptides comprise at least one substitution at the following positions: That is, Phe or Ile at position 118, Asp, Glu, Gly, Ala, or Lys at position 119, Tyr, Met, Leu, Ile, or Asp at position 120, Thr or Ala at position 122, Gly at position 210, Phe at position 211, His, Tyr, Ser, or Phe at position 212, or Asp at position 213. In some embodiments, two, three, four, five, six, seven, or all eight of positions 118, 119, 120, 122, 210, 211, 212, and 213 have a substitution as specified in this paragraph. In some embodiments, the modified CH3 domain polypeptide can include conservative substitutions of particular amino acids at one or more of the positions in the above sets, e.g., amino acids in groups based on the same charge, on hydrophobicity, on the ring structure of their side chains (e.g., aromatic amino acids), or on size, and / or whether polar or non-polar.
[0123] In some embodiments, a modified CH3 domain polypeptide that specifically binds to a transferrin receptor has at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to amino acids 114-220 of any one of SEQ ID NOs:30-46. In some embodiments, such a modified CH3 domain polypeptide comprises amino acids 118-122 and / or amino acids 210-213 of any one of SEQ ID NOs:30-46.
[0124] In some embodiments, the modified CH3 domain polypeptide has at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to amino acids 114-220 of SEQ ID NO:1, with the proviso that the percent identity does not include the set of positions 118, 119, 120, 122, 210, 211, 212, and 213. In some embodiments, the modified CH3 domain polypeptide comprises amino acids 118-122 and / or amino acids 210-213 set forth in any one of SEQ ID NOs:30-46.
[0125] In some embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 140-153. In other embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 140-153, but with one or two amino acid substitutions in the sequence.
[0126] In some embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 154-157. In other embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 154-157, but with one amino acid substitution or with two amino acid substitutions in the sequence.
[0127] In further embodiments, the transferrin receptor binding polypeptide comprises amino acids 118-213 of any one of SEQ ID NOs:30-46. In further embodiments, the polypeptide can comprise an amino acid sequence having at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to amino acids 118-213 of any one of SEQ ID NOs:30-46.
[0128] In some embodiments, the polypeptide comprises any one of SEQ ID NOs:30-46. In further embodiments, the polypeptide comprises any one of SEQ ID NOs:30-46 without the first three amino acid residues "PCP" at the amino terminus. In further embodiments, the polypeptide can have at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to any one of SEQ ID NOs:30-46 or any one of SEQ ID NOs:30-46 determined without the first three amino acid residues "PCP" at the amino terminus.
[0129] CH2 Transferrin Receptor Binding Polypeptide In some embodiments, the domain to be modified is a human Ig CH2 domain, such as an IgG CH2 domain. The CH2 domain may be from any IgG subtype, i.e., IgG1, IgG2, IgG3, or IgG4. In the context of IgG antibodies, the CH2 domain refers to the segment of amino acids from about 231 to about 340, when numbered according to the EU numbering scheme. Positions within the CH2 domain for purposes of identifying a set of corresponding amino acid positions for transferrin receptor binding are determined relative to SEQ ID NO:2 or relative to amino acids 4-113 of SEQ ID NO:1. Substitutions are also determined relative to SEQ ID NO:1, i.e., an amino acid is considered to be a substitution for the amino acid at the corresponding position in SEQ ID NO:1. SEQ ID NO:1 includes a partial hinge region sequence, PCP, as amino acids 1-3. Although these three residues are not part of the Fc region, the numbering of the positions within the CH2 domain with reference to SEQ ID NO:1 includes these first three amino acids.
[0130] As noted above, the set of residues in a CH2 domain that may be modified in accordance with the present invention are numbered herein with reference to SEQ ID NO:1. For example, any CH2 domain, such as the CH2 domain of an IgG1, IgG2, IgG3, or IgG4, may have a modification (e.g., an amino acid substitution) at one or more of the sets of residues that correspond to the residues at the recited positions in SEQ ID NO:1. An alignment of the amino acid sequence of human IgG1 of SEQ ID NO:1 with human IgG2, IgG3, and IgG4 is shown in Figure 38. The respective positions of the IgG2, IgG3, and IgG4 sequences that correspond to any particular position in SEQ ID NO:1 can be readily determined.
[0131] In one embodiment, the modified CH2 domain polypeptide that specifically binds to the transferrin receptor binds to an epitope within the apical domain of the transferrin receptor. The sequence of the apical domain of the human transferrin receptor is set forth in SEQ ID NO:107, which corresponds to amino acids 198-378 of the uniprotein sequence P02786 of human transferrin receptor 1. The modified CH2 domain polypeptide may bind to the transferrin receptor without blocking or otherwise inhibiting the binding of transferrin to the receptor. In some embodiments, the binding of transferrin to the TfR is not substantially inhibited. In some embodiments, the binding of transferrin to the TfR is inhibited by less than about 50% (e.g., less than about 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%). In some embodiments, binding of transferrin to TfR is inhibited by less than about 20% (e.g., less than about 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1%).
[0132] Transferrin receptor-binding group (iii) of CH2: 47, 49, 56, 58, 59, 60, 61, 62, and 63 In some embodiments, modified CH2 domain polypeptides according to the invention contain at least three or at least four, typically five, six, seven, eight, or nine substitutions at the set of amino acid positions including positions 47, 49, 56, 58, 59, 60, 61, 62, and 63 (set iii). Exemplary substitutions that can be introduced at these positions are shown in Table 1. In some embodiments, modified CH2 domain polypeptides contain Glu at position 60 and / or Trp at position 61. In some embodiments, the modified CH2 domain polypeptide comprises at least one substitution at the following positions: Glu, Gly, Gln, Ser, Ala, Asn, Tyr, or Trp at position 47; Ile, Val, Asp, Glu, Thr, Ala, or Tyr at position 49; Asp, Pro, Met, Leu, Ala, Asn, or Phe at position 56; Arg, Ser, Ala, or Gly at position 58; Tyr, Trp, Arg, or Val at position 59; Glu at position 60; Trp or Tyr at position 61; Gln, Tyr, His, Ile, Phe, Val, or Asp at position 62; or Leu, Trp, Arg, Asn, Tyr, or Val at position 63. In some embodiments, two, three, four, five, six, seven, eight, or all nine of positions 47, 49, 56, 58, 59, 60, 61, 62, and 63 have substitutions as specified in this paragraph. In some embodiments, the modified CH2 domain polypeptide can include conservative substitutions of particular amino acids at one or more of the positions in the above sets, e.g., amino acids in groups based on the same charge, hydrophobicity, side chain ring structure (e.g., aromatic amino acids), or size, and / or polar or nonpolar.
[0133] In some embodiments, the modified CH2 domain polypeptide comprises Glu, Gly, Gln, Ser, Ala, Asn, or Tyr at position 47, He, Val, Asp, Glu, Thr, Ala, or Tyr at position 49, Asp, Pro, Met, Leu, Ala, or Asn at position 56, Arg, Ser, or Ala at position 58, Tyr, Trp, Arg, or Val at position 59, Glu at position 60, Trp at position 61, Gln, Tyr, His, He, Phe, or Val at position 62, and / or Leu, Trp, Arg, Asn, or Tyr at position 63. In some embodiments, the modified CH2 domain polypeptide comprises Arg at position 58, Tyr or Trp at position 59, Glu at position 60, Trp at position 61, and / or Asp or Trp at position 63.
[0134] In some embodiments, a modified CH2 domain polypeptide that specifically binds to a transferrin receptor has at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to amino acids 4-113 of any one of SEQ ID NOs:47-62. In some embodiments, such a modified CH2 domain polypeptide comprises amino acids 47-49 and / or amino acids 56-63 of any one of SEQ ID NOs:47-62.
[0135] In some embodiments, modified CH2 domain polypeptides of the invention have at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to amino acids 4-113 of SEQ ID NO:1, with the proviso that the percent identity does not include the set of positions 47, 49, 56, 58, 59, 60, 61, 62, and 63. In some embodiments, modified CH2 domain polypeptides include amino acids 47-49 and / or amino acids 56-63 set forth in any one of SEQ ID NOs:47-62.
[0136] In some embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:158-171. In other embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:158-171, but with one amino acid substitution in the sequence.
[0137] In some embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:172-186. In other embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:172-186, but with one amino acid substitution or with two amino acid substitutions in the sequence. In other embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:172-186, but with three or four amino acid substitutions in the sequence.
[0138] In further embodiments, the transferrin receptor binding polypeptide comprises amino acids 47-63 of any one of SEQ ID NOs:47-62. In further embodiments, the polypeptide can comprise an amino acid sequence having at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to amino acids 47-63 of any one of SEQ ID NOs:47-63.
[0139] In some embodiments, the polypeptide comprises any one of SEQ ID NOs:47-62. In further embodiments, the polypeptide comprises any one of SEQ ID NOs:47-62 without the first three amino acid residues "PCP" at the amino terminus. In further embodiments, the polypeptide can have at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to any one of SEQ ID NOs:47-62 or any one of SEQ ID NOs:47-62 determined without the first three amino acid residues "PCP" at the amino terminus.
[0140] Transferrin receptor-binding group (iv) of CH2: 39, 40, 41, 42, 43, 44, 68, 70, 71, and 72 In some embodiments, modified CH2 domain polypeptides according to the invention contain at least three or at least four, typically five, six, seven, eight, nine, or ten substitutions at the set of amino acid positions including positions 39, 40, 41, 42, 43, 44, 68, 70, 71, and 72 (set iv). Exemplary substitutions that can be introduced at these positions are shown in Table 2. In some embodiments, modified CH2 domain polypeptides contain Pro at position 43, Glu at position 68, and / or Tyr at position 70. In some embodiments, the modified CH2 domain polypeptide comprises at least one substitution at the following positions: Pro, Phe, Ala, Met, or Asp at position 39; Gln, Pro, Arg, Lys, Ala, Ile, Leu, Glu, Asp, or Tyr at position 40; Thr, Ser, Gly, Met, Val, Phe, Trp, or Leu at position 41; Pro, Val, Ala, Thr, or Asp at position 42; Pro, Val, or Phe at position 43; Trp, Gln, Thr, or Glu at position 44; Glu, Val, Thr, Leu, or Trp at position 68; Tyr, His, Val, or Asp at position 70; Thr, His, Gln, Arg, Asn, or Val at position 71; or Tyr, Asn, Asp, Ser, or Pro at position 72. In some embodiments, two, three, four, five, six, seven, eight, nine, or all ten of positions 39, 40, 41, 42, 43, 44, 68, 70, 71, and 72 have a substitution as specified in this paragraph. In some embodiments, the modified CH2 domain polypeptide can include conservative substitutions of particular amino acids at one or more of the positions in the above sets, e.g., amino acids in groups based on the same charge, hydrophobicity, side chain ring structure (e.g., aromatic amino acids), or size, and / or polar or nonpolar.
[0141] In some embodiments, the modified CH2 domain polypeptide comprises Pro, Phe, or Ala at position 39, Gln, Pro, Arg, Lys, Ala, or Ile at position 40, Thr, Ser, Gly, Met, Val, Phe, or Trp at position 41, Pro, Val, or Ala at position 42, Pro at position 43, Trp or Gln at position 44, Glu at position 68, Tyr at position 70, Thr, His, or Gln at position 71, and / or Tyr, Asn, Asp, or Ser at position 72.
[0142] In some embodiments, the modified CH2 domain polypeptide comprises Met at position 39, Leu or Glu at position 40, Trp at position 41, Pro at position 42, Val at position 43, Thr at position 44, Val or Thr at position 68, His at position 70, His, Arg, or Asn at position 71, and / or Pro at position 72.
[0143] In some embodiments, the modified CH2 domain polypeptide includes Asp at position 39, Asp at position 40, Leu at position 41, Thr at position 42, Phe at position 43, Gln at position 44, Val or Leu at position 68, Val at position 70, Thr at position 71, and / or Pro at position 72.
[0144] In some embodiments, a modified CH2 domain polypeptide that specifically binds to a transferrin receptor has at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to amino acids 4-113 of any one of SEQ ID NOs:63-85. In some embodiments, such a modified CH2 domain polypeptide comprises amino acids 39-44 and / or amino acids 68-72 of any one of SEQ ID NOs:63-85.
[0145] In some embodiments, modified CH2 domain polypeptides of the invention have at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to amino acids 4-113 of SEQ ID NO:1, with the proviso that the percent identity does not include the set of positions 39, 40, 41, 42, 43, 44, 68, 70, 71, and 72. In some embodiments, modified CH2 domain polypeptides include amino acids 39-44 and / or amino acids 68-72 set forth in any one of SEQ ID NOs:63-85.
[0146] In some embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:187-204. In other embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:187-204, but with one or two amino acid substitutions in the sequence. In other embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:187-204, but with three amino acid substitutions in the sequence.
[0147] In some embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:205-215. In other embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:205-215, but with one amino acid substitution or with two amino acid substitutions in the sequence.
[0148] In further embodiments, the transferrin receptor binding polypeptide comprises amino acids 39-72 of any one of SEQ ID NOs:63-85. In further embodiments, the polypeptide comprises an amino acid sequence having at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to amino acids 39-72 of any one of SEQ ID NOs:63-85.
[0149] In some embodiments, the polypeptide comprises any one of SEQ ID NOs:63-85. In further embodiments, the polypeptide comprises any one of SEQ ID NOs:63-85 without the first three amino acid residues "PCP" at the amino terminus. In further embodiments, the polypeptide can have at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to any one of SEQ ID NOs:63-85 or any one of SEQ ID NOs:63-85 determined without the first three amino acid residues "PCP" at the amino terminus.
[0150] Transferrin receptor-binding group of CH2 (v): 41, 42, 43, 44, 45, 65, 66, 67, 69, and 73 In some embodiments, modified CH2 domain polypeptides according to the invention contain at least three or at least four, and typically five, six, seven, eight, nine, or ten substitutions at the set of amino acid positions including positions 41, 42, 43, 44, 45, 65, 66, 67, 69, and 73 (set v). Exemplary substitutions that can be introduced at these positions are shown in Table 3. In some embodiments, the modified CH2 domain polypeptide comprises at least one substitution at the following positions: Val or Asp at position 41, Pro, Met, or Asp at position 42, Pro or Trp at position 43, Arg, Trp, Glu, or Thr at position 44, Met, Tyr, or Trp at position 45, Leu or Trp at position 65, Thr, Val, Ile, or Lys at position 66, Ser, Lys, Ala, or Leu at position 67, His, Leu, or Pro at position 69, or Val or Trp at position 73. In some embodiments, two, three, four, five, six, seven, eight, nine, or all ten of positions 41, 42, 43, 44, 45, 65, 66, 67, 69, and 73 have a substitution as specified in this paragraph. In some embodiments, the modified CH2 domain polypeptide can include conservative substitutions of particular amino acids at one or more of the positions in the above sets, e.g., amino acids in groups based on the same charge, on hydrophobicity, on the ring structure of their side chains (e.g., aromatic amino acids), or on size, and / or whether polar or non-polar.
[0151] In some embodiments, the modified CH2 domain polypeptide contains Val at position 41, Pro at position 42, Pro at position 43, Arg or Trp at position 44, Met at position 45, Leu at position 65, Thr at position 66, Ser at position 67, His at position 69, and / or Val at position 73.
[0152] In some embodiments, the modified CH2 domain polypeptide comprises Asp at position 41, Met or Asp at position 42, Trp at position 43, Glu or Thr at position 44, Tyr or Trp at position 45, Trp at position 65, Val, Ile, or Lys at position 66, Lys, Ala, or Leu at position 67, Leu or Pro at position 69, and / or Trp at position 73.
[0153] In some embodiments, a modified CH2 domain polypeptide that specifically binds to a transferrin receptor has at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to amino acids 4-113 of any one of SEQ ID NOs:86-90. In some embodiments, such a modified CH3 domain polypeptide comprises amino acids 41-45 and / or amino acids 65-73 of any one of SEQ ID NOs:86-90.
[0154] In some embodiments, modified CH2 domain polypeptides of the invention have at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to amino acids 4-113 of SEQ ID NO:1, excluding the set of percent identities: 41, 42, 43, 44, 45, 65, 66, 67, 69, and 73. In some embodiments, modified CH2 domain polypeptides include amino acids 41-45 and / or amino acids 65-73 set forth in any one of SEQ ID NOs:86-90.
[0155] In some embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:216-220. In other embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:216-220, but with one or two amino acid substitutions in the sequence.
[0156] In some embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:221-224. In other embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:221-224, but with one amino acid substitution or with two amino acid substitutions in the sequence. In other embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:221-224, but with three or four amino acid substitutions in the sequence.
[0157] In further embodiments, the transferrin receptor binding polypeptide comprises amino acids 41-73 of any one of SEQ ID NOs:86-90. In further embodiments, the polypeptide can comprise a sequence having at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to amino acids 41-73 of any one of SEQ ID NOs:86-90.
[0158] In some embodiments, the polypeptide comprises any one of SEQ ID NOs:86-90. In further embodiments, the polypeptide comprises any one of SEQ ID NOs:86-90 without the first three amino acid residues "PCP" at the amino terminus. In further embodiments, the polypeptide can have at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to any one of SEQ ID NOs:86-90, or any one of SEQ ID NOs:86-90 determined without the first three amino acid residues "PCP" at the amino terminus.
[0159] CH2, transferrin receptor binding group (vi): 45, 47, 49, 95, 97, 99, 102, 103, and 104 In some embodiments, modified CH2 domain polypeptides according to the invention comprise at least three or at least four, typically five, six, seven, eight, or nine substitutions at the set of amino acid positions comprising positions 45, 47, 49, 95, 97, 99, 102, 103, and 104 (set vi). Exemplary substitutions that can be introduced at these positions are shown in Table 4. In some embodiments, modified CH2 domain polypeptides comprise a Trp at position 103. In some embodiments, the modified CH2 domain polypeptide comprises at least one substitution at the following positions: Trp, Val, Ile, or Ala at position 45; Trp or Gly at position 47; Tyr, Arg, or Glu at position 49; Ser, Arg, or Gln at position 95; Val, Ser, or Phe at position 97; Ile, Ser, or Trp at position 99; Trp, Thr, Ser, Arg, or Asp at position 102; Trp at position 103; and Ser, Lys, Arg, or Val at position 104. In some embodiments, two, three, four, five, six, seven, eight, or all nine of positions 45, 47, 49, 95, 97, 99, 102, 103, and 104 have a substitution as specified in this paragraph. In some embodiments, the modified CH2 domain polypeptide can include conservative substitutions of particular amino acids at one or more of the positions in the above sets, e.g., amino acids in groups based on the same charge, on hydrophobicity, on the ring structure of their side chains (e.g., aromatic amino acids), or on size, and / or whether polar or non-polar.
[0160] In some embodiments, the modified CH2 domain polypeptide comprises two, three, four, five, six, seven, eight, or nine positions selected from the following: Trp, Val, Ile, or Ala at position 45; Trp or Gly at position 47; Tyr, Arg, or Glu at position 49; Ser, Arg, or Gln at position 95; Val, Ser, or Phe at position 97; Ile, Ser, or Trp at position 99; Trp, Thr, Ser, Arg, or Asp at position 102; Trp at position 103; and Ser, Lys, Arg, or Val at position 104.
[0161] In some embodiments, the modified CH2 domain polypeptide comprises Val or Ile at position 45, Gly at position 47, Arg at position 49, Arg at position 95, Ser at position 97, Ser at position 99, Thr, Ser, or Arg at position 102, Trp at position 103, and / or Lys or Arg at position 104.
[0162] In some embodiments, a modified CH2 domain polypeptide that specifically binds to a transferrin receptor has at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to amino acids 4-113 of any one of SEQ ID NOs:91-95. In some embodiments, such a modified CH3 domain polypeptide comprises amino acids 45-49 and / or amino acids 95-104 of any one of SEQ ID NOs:91-95.
[0163] In some embodiments, modified CH2 domain polypeptides of the invention have at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to amino acids 4-113 of SEQ ID NO:1, with the proviso that the percent identity does not include the set of positions 45, 47, 49, 95, 97, 99, 102, 103, and 104. In some embodiments, modified CH2 domain polypeptides include amino acids 45-49 and / or amino acids 95-104 set forth in any one of SEQ ID NOs:91-95.
[0164] In some embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:225-228. In other embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:225-228, but with one or two amino acid substitutions in the sequence.
[0165] In some embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:229-233. In other embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:229-223, but with one amino acid substitution or with two amino acid substitutions in the sequence. In other embodiments, the transferrin receptor binding polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:229-233, but with three, four or five amino acid substitutions in the sequence.
[0166] In further embodiments, the transferrin receptor binding polypeptide comprises amino acids 45-104 of any one of SEQ ID NOs:91-95. In further embodiments, the polypeptide can have a sequence having at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to amino acids 45-104 of any one of SEQ ID NOs:91-95.
[0167] In some embodiments, the polypeptide comprises any one of SEQ ID NOs:91-95. In further embodiments, the polypeptide comprises any one of SEQ ID NOs:91-95 without the first three amino acid residues "PCP" at the amino terminus. In further embodiments, the polypeptide can have at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to any one of SEQ ID NOs:91-95 or any one of SEQ ID NOs:91-95 determined without the first three amino acid residues "PCP" at the amino terminus.
[0168] V. Further Mutations in Fc Regions Containing Modified CH3 or CH2 Domain Polypeptides The Fc polypeptides provided herein that are modified to bind a BBB receptor and initiate transport across the BBB may contain further mutations, e.g., to increase serum stability, modulate effector function, affect glycosylation, reduce immunogenicity in humans, and / or enable knob-and-hole heterodimerization of the Fc polypeptide.
[0169] In some embodiments, modified Fc polypeptides in accordance with the invention have at least about 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% amino acid sequence identity to a corresponding wild-type Fc polypeptide (e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc polypeptide).
[0170] Modified Fc polypeptides according to the invention may have other mutations introduced outside the designated set of amino acids, e.g., to affect glycosylation, to increase serum half-life, or, for the CH3 domain, to allow knob-and-hole heterodimerization of the polypeptides making up the modified CH3 domain. Generally, this method involves introducing a protrusion ("knob") at the interface of a first polypeptide and a corresponding hole ("hole") at the interface of a second polypeptide, such that the protrusion can be positioned within the hole to promote heterodimer formation and prevent homodimer formation. The protrusion is formed by replacing a small amino acid side chain at the interface of the first polypeptide with a larger side chain (e.g., tyrosine or tryptophan). A complementary hole of the same or similar size as the protrusion is formed at the interface of the second polypeptide by replacing the large amino acid side chain with a smaller one (e.g., alanine or threonine). Such further mutations are introduced at locations within the polypeptide that do not negatively affect binding of the modified CH3 or CH2 domain to the transferrin receptor.
[0171] In one exemplary embodiment of a knobs-and-holes approach to dimerization, a first Fc polypeptide subunit to be dimerized has a tryptophan instead of the native threonine at a position corresponding to position 139 of SEQ ID NO:1, and a second Fc polypeptide subunit of the dimer has a valine instead of the native tyrosine at a position corresponding to position 180 of SEQ ID NO:1. The second subunit of the Fc polypeptide may further comprise a substitution of serine for the native threonine at the position corresponding to position 139 of SEQ ID NO:1, and an alanine for the native leucine at the position corresponding to position 141 of SEQ ID NO:1.
[0172] The modified Fc polypeptides described herein can also be engineered to have other modifications for heterodimerization (e.g., electrostatic manipulation of contact residues within the naturally charged CH3-CH3 interface, or hydrophobic patch modifications, etc.).
[0173] In some embodiments, modifications can be introduced to increase serum half-life. For example, in some embodiments, the modified Fc polypeptides described herein comprise a CH2 domain that comprises a Tyr at a position corresponding to position 25 of SEQ ID NO:1, a Thr at a position corresponding to position 27 of SEQ ID NO:1, and a Glu at a position corresponding to position 29 of SEQ ID NO:1. Alternatively, the modified Fc polypeptides described herein may comprise the substitutions M201L and N207S when numbered relative to SEQ ID NO:1. Alternatively, the modified Fc polypeptides described herein may comprise the substitutions N207S or N207A when numbered relative to SEQ ID NO:1.
[0174] Effector functions of Fc In some embodiments, the modified Fc polypeptides described herein have effector function (i.e., their Fc regions have the ability to induce a particular biological function upon binding to an Fc receptor expressed on an effector cell that mediates the effector function). Effector cells include, but are not limited to, monocytes, macrophages, neutrophils, dendritic cells, eosinophils, mast cells, platelets, B cells, large granular lymphocytes, Langerhans cells, natural killer (NK) cells, and cytotoxic T cells.
[0175] Examples of antibody effector functions include, but are not limited to, C1q binding and complement-dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), downregulation of cell surface receptors (e.g., B cell receptors), and B cell activation. Effector functions may vary depending on the antibody class. For example, natural human IgG1 and IgG3 antibodies can induce ADCC and CDC activity upon binding to the appropriate Fc receptor present on immune system cells, and natural human IgG1, IgG2, IgG3, and IgG4 can induce ADCP function upon binding to the appropriate Fc receptor present on immune cells.
[0176] In some embodiments, the modified Fc polypeptides described herein can have additional modifications that reduce effector function. Alternatively, in some embodiments, the modified Fc regions comprising modified CH2 or CH3 domains of the invention can include additional modifications that enhance effector function.
[0177] Exemplary Fc polypeptide mutations that modulate effector function include, but are not limited to, substitutions in the CH2 domain, e.g., at positions corresponding to positions 7 and 8 of SEQ ID NO:1. In some embodiments, the substitutions in the modified CH2 domain include Ala at positions 7 and 8 of SEQ ID NO:1. In some embodiments, the substitutions in the modified CH2 domain include Ala at positions 7 and 8 and Gly at position 102 of SEQ ID NO:1.
[0178] Further Fc polypeptide mutations that modulate effector function include, but are not limited to, one or more substitutions at positions 238, 265, 269, 270, 297, 327, and 329 (which in the EU numbering scheme correspond to positions 11, 38, 42, 43, 70, 100, and 102 when numbered with reference to SEQ ID NO:1). Exemplary substitutions (when numbered according to the EU numbering scheme) include the following: Position 329 can have a mutation in which proline is replaced with glycine or arginine or an amino acid residue of sufficient size to disrupt the Fc / Fcγ receptor interface formed between proline 329 of Fc and tryptophan residues Trp87 and Trp110 of FcγRIII. Further exemplary substitutions include S228P, E233P, L235E, N297A, N297D, and P331S. Multiple substitutions may be present, for example, L234A and L235A in the Fc region of human IgG1, L234A, L235A, and P329G in the Fc region of human IgG1, S228P and L235E in the Fc region of human IgG4, L234A and G237A in the Fc region of human IgG1, L234A, L235A, and G237A in the Fc region of human IgG1, V234A and G237A in the Fc region of human IgG2, L235A, G237A, and E318A in the Fc region of human IgG4, and S228P and L236E in the Fc region of human IgG4. In some embodiments, modified Fc polypeptides of the invention may have one or more amino acid substitutions that modulate ADCC (e.g., substitutions at positions 298, 333, and / or 334 of the Fc region according to the EU numbering scheme).
[0179] In some embodiments, the modified Fc polypeptides described herein may have one or more amino acid substitutions that increase or decrease ADCC, or may have mutations that alter C1q binding and / or CDC.
[0180] Exemplary Fc Polypeptides Containing Additional Mutations The modified Fc polypeptides described herein (e.g., any one of clones CH3C.35.20.1, CH3C.35.23.2, CH3C.35.23.3, CH3C.35.23.4, CH3C.35.21.17.2, CH3C.35.23) may include knob mutations (e.g., T139W when numbered with reference to SEQ ID NO:1), hole mutations (e.g., T139S, L141A, and Y180V when numbered with reference to SEQ ID NO:1), mutations that modulate effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered with reference to SEQ ID NO:1), and / or mutations that enhance serum stability (e.g., (i) the amino acid sequence of SEQ ID NO:1, (ii) the amino acid sequence of SEQ ID NO:1, and (iii) the amino acid sequence of SEQ ID NO:1). The sequence may include additional mutations including (i) M25Y, S27T, and T29E, when numbered with reference to SEQ ID NO:1; or (ii) N207S, with or without M201L, when numbered with reference to SEQ ID NO:1.
[0181] In some embodiments, a modified Fc polypeptide described herein (e.g., any one of clones CH3C.35.20.1, CH3C.35.23.2, CH3C.35.23.3, CH3C.35.23.4, CH3C.35.21.17.2, and CH3C.35.23) can have a knob mutation (e.g., T139W when numbered relative to SEQ ID NO:1) and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of any one of SEQ ID NOs:4-95 and 236-299. In some embodiments, a modified Fc polypeptide having the sequence of any one of SEQ ID NOs:4-95 and 236-299 can be modified to have a knob mutation.
[0182] In some embodiments, the modified Fc polypeptides described herein (e.g., any one of clones CH3C.35.20.1, CH3C.35.23.2, CH3C.35.23.3, CH3C.35.23.4, CH3C.35.21.17.2, and CH3C.35.23) can have a knob mutation (e.g., T139W when numbered relative to SEQ ID NO:1), a mutation that modulates effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of any one of SEQ ID NOs:4-95 and 236-299. In some embodiments, a modified Fc polypeptide having the sequence of any one of SEQ ID NOs: 4-95 and 236-299 can be modified to have a knob mutation and a mutation that modulates effector function.
[0183] In some embodiments, the modified Fc polypeptides described herein (e.g., any one of clones CH3C.35.20.1, CH3C.35.23.2, CH3C.35.23.3, CH3C.35.23.4, CH3C.35.21.17.2, and CH3C.35.23) can have a knob mutation (e.g., T139W when numbered relative to SEQ ID NO:1), a mutation that increases serum stability (e.g., M25Y, S27T, and T29E when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of any one of SEQ ID NOs:4-95 and 236-299. In some embodiments, a modified Fc polypeptide having the sequence of any one of SEQ ID NOs:4-95 and 236-299 can be modified to have a knob mutation and a mutation that increases serum stability.
[0184] In some embodiments, the modified Fc polypeptides described herein (e.g., any one of clones CH3C.35.20.1, CH3C.35.23.2, CH3C.35.23.3, CH3C.35.23.4, CH3C.35.21.17.2, and CH3C.35.23) include a knob mutation (e.g., T139W when numbered with reference to SEQ ID NO:1), a mutation that modulates effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered with reference to SEQ ID NO:1), a mutation that enhances serum stability (e.g., M25Y, S27T, and T29E when numbered with reference to SEQ ID NO:1), and a mutation that modulates effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered with reference to SEQ ID NO:1). The modified Fc polypeptide may have at least 85% identity, at least 90% identity, or at least 95% identity to any one of SEQ ID NOs: 4-95 and 236-299. In some embodiments, a modified Fc polypeptide having the sequence of any one of SEQ ID NOs: 4-95 and 236-299 may be modified to have knob mutations, mutations that modulate effector function, and mutations that increase serum stability.
[0185] In some embodiments, a modified Fc polypeptide described herein (e.g., any one of clones CH3C.35.20.1, CH3C.35.23.2, CH3C.35.23.3, CH3C.35.23.4, CH3C.35.21.17.2, and CH3C.35.23) can have a hole mutation (e.g., T139S, L141A, and Y180V, when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of any one of SEQ ID NOs: 4-95 and 236-299. In some embodiments, a modified Fc polypeptide having the sequence of any one of SEQ ID NOs: 4-95 and 236-299 can be modified to have a hole mutation.
[0186] In some embodiments, the modified Fc polypeptides described herein (e.g., any one of clones CH3C.35.20.1, CH3C.35.23.2, CH3C.35.23.3, CH3C.35.23.4, CH3C.35.21.17.2 and CH3C.35.23) can have a whole mutation (e.g., T139S, L141A, and Y180V when numbered relative to SEQ ID NO:1), a mutation that modulates effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of any one of SEQ ID NOs:4-95 and 236-299. In some embodiments, a modified Fc polypeptide having the sequence of any one of SEQ ID NOs: 4-95 and 236-299 can be modified to have a hole mutation and a mutation that modulates effector function.
[0187] In some embodiments, the modified Fc polypeptides described herein (e.g., any one of clones CH3C.35.20.1, CH3C.35.23.2, CH3C.35.23.3, CH3C.35.23.4, CH3C.35.21.17.2, and CH3C.35.23) can have whole mutations (e.g., T139S, L141A, and Y180V, when numbered relative to SEQ ID NO:1), mutations that increase serum stability (e.g., M25Y, S27T, and T29E, when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to any one of SEQ ID NOs:4-95 and 236-299. In some embodiments, a modified Fc polypeptide having any one of SEQ ID NOs: 4-95 and 236-299 can be modified to have a whole mutation and a mutation that increases serum stability.
[0188] In some embodiments, the modified Fc polypeptides described herein (e.g., any one of clones CH3C.35.20.1, CH3C.35.23.2, CH3C.35.23.3, CH3C.35.23.4, CH3C.35.21.17.2, and CH3C.35.23) include any one of the following mutations: hole mutations (e.g., T139S, L141A, and Y180V when numbered with reference to SEQ ID NO:1), mutations that modulate effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered with reference to SEQ ID NO:1), mutations that enhance serum stability (e.g., M25Y, S27T, and T29E when numbered with reference to SEQ ID NO:1), and mutations that enhance serologic stability (e.g., M25Y, S27T, and T29E when numbered with reference to SEQ ID NO:1). The modified Fc polypeptide may have at least 85% identity, at least 90% identity, or at least 95% identity to any one of SEQ ID NOs: 4-95 and 236-299. In some embodiments, a modified Fc polypeptide having any one of SEQ ID NOs: 4-95 and 236-299 may be modified to have a hole mutation, a mutation that modulates effector function, and a mutation that increases serum stability.
[0189] Clone CH3C.35.20.1 In some embodiments, clone CH3C.35.20.1 can have a knob mutation (e.g., T139W when numbered relative to SEQ ID NO:1) and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:349. In some embodiments, clone CH3C.35.20.1 with the knob mutation has the sequence of SEQ ID NO:349.
[0190] In some embodiments, clone CH3C.35.20.1 can have a knob mutation (e.g., T139W when numbered relative to SEQ ID NO:1), a mutation that modulates effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:350 or 351. In some embodiments, clone CH3C.35.20.1 having a knob mutation and a mutation that modulates effector function has the sequence of SEQ ID NO:350 or 351.
[0191] In some embodiments, clone CH3C.35.20.1 can have a knob mutation (e.g., T139W when numbered with respect to SEQ ID NO:1), a serum stability enhancing mutation (e.g., M25Y, S27T, and T29E when numbered with respect to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:352. In some embodiments, clone CH3C.35.20.1 with the knob mutation and the serum stability enhancing mutation has the sequence of SEQ ID NO:352.
[0192] In some embodiments, clone CH3C.35.20.1 can have a knob mutation (e.g., T139W when numbered with respect to SEQ ID NO:1), a mutation that modulates effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered with respect to SEQ ID NO:1), a mutation that enhances serum stability (e.g., M25Y, S27T, and T29E when numbered with respect to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:353 or 354. In some embodiments, clone CH3C.35.20.1 with knob mutations, mutations that modulate effector function, and mutations that enhance serum stability has the sequence of SEQ ID NO:353 or 354.
[0193] In some embodiments, clone CH3C.35.20.1 can have hole mutations (e.g., T139S, L141A, and Y180V when numbered relative to SEQ ID NO:1) and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:355. In some embodiments, clone CH3C.35.20.1 with hole mutations has the sequence of SEQ ID NO:355.
[0194] In some embodiments, clone CH3C.35.20.1 can have hole mutations (e.g., T139S, L141A, and Y180V when numbered relative to SEQ ID NO:1), mutations that modulate effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:356 or 357. In some embodiments, clone CH3C.35.20.1 with hole mutations and mutations that modulate effector function has the sequence of SEQ ID NO:356 or 357.
[0195] In some embodiments, clone CH3C.35.20.1 can have whole mutations (e.g., T139S, L141A, and Y180V when numbered relative to SEQ ID NO:1), mutations that increase serum stability (e.g., M25Y, S27T, and T29E when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:358. In some embodiments, clone CH3C.35.20.1 with whole mutations and mutations that increase serum stability has the sequence of SEQ ID NO:358.
[0196] In some embodiments, clone CH3C.35.20.1 can have whole mutations (e.g., T139S, L141A, and Y180V when numbered with respect to SEQ ID NO:1), mutations that modulate effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered with respect to SEQ ID NO:1), mutations that increase serum stability (e.g., M25Y, S27T, and T29E when numbered with respect to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:359 or 360. In some embodiments, clone CH3C.35.20.1 with whole mutations, mutations that modulate effector function, and mutations that increase serum stability has the sequence of SEQ ID NO:359 or 360.
[0197] Clone CH3C.35.23.2 In some embodiments, clone CH3C.35.23.2 can have a knob mutation (e.g., T139W when numbered relative to SEQ ID NO:1) and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:361. In some embodiments, clone CH3C.35.23.2 with the knob mutation has the sequence of SEQ ID NO:361.
[0198] In some embodiments, clone CH3C.35.23.2 can have a knob mutation (e.g., T139W when numbered relative to SEQ ID NO:1), a mutation that modulates effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:362 or 363. In some embodiments, clone CH3C.35.23.2 with a knob mutation and a mutation that modulates effector function has the sequence of SEQ ID NO:362 or 363.
[0199] In some embodiments, clone CH3C.35.23.2 can have a knob mutation (e.g., T139W when numbered relative to SEQ ID NO:1), a serum stability enhancing mutation (e.g., M25Y, S27T, and T29E when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:364. In some embodiments, clone CH3C.35.23.2 with the knob mutation and the serum stability enhancing mutation has the sequence of SEQ ID NO:364.
[0200] In some embodiments, clone CH3C.35.23.2 can have a knob mutation (e.g., T139W when numbered with respect to SEQ ID NO:1), a mutation that modulates effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered with respect to SEQ ID NO:1), a mutation that enhances serum stability (e.g., M25Y, S27T, and T29E when numbered with respect to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:365 or 366. In some embodiments, clone CH3C.35.23.2 with knob mutations, mutations that modulate effector function, and mutations that enhance serum stability has the sequence of SEQ ID NO:365 or 366.
[0201] In some embodiments, clone CH3C.35.23.2 can have hole mutations (e.g., T139S, L141A, and Y180V when numbered relative to SEQ ID NO:1) and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:367. In some embodiments, clone CH3C.35.23.2 with hole mutations has the sequence of SEQ ID NO:367.
[0202] In some embodiments, clone CH3C.35.23.2 can have hole mutations (e.g., T139S, L141A, and Y180V when numbered relative to SEQ ID NO:1), mutations that modulate effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:368 or 369. In some embodiments, clone CH3C.35.23.2 with hole mutations and mutations that modulate effector function has the sequence of SEQ ID NO:368 or 369.
[0203] In some embodiments, clone CH3C.35.23.2 can have whole mutations (e.g., T139S, L141A, and Y180V when numbered relative to SEQ ID NO:1), mutations that increase serum stability (e.g., M25Y, S27T, and T29E when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:370. In some embodiments, clone CH3C.35.23.2 with whole mutations and mutations that increase serum stability has the sequence of SEQ ID NO:370.
[0204] In some embodiments, clone CH3C.35.23.2 can have whole mutations (e.g., T139S, L141A, and Y180V when numbered with respect to SEQ ID NO:1), mutations that modulate effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered with respect to SEQ ID NO:1), mutations that increase serum stability (e.g., M25Y, S27T, and T29E when numbered with respect to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:371 or 372. In some embodiments, clone CH3C.35.23.2 with whole mutations, mutations that modulate effector function, and mutations that increase serum stability has the sequence of SEQ ID NO:371 or 372.
[0205] Clone CH3C.35.23.3 In some embodiments, clone CH3C.35.23.3 can have a knob mutation (e.g., T139W when numbered relative to SEQ ID NO:1) and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:373. In some embodiments, clone CH3C.35.23.3 with the knob mutation has the sequence of SEQ ID NO:373.
[0206] In some embodiments, clone CH3C.35.23.3 can have a knob mutation (e.g., T139W when numbered relative to SEQ ID NO:1), a mutation that modulates effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:374 or 375. In some embodiments, clone CH3C.35.23.3 with a knob mutation and a mutation that modulates effector function has the sequence of SEQ ID NO:374 or 375.
[0207] In some embodiments, clone CH3C.35.23.3 can have a knob mutation (e.g., T139W when numbered relative to SEQ ID NO:1), a serum stability enhancing mutation (e.g., M25Y, S27T, and T29E when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:376. In some embodiments, clone CH3C.35.23.3 with the knob mutation and the serum stability enhancing mutation has the sequence of SEQ ID NO:376.
[0208] In some embodiments, clone CH3C.35.23.3 can have a knob mutation (e.g., T139W when numbered with respect to SEQ ID NO:1), a mutation that modulates effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered with respect to SEQ ID NO:1), a mutation that enhances serum stability (e.g., M25Y, S27T, and T29E when numbered with respect to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:377 or 378. In some embodiments, clone CH3C.35.23.3 with knob mutations, mutations that modulate effector function, and mutations that enhance serum stability has the sequence of SEQ ID NO:377 or 378.
[0209] In some embodiments, clone CH3C.35.23.3 can have hole mutations (e.g., T139S, L141A, and Y180V when numbered relative to SEQ ID NO:1) and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:379. In some embodiments, clone CH3C.35.23.3 with hole mutations has the sequence of SEQ ID NO:379.
[0210] In some embodiments, clone CH3C.35.23.3 can have hole mutations (e.g., T139S, L141A, and Y180V when numbered relative to SEQ ID NO:1), mutations that modulate effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:380 or 381. In some embodiments, clone CH3C.35.23.3 with hole mutations and mutations that modulate effector function has the sequence of SEQ ID NO:380 or 381.
[0211] In some embodiments, clone CH3C.35.23.3 can have whole mutations (e.g., T139S, L141A, and Y180V when numbered relative to SEQ ID NO:1), serum stability enhancing mutations (e.g., M25Y, S27T, and T29E when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:382. In some embodiments, clone CH3C.35.23.3 with whole mutations and serum stability enhancing mutations has the sequence of SEQ ID NO:382.
[0212] In some embodiments, clone CH3C.35.23.3 can have whole mutations (e.g., T139S, L141A, and Y180V when numbered with respect to SEQ ID NO:1), mutations that modulate effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered with respect to SEQ ID NO:1), mutations that increase serum stability (e.g., M25Y, S27T, and T29E when numbered with respect to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:383 or 384. In some embodiments, clone CH3C.35.23.3 with whole mutations, mutations that modulate effector function, and mutations that increase serum stability has the sequence of SEQ ID NO:383 or 384.
[0213] Clone CH3C.35.23.4 In some embodiments, clone CH3C.35.23.4 can have a knob mutation (e.g., T139W when numbered relative to SEQ ID NO:1) and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:385. In some embodiments, clone CH3C.35.23.4 with the knob mutation has the sequence of SEQ ID NO:385.
[0214] In some embodiments, clone CH3C.35.23.4 can have a knob mutation (e.g., T139W when numbered relative to SEQ ID NO:1), a mutation that modulates effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:386 or 387. In some embodiments, clone CH3C.35.23.4 with a knob mutation and a mutation that modulates effector function has the sequence of SEQ ID NO:386 or 387.
[0215] In some embodiments, clone CH3C.35.23.4 can have a knob mutation (e.g., T139W when numbered relative to SEQ ID NO:1), a serum stability enhancing mutation (e.g., M25Y, S27T, and T29E when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:388. In some embodiments, clone CH3C.35.23.4 with the knob mutation and the serum stability enhancing mutation has the sequence of SEQ ID NO:388.
[0216] In some embodiments, clone CH3C.35.23.4 can have a knob mutation (e.g., T139W when numbered with respect to SEQ ID NO:1), a mutation that modulates effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered with respect to SEQ ID NO:1), a mutation that enhances serum stability (e.g., M25Y, S27T, and T29E when numbered with respect to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:389 or 390. In some embodiments, clone CH3C.35.23.4 with knob mutations, mutations that modulate effector function, and mutations that enhance serum stability has the sequence of SEQ ID NO:389 or 390.
[0217] In some embodiments, clone CH3C.35.23.4 can have hole mutations (e.g., T139S, L141A, and Y180V when numbered relative to SEQ ID NO:1) and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:391. In some embodiments, clone CH3C.35.23.4 with hole mutations has the sequence of SEQ ID NO:391.
[0218] In some embodiments, clone CH3C.35.23.4 can have hole mutations (e.g., T139S, L141A, and Y180V when numbered relative to SEQ ID NO:1), mutations that modulate effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:392 or 393. In some embodiments, clone CH3C.35.23.4 with hole mutations and mutations that modulate effector function has the sequence of SEQ ID NO:392 or 393.
[0219] In some embodiments, clone CH3C.35.23.4 can have whole mutations (e.g., T139S, L141A, and Y180V when numbered relative to SEQ ID NO:1), mutations that increase serum stability (e.g., M25Y, S27T, and T29E when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:394. In some embodiments, clone CH3C.35.23.4 with whole mutations and mutations that increase serum stability has the sequence of SEQ ID NO:394.
[0220] In some embodiments, clone CH3C.35.23.4 can have whole mutations (e.g., T139S, L141A, and Y180V when numbered with respect to SEQ ID NO:1), mutations that modulate effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered with respect to SEQ ID NO:1), mutations that increase serum stability (e.g., M25Y, S27T, and T29E when numbered with respect to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:395 or 396. In some embodiments, clone CH3C.35.23.4 with whole mutations, mutations that modulate effector function, and mutations that increase serum stability has the sequence of SEQ ID NO:395 or 396.
[0221] Clone CH3C.35.21.17.2 In some embodiments, clone CH3C.35.21.17.2 can have a knob mutation (e.g., T139W when numbered relative to SEQ ID NO:1) and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:397. In some embodiments, clone CH3C.35.21.17.2 with the knob mutation has the sequence of SEQ ID NO:397.
[0222] In some embodiments, clone CH3C.35.21.17.2 can have a knob mutation (e.g., T139W when numbered relative to SEQ ID NO:1), a mutation that modulates effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:398 or 399. In some embodiments, clone CH3C.35.21.17.2 with a knob mutation and a mutation that modulates effector function has the sequence of SEQ ID NO:398 or 399.
[0223] In some embodiments, clone CH3C.35.21.17.2 can have a knob mutation (e.g., T139W when numbered relative to SEQ ID NO:1), a serum stability enhancing mutation (e.g., M25Y, S27T, and T29E when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:400. In some embodiments, clone CH3C.35.21.17.2 with the knob mutation and the serum stability enhancing mutation has the sequence of SEQ ID NO:400.
[0224] In some embodiments, clone CH3C.35.21.17.2 can have a knob mutation (e.g., T139W when numbered with respect to SEQ ID NO:1), a mutation that modulates effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered with respect to SEQ ID NO:1), a mutation that enhances serum stability (e.g., M25Y, S27T, and T29E when numbered with respect to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:401 or 402. In some embodiments, clone CH3C.35.21.17.2 with knob mutations, mutations that modulate effector function, and mutations that enhance serum stability has the sequence of SEQ ID NO:401 or 402.
[0225] In some embodiments, clone CH3C.35.21.17.2 can have hole mutations (e.g., T139S, L141A, and Y180V when numbered relative to SEQ ID NO:1) and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:403. In some embodiments, clone CH3C.35.21.17.2 with hole mutations has the sequence of SEQ ID NO:403.
[0226] In some embodiments, clone CH3C.35.21.17.2 can have hole mutations (e.g., T139S, L141A, and Y180V when numbered relative to SEQ ID NO:1), mutations that modulate effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:404 or 405. In some embodiments, clone CH3C.35.21.17.2 with hole mutations and mutations that modulate effector function has the sequence of SEQ ID NO:404 or 405.
[0227] In some embodiments, clone CH3C.35.21.17.2 can have whole mutations (e.g., T139S, L141A, and Y180V when numbered relative to SEQ ID NO:1), mutations that increase serum stability (e.g., M25Y, S27T, and T29E when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:406. In some embodiments, clone CH3C.35.21.17.2 with whole mutations and mutations that increase serum stability has the sequence of SEQ ID NO:406.
[0228] In some embodiments, clone CH3C.35.21.17.2 can have whole mutations (e.g., T139S, L141A, and Y180V when numbered with respect to SEQ ID NO:1), mutations that modulate effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered with respect to SEQ ID NO:1), mutations that increase serum stability (e.g., M25Y, S27T, and T29E when numbered with respect to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:407 or 408. In some embodiments, clone CH3C.35.21.17.2 with whole mutations, mutations that modulate effector function, and mutations that increase serum stability has the sequence of SEQ ID NO:407 or 408.
[0229] Clone CH3C.35.23 In some embodiments, clone CH3C.35.23 can have a knob mutation (e.g., T139W when numbered relative to SEQ ID NO:1) and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:409. In some embodiments, clone CH3C.35.23 with the knob mutation has the sequence of SEQ ID NO:409.
[0230] In some embodiments, clone CH3C.35.23 can have a knob mutation (e.g., T139W when numbered relative to SEQ ID NO:1), a mutation that modulates effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:410 or 411. In some embodiments, clone CH3C.35.23 with a knob mutation and a mutation that modulates effector function has the sequence of SEQ ID NO:410 or 411.
[0231] In some embodiments, clone CH3C.35.23 can have a knob mutation (e.g., T139W when numbered relative to SEQ ID NO:1), a serum stability enhancing mutation (e.g., M25Y, S27T, and T29E when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:412. In some embodiments, clone CH3C.35.23 with the knob mutation and the serum stability enhancing mutation has the sequence of SEQ ID NO:412.
[0232] In some embodiments, clone CH3C.35.23 can have a knob mutation (e.g., T139W when numbered with respect to SEQ ID NO:1), a mutation that modulates effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered with respect to SEQ ID NO:1), a mutation that enhances serum stability (e.g., M25Y, S27T, and T29E when numbered with respect to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:413 or 414. In some embodiments, clone CH3C.35.23 with knob mutations, mutations that modulate effector function, and mutations that enhance serum stability has the sequence of SEQ ID NO:413 or 414.
[0233] In some embodiments, clone CH3C.35.23 can have hole mutations (e.g., T139S, L141A, and Y180V when numbered relative to SEQ ID NO:1) and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:415. In some embodiments, clone CH3C.35.23 with hole mutations has the sequence of SEQ ID NO:415.
[0234] In some embodiments, clone CH3C.35.23 can have hole mutations (e.g., T139S, L141A, and Y180V when numbered relative to SEQ ID NO:1), mutations that modulate effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:416 or 417. In some embodiments, clone CH3C.35.23 with hole mutations and mutations that modulate effector function has the sequence of SEQ ID NO:416 or 417.
[0235] In some embodiments, clone CH3C.35.23 can have whole mutations (e.g., T139S, L141A, and Y180V when numbered relative to SEQ ID NO:1), mutations that increase serum stability (e.g., M25Y, S27T, and T29E when numbered relative to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:418. In some embodiments, clone CH3C.35.23 with whole mutations and mutations that increase serum stability has the sequence of SEQ ID NO:418.
[0236] In some embodiments, clone CH3C.35.23 can have whole mutations (e.g., T139S, L141A, and Y180V when numbered with respect to SEQ ID NO:1), mutations that modulate effector function (e.g., L7A, L8A, and / or P102G (e.g., L7A and L8A) when numbered with respect to SEQ ID NO:1), mutations that increase serum stability (e.g., M25Y, S27T, and T29E when numbered with respect to SEQ ID NO:1), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of SEQ ID NO:419 or 420. In some embodiments, clone CH3C.35.23 with whole mutations, mutations that modulate effector function, and mutations that increase serum stability has the sequence of SEQ ID NO:419 or 420.
[0237] VI. BBB Receptor Binding Protein Formats In some embodiments, the modified BBB receptor binding polypeptides of the invention comprising a modified Fc polypeptide and an FcRn binding site as described herein are subunits of a protein dimer. In some embodiments, the dimer is a heterodimer. In some embodiments, the dimer is a homodimer. In some embodiments, the dimer comprises one Fc polypeptide that binds to a BBB receptor (i.e., is monovalent for binding to the BBB receptor). In some embodiments, the dimer comprises a second polypeptide that binds to a BBB receptor. The second polypeptide may comprise the same modified Fc polypeptide to provide a bivalent homodimeric protein, or a second modified Fc polypeptide of the invention may provide a second BBB receptor binding site.
[0238] The BBB receptor binding polypeptides of the present invention and dimeric or multimeric proteins comprising the polypeptides can have a wide range of binding affinities, for example, based on the format of the polypeptide. For example, in some embodiments, polypeptides comprising the modified Fc polypeptides described herein have affinities for BBB receptors ranging from 1 pM to 10 μM. In some embodiments, the affinity can be measured in a monovalent format. In other embodiments, the affinity can be measured in a bivalent format, for example, as a protein dimer comprising the modified Fc polypeptide.
[0239] Methods for analyzing binding affinity, binding kinetics, and cross-reactivity to analyze binding to BBB receptors are well known in the art. These methods include, but are not limited to, solid-phase binding assays (e.g., ELISA assays), immunoprecipitation, surface plasmon resonance (e.g., Biacore™ (GE Healthcare, Piscataway, NJ)), kinetic exclusion assays (e.g., KinExA®), flow cytometry, fluorescence-activated cell sorting (FACS), biolayer interferometry (e.g., Octet® (ForteBio, Inc., Menlo Park, CA)), and Western blot analysis. In some embodiments, ELISA is used to examine binding affinity and / or cross-reactivity. Methods for performing ELISA assays are well known in the art and are also described in the Examples section below. In some embodiments, surface plasmon resonance (SPR) is used to examine binding affinity, binding kinetics, and / or cross-reactivity. In some embodiments, kinetic exclusion assays are used to determine binding affinity, binding kinetics, and / or cross-reactivity. In some embodiments, biolayer interferometry is used to determine binding affinity, binding kinetics, and / or cross-reactivity. FcRn binding of BBB receptor binding polypeptides can also be assessed using these types of assays. FcRn binding is usually assayed under acidic conditions, for example, at a pH of about 5 to about 6.
[0240] VII. BBB Receptor Binding Protein Conjugates In some embodiments, the modified polypeptide that binds to a receptor of the BBB to initiate transport across the BBB comprises a modified Fc polypeptide as described herein and further comprises a partial or complete hinge region. The hinge region may be from any immunoglobulin subclass or isotype. An exemplary immunoglobulin hinge is an IgG hinge region, such as an IgG1 hinge region (e.g., the amino acid sequence of the human IgG1 hinge EPKSCDKTHTCPPCP (SEQ ID NO:234)). In further embodiments, the polypeptide that may include a hinge or partial hinge region is further linked to another moiety, such as an immunoglobulin variable region, to create a BBB receptor binding polypeptide-variable region fusion polypeptide. The variable region may bind to any antigen of interest, such as a therapeutic neurological target or a diagnostic neurological target.
[0241] In some embodiments, the BBB receptor binding polypeptide (e.g., modified Fc polypeptide) is linked to the variable region via a linker. As indicated in the paragraph above, the BBB receptor binding polypeptide (e.g., modified Fc polypeptide) can be linked to the variable region by a hinge region. In some embodiments, the BBB receptor binding polypeptide (e.g., modified Fc polypeptide) can be linked to the variable region by a peptide linker. The peptide linker can be configured to allow rotation of the variable region and the BBB receptor binding polypeptide relative to each other and / or is resistant to digestion by proteases. In some embodiments, the linker can be a flexible linker, for example, including amino acids such as Gly, Asn, Ser, Thr, Ala, etc. Such linkers can be designed using well-known parameters. For example, the linker can have a repeating sequence such as a Gly-Ser repeat.
[0242] The variable region can be in any antibody format, such as Fab or svFv format, in some embodiments, the antibody variable region sequence comprises two antibody variable region heavy chains and two antibody variable region light chains, or fragments of each thereof.
[0243] In some embodiments, the variable region linked to the BBB receptor binding polypeptide (e.g., modified Fc polypeptide) is capable of binding to a tau protein (e.g., human tau protein) or a fragment thereof. In some embodiments, the variable region is capable of binding to phosphorylated tau protein, non-phosphorylated tau protein, a splice isoform of tau protein, an N-terminally truncated tau protein, a C-terminally truncated tau protein, and / or fragments thereof.
[0244] In some embodiments, the variable region linked to the BBB receptor binding polypeptide (e.g., modified Fc polypeptide) can bind to a beta-secretase 1 (BACE1) protein (e.g., a human BACE1 protein) or a fragment thereof. In some embodiments, the variable region can bind to one or more splice isoforms of the BACE1 protein or a fragment thereof.
[0245] In some embodiments, the variable region linked to the BBB receptor binding polypeptide (e.g., a modified Fc polypeptide) is capable of binding to a triggering receptor 2 (TREM2) protein expressed on myeloid cells (e.g., a human TREM2 protein) or a fragment thereof.
[0246] In some embodiments, the variable region linked to a BBB receptor binding polypeptide (e.g., a modified Fc polypeptide) is capable of binding to an alpha-synuclein protein (e.g., a human alpha-synuclein protein) or a fragment thereof. In some embodiments, the variable region is capable of binding to monomeric alpha-synuclein, oligomeric alpha-synuclein, alpha-synuclein fibrils, soluble alpha-synuclein, and / or fragments thereof.
[0247] BBB receptor binding polypeptides (e.g., modified Fc polypeptides) can also be linked to polypeptides other than immunoglobulin variable regions that target an antigen of interest. In some embodiments, such polypeptides are linked to the BBB receptor binding polypeptide using a peptide linker, such as the flexible linkers described above.
[0248] In some embodiments, the BBB receptor binding polypeptide may be linked to a polypeptide, e.g., a therapeutic polypeptide, that is desirable for targeting cells expressing the BBB receptor binding polypeptide. In some embodiments, the BBB receptor polypeptide is linked to a polypeptide having biological activity for transport across the BBB, e.g., a soluble protein, e.g., the extracellular domain of a receptor or a growth factor, cytokine, or enzyme.
[0249] In yet other embodiments, the BBB receptor binding polypeptide can be linked to a peptide or protein useful for protein purification, such as polyhistidine, epitope tags such as FLAG, c-Myc, hemagglutinin tags, glutathione S-transferase (GST), thioredoxin, protein A, protein G, or maltose binding protein (MBP). Optionally, the peptide or protein fused to the BBB binding polypeptide can contain a protease cleavage site, such as a cleavage site for factor Xa or thrombin. In certain embodiments, the linkage is cleavable by an enzyme present in the central nervous system.
[0250] Substances other than polypeptides can also be linked to BBB receptor binding polypeptides.Such substances include cytotoxic agents, imaging agents, DNA or RNA molecules, or compounds.In some embodiments, the substance is a therapeutic or imaging compound.In some embodiments, the substance is a small molecule, for example, less than 1000 Da, less than 750 Da, or less than 500 Da.
[0251] The substance, whether polypeptide or non-polypeptide, may be linked to the N-terminal or C-terminal region of the BBB receptor binding polypeptide, or may be attached to any region of the polypeptide, so long as the substance does not interfere with binding of the BBB receptor binding polypeptide to the BBB receptor and the FcRn receptor.
[0252] In different embodiments, conjugates can be made using well-known chemical cross-linking reagents and protocols. For example, there are many chemical cross-linking agents that are known to those skilled in the art and are useful for cross-linking polypeptides with agents of interest. For example, cross-linking agents are heterobifunctional cross-linking agents that can be used to link molecules stepwise. Heterobifunctional cross-linking agents allow the design of more specific linking methods for protein binding, thereby reducing the occurrence of unwanted side reactions such as homoprotein polymers. A wide variety of heterobifunctional crosslinkers are known in the art, including N-hydroxysuccinimide (NHS) or its water-soluble analog N-hydroxysulfosuccinimide (sulfo-NHS), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), N-succinimidyl (4-iodoacetyl)aminobenzoate (SIAB), succinimidyl 4-(p-maleimidophenyl)butyrate (SMPB), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), 4-succinimidyloxycarbonyl-a-methyl-a-(2-pyridyldithio)-toluene (SMPT), N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP), and succinimidyl Examples of crosslinkers include 6-[3-(2-pyridyldithio)propionate]hexanoate (LC-SPDP). These crosslinkers with an N-hydroxysuccinimide moiety can be obtained as N-hydroxysulfosuccinimide analogs, which generally have higher water solubility. Additionally, these crosslinkers with disulfide bridges in the linking chain can be synthesized as alkyl derivatives instead, which can reduce the amount of linker cleavage in vivo. In addition to heterobifunctional crosslinkers, many other crosslinkers exist, including homobifunctional and photoreactive crosslinkers.Disuccinimidyl suberate (DSS), bismaleimidohexane (BMH), and dimethyl pimelimidate dihydrochloride (DMP) are examples of useful homobifunctional crosslinkers, and bis-[B-(4-azidosalicylamido)ethyl]disulfide (BASED) and N-succinimidyl-6(4'-azido-2'-nitrophenylamino)hexanoate (SANPAH) are examples of useful photoreactive crosslinkers.
[0253] The agent of interest may be a therapeutic agent, such as a cytotoxic agent, or that includes a chemical moiety, hi some embodiments, the agent may be a peptide or small molecule therapeutic or imaging agent.
[0254] VIII. Methods of Engineering Fc Polypeptides to Bind to BBB Receptors Overview of operation In a further aspect, methods are provided for engineering an Fc polypeptide to have binding specificity for a BBB receptor, in some embodiments, modifying the Fc polypeptide comprises substituting various amino acids of a set of solvent-exposed amino acid residues, e.g., set (i) and / or set (ii) as described herein.
[0255] In some embodiments, the method comprises modifying a polynucleotide encoding an Fc polypeptide to have amino acid changes at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or all positions of a set of solvent-exposed surface amino acids. In some embodiments, the method comprises modifying a polynucleotide encoding an Fc polypeptide to have amino acid changes at a desired number of positions of two or more sets of amino acids. The amino acids introduced at the desired positions can be generated by randomization or partial randomization to create a library of Fc polypeptides with amino acid substitutions at various positions of a set. In some embodiments, the Fc polypeptide can include a portion of, or the entire, complete hinge region.
[0256] Polypeptides, including mutant Fc polypeptides, can be expressed using any number of systems. For example, in some embodiments, mutant polypeptides can be expressed in a display system, e.g., a viral display system, a cell surface display system, e.g., a yeast display system, an mRNA display system, or a polysome display system. In other exemplary embodiments, mutant polypeptides are expressed as soluble polypeptides secreted from the host cell. The library can be screened using well-known methods to identify polypeptides that bind to the BBB receptor of interest, and further characterized to determine binding kinetics. Further mutations can then be introduced into selected clones, either at each position of the initial set of amino acids, or at other positions outside the set, e.g., solvent-exposed amino acids near the paratope.
[0257] Exemplary embodiments of the method of operation A DNA template sequence can be generated that has a wild-type Fc polypeptide, or a fragment thereof, such as a CH2 or CH3 domain. In some embodiments, the mutated template sequence further encodes an antibody variable region. In some embodiments, the template sequence encodes an Fc polypeptide that is mutated at a desired position and expressed without an antibody variable region.
[0258] The expression system can be any system that can be used to screen mutant polypeptides for binding to the BBB receptor of interest. In some embodiments, the template sequence is made in a phagemid vector. In certain embodiments, the template sequence is genetically fused to the pIII coat protein of a phage.
[0259] In some embodiments, the mutated Fc polypeptide is produced in a yeast display vector.For example, the template sequence can be fused to yeast cell wall protein Aga2p, for example, to the N-terminus or C-terminus of Aga2p.The yeast strain can be capable of inducible expression of Aga2p coat protein, for example, the yeast strain can be EBY100.
[0260] In some embodiments, random mutagenesis methods, such as error-prone PCR, are used to introduce mutations at desired amino acid positions.
[0261] After mutagenesis, the mutated nucleic acid is introduced into a display system of interest, expressed, and screened for binding to the BBB receptor of interest. Any number of screening methods can be used. In an exemplary embodiment, the expressed protein is screened using ELISA.
[0262] Further rounds of mutations can be performed on selected Fc polypeptides that bind to the BBB receptor of interest to introduce further mutations at desired sets of amino acids, or at positions outside the designated positions for a particular set. In some embodiments, further mutations are introduced using "NNK" randomization. NNK randomization uses primers that contain degenerate NNK tricodons, where N stands for "A, C, G, or T" and K stands for "G or T". For example, NNK randomization mixes trinucleotides in a specific ratio to obtain a predefined mixture of specific amino acids (e.g., 70% wild type), or mixes trinucleotides with or without bias for specific amino acids. Libraries are generated by PCR amplification of fragments of the Fc region corresponding to the regions of randomization, followed by assembly with end primers for ligation into a vector, such as a phagemid vector. Alternatively, Kunkel mutagenesis or other mutagenesis methods can be used to introduce further mutations to introduce diversity at desired positions.
[0263] The binding properties of the mutated Fc polypeptides can be assessed using various assays, for example, binding affinity and / or cross-reactivity can be examined by ELISA, surface plasmon resonance, equilibrium exclusion assays, or interferometry assays.
[0264] Once a modified BBB receptor binding polypeptide with the desired binding properties has been identified, the polypeptide is further screened for transport across the BBB and / or another pharmacokinetic parameter. Methods for screening for transport include assessing uptake of the BBB receptor polypeptide into the brain using animal models. Uptake can be assessed by a variety of assays, for example, measuring the protein concentration or activity of a biologically active protein or other substance attached to the BBB receptor binding protein. Protein concentration can be conveniently measured by immunoassays using an antibody that specifically binds to the BBB receptor binding polypeptide or an antibody as a secondary reagent that binds to a reagent specific for the BBB receptor binding polypeptide. In some embodiments, transport across the blood-brain barrier is assessed by measuring the amount of substance linked to the BBB receptor binding polypeptide that is taken up into the brain. As detailed above, such substances can be polypeptides such as immunoglobulin variable regions that bind antigens, enzymes, or other polypeptide agents. Further parameters such as serum half-life of the BBB receptor binding polypeptide can also be assessed in animal models.
[0265] In some embodiments, the transport of BBB receptor binding polypeptides can be evaluated by measuring the biological activity of the substance linked to the BBB receptor binding polypeptide in the brain. For example, the activity of an enzyme linked to a BBB receptor binding polypeptide can be evaluated by directly assaying for enzyme activity in the brain or in a region of the brain. Alternatively, the activity of an enzyme can be evaluated by measuring the concentration of the enzyme's substrate in the brain that remains after transport by the BBB receptor binding polypeptide. In some embodiments, the activity of an antibody therapeutic linked to a BBB receptor binding polypeptide can be evaluated by measuring the concentration or activity of the target antigen to which the therapeutic antibody binds. Binding to the BBB receptor mediated by the modified Fc polypeptides of the invention increases the uptake of the biologically active substance linked to the BBB receptor binding polypeptide, usually by at least 5-fold, often at least 10-fold, or at least 20-fold, or more, compared to the uptake of the substance in the absence of the modified Fc polypeptide.
[0266] IX. TfR Constructs The present disclosure also features an isolated recombinant transferrin receptor (TfR) construct comprising a monomeric TfR apical domain, the construct not comprising a protease-like domain or a helical domain of TfR. In one embodiment, the construct presents a conserved epitope or antigen and / or retains the approximate three-dimensional structure of the apical domain of native human TfR or has an RMSD of less than about 2. In one embodiment, the three-dimensional structure is determined by X-ray crystallography. In one embodiment, the construct comprises a human TfR apical domain.
[0267] The disclosure also features a TfR construct that includes one or more portions of the TfR apical domain that are circularly permuted relative to the full-length TfR sequence. The TfR construct can be comprised of two different portions of the TfR apical domain that are fused to each other in tandem with an optional linker. The TfR construct can include (a) a first polypeptide that includes the sequence of a first portion of the TfR apical domain, (b) an optional linker, and (c) a second polypeptide that includes the sequence of a second portion of the TfR apical domain, where the sequence of the first portion of the TfR apical domain is C-terminal to the sequence of the second portion of the TfR apical domain relative to the full-length TfR sequence, and the first polypeptide, the optional linker, and the second polypeptide are fused in tandem (i.e., the C-terminus of the first polypeptide is fused to the N-terminus of the optional linker, and the C-terminus of the optional linker is fused to the N-terminus of the second polypeptide). In certain embodiments, the TfR construct does not include a linker. Thus, the first polypeptide in the TfR construct can be directly fused to the second polypeptide. The TfR constructs described herein can bind to arenaviruses (e.g., Machupo virus).
[0268] The TfR constructs are a first polypeptide comprising a sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) to the sequence of TIFF0007577447000021.tif5134, and an optional linker; and a second polypeptide comprising a sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) to the sequence of TIFF0007577447000022.tif12159, wherein the first polypeptide, optional linker, and second polypeptide are fused in tandem.
[0269] In some embodiments, the first polypeptide comprises at the C-terminus the sequence TIFF0007577447000023.tif4128, or a fragment thereof. As a non-limiting example, a C-terminal fragment of the first polypeptide may have the sequence In some embodiments, the first polypeptide has at its N-terminus the sequence TIFF0007577447000025.tif5128, or a fragment thereof. has TIFF0007577447000026.tif12170.
[0270] In some embodiments, the second polypeptide comprises at the C-terminus the sequence TIFF0007577447000027.tif5128, or a fragment thereof. As a non-limiting example, a C-terminal fragment of the second polypeptide may further include a sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) to TIFF0007577447000027.tif5128, or a fragment thereof. In some embodiments, the second polypeptide has at its N-terminus the sequence TIFF0007577447000029.tif5128, or a fragment thereof. I have TIFF0007577447000030.tif19166.
[0271] In some embodiments, the first polypeptide of the TfR construct has the sequence In some embodiments, the second polypeptide comprises a sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) to TIFF0007577447000031.tif12150. In certain embodiments, the TfR construct comprises a first polypeptide having a sequence of SEQ ID NO:449 and a second polypeptide having a sequence of SEQ ID NO:450, wherein the C-terminus of the first polypeptide is fused to the N-terminus of the second polypeptide. In certain embodiments, the TfR construct comprises a first polypeptide having a sequence of SEQ ID NO:449 and a second polypeptide having a sequence of SEQ ID NO:450, wherein the C-terminus of the first polypeptide is fused to the N-terminus of the second polypeptide. A first polypeptide having a sequence of TIFF0007577447000033.tif12150; and a second polypeptide having a sequence of TIFF0007577447000034.tif12159, wherein the C-terminus of the first polypeptide is fused to the N-terminus of the second polypeptide.
[0272] In certain embodiments, the TfR constructs described herein have properties such as improved three-dimensional structure, including native folding, and presenting similar conserved epitopes or antigens as in the native state. For example, in three-dimensional space, the TfR constructs fold in a manner that closely mimics the apical domain of the transferrin receptor in its native folded state when portions of the intact transferrin receptor are complexed.
[0273] In another example, the structural features of the TfR constructs described herein allow the TfR constructs to be displayed in their native three-dimensional folded state on a variety of cells, such as phage, yeast, and / or other cell types, including eukaryotic cells. Display of the TfR constructs described herein in their proper native folded state leads to improved results when using the TfR constructs to identify high affinity proteins, antibodies, or other binding molecules that bind to the apical domain of the transferrin receptor in vivo under natural conditions found when administering therapeutic molecules to treat various diseases or disorders, for example, in the manner described herein. For example, when the entire transferrin receptor protein is expressed and displayed on the cell surface, the protein is displayed as a dimer, which creates an avidity effect that leads to the identification of binding proteins with low affinity for the TfR apical domain. The structural features of the TfR constructs described herein allow the apical domain to be expressed and presented as a monomer on the cell surface, allowing the study and characterization of monomeric interactions between binding molecules and the apical domain, allowing the identification of higher affinity molecules.
[0274] Manufacturing method Another aspect of the present disclosure relates to an isolated recombinant transferrin receptor (TfR) construct comprising a monomeric TfR apical domain, the construct not comprising the protease-like domain or helical domain of TfR. In one embodiment, the construct presents a conserved epitope or antigen and / or retains the approximate three-dimensional structure of the native human TfR apical domain (e.g., SEQ ID NO:107) or has an RMSD of less than about 2. In another embodiment, the three-dimensional structure is measured by X-ray crystallography. One method used to determine the three-dimensional structure is X-ray crystallography. Crystals can be prepared using flash cooling by direct immersion in liquid nitrogen, for example, using a crystallization mother liquor with the addition of a polar solvent such as 20% (v / v) ethylene glycol. X-ray intensity data can be collected at an advanced photon source (APS) (SER-CAT beamline at the Advanced Photon Source, Argonne National Laboratory) using a high-speed detector (Rayonix300). The collected data can be indexed, integrated, and scaled using the HKL-2000 (HKL Research, Inc.) program. The crystal structure of the complex can be determined by molecular replacement with PHASER using the TfR apical domain monomer as the initial search model. This model can then be refined using REFMAC with rigid body refinement followed by restraint refinement. All crystallographic calculations can be performed using the CCP4 suite of programs (Winn et al., Acta. Cryst. D67:235-242 (2011)). Model building of the complex into electron density can be performed using the graphics program COOT (Emsley et al., Acta. Cryst. D66:486-501 (2010)).
[0275] In another embodiment, the degree of conservation of epitopes, antigens, or approximate three-dimensional structures between the TfR apical domain constructs described herein and the corresponding native full-length TfR is determined. In one example, the human TfR apical domain constructs described herein are compared to native full-length human TfR. Such a determination method can be performed by aligning the crystal structure of the apical domain in the TfR apical domain constructs described herein (any of SEQ ID NOs: 109, 110, 301, 468, and 469 (e.g., 109, 110, and 301)) and native full-length TfR (e.g., human TfR, such as PDB code: 3KAS). The root mean square deviation (RMSD) between the two structures can then be determined by methods well known in the art, such as, for example, using MOE v2016.0802 (Chemical Computing Group).
[0276] In one embodiment, the RMSD between the TfR apical domain construct described herein and the apical domain of a native full-length TfR is less than about 4, less than about 3, or less than about 2, and is in the range of about 1 to about 2.
[0277] In one embodiment, the RMSD between the TfR apical domain constructs described herein and the apical domain of a native full-length TfR is between the range of about 1 and about 1.5.
[0278] In one embodiment, the RMSD between any one of the TfR apical domain constructs having the sequence of any one of SEQ ID NOs: 109, 110, 301, 468, and 469 (e.g., 109, 110, and 301) and the apical domain of a native full-length TfR is between about 1 and about 1.5. In one example, the RMSD is about 1.2.
[0279] Another aspect relates to a method for making, purifying, and isolating a recombinant TfR apical domain construct, the method comprising expressing a TfR apical domain gene comprising a first polynucleotide, an optional linker polynucleotide, and a second polynucleotide fused in tandem, the first polynucleotide encoding a C-terminal fragment of the domain, the optional linker polynucleotide encoding an optional protein linker, and the second polynucleotide encoding an N-terminal fragment of the domain. In one embodiment, each polynucleotide is fused in tandem such that, upon expression, the first amino acid of the N-terminal fragment of the domain is linked in primary sequence to the last amino acid of the C-terminal fragment. In another embodiment, the TfR apical domain gene comprises the optional linker such that, upon expression, the first amino acid of the N-terminal fragment of the domain is linked in primary sequence to the last amino acid of the linker, and the first amino acid of the linker is linked in primary sequence to the last amino acid of the C-terminal fragment. In another embodiment, the gene comprises a tandem arrangement of a first polynucleotide, an optional linker polynucleotide, and a second polynucleotide such that, upon expression, the expressed protein is in the form of a circular structure. The method further comprises purifying the expressed protein to obtain an isolated recombinant TfR apical domain construct.
[0280] In one example, the first amino acid of the N-terminal fragment of a second polypeptide in a TfR construct and the last amino acid of the C-terminal fragment of a first polypeptide in a TfR construct are selected to be within or near the apical domain of the TfR, such that when expressed, the proteins exhibit the conserved approximate three-dimensional structure and folding of the domains as seen in the full-length TfR protein and its dimerized form. In one example, the amino acids are selected based on their proximity to each other in three-dimensional space, which can be obtained from a known crystal structure of the full-length transferrin receptor (e.g., PDB code 1SUV (7.5 Å resolution); Cheng, Y., et al., Cell 116:565-576 (2004) or, at a higher resolution of 2.4 Å, PDM code 3KAS; Abraham, J., et al., Nat. Struct. Mol. Biol. 17:438-444 (2010), both of which are incorporated by reference in their entirety for all purposes), or from a computer model of the receptor, or by methods well known to those of skill in the art.
[0281] In another embodiment, each amino acid is selected from the anti-parallel beta strands between the apical domain and the remainder of the receptor protein. In another example, the amino acids are selected from two polypeptide regions, i.e., loops, that connect the beta strands. In another example, the amino acids are selected from two polypeptide regions that connect the beta strands, the polypeptide regions including a C-terminal region that includes the sequence VSN and an N-terminal region that includes the sequence KDSAQNS (SEQ ID NO:471). In one example, the amino acid selected for the N-terminal region of the second polypeptide in the TfR construct is D (of sequence DSAQN (SEQ ID NO:472)), which is linked to the last amino acid, N (of sequence LTVSN (SEQ ID NO:473)), of the C-terminal region of the first polypeptide in the TfR construct. In another embodiment, the amino acids are selected as further described in Example 2 to provide apical domain proteins of human and cynomolgus monkey SEQ ID NOs:109 and 110, respectively.
[0282] Thus, in another embodiment, a method for making, purifying, and isolating a recombinant TfR apical domain construct further comprises: (i) identifying N-terminal and C-terminal fragments and their respective amino acids within or near the apical domain of TfR for reordering; (ii) designing a gene expression vector comprising polynucleotides encoding the N-terminal and C-terminal fragments and their respective amino acids, wherein the polynucleotides are fused together such that, upon expression, the first amino acid of the N-terminal fragment of the domain is fused in primary sequence to the last amino acid of the C-terminal fragment; and (iii) expressing the apical domain construct.
[0283] In other embodiments, the TfR constructs described herein allow detailed studies of the interactions between binding molecules and the TfR apical domain, e.g., using X-ray crystallography and nuclear magnetic resonance spectroscopy (which is made possible by the constructs described herein because the full-length TfR complex has a relatively large molecular weight, while the TfR apical domain construct has a relatively low molecular weight sufficient for these studies).
[0284] Linker The linker between two polypeptides in a TfR construct can contain 1-10 amino acids (e.g., 1-8, 1-6, 1-4, or 1 or 2 amino acids, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids). Suitable linkers include, for example, linkers that contain flexible amino acid residues such as glycine and serine. Examples of linkers include, but are not limited to, TIFF0007577447000035.tif19159 is an example.
[0285] In other embodiments, the linker between two polypeptides in a TfR construct may be a protein loop domain, and the distance between the N-terminus and C-terminus of the protein loop domain is less than 5 Å (e.g., a distance of less than 4 Å, 3 Å, 2 Å, or 1 Å). In some embodiments, the protein loop domain may be a globular protein. In some embodiments, a protein loop domain can have 800 or fewer amino acids (e.g., 800, 780, 760, 740, 720, 700, 680, 660, 640, 620, 600, 580, 560, 540, 520, 500, 480, 460, 440, 420, 400, 380, 360, 340, 320, 300, 280, 260, 240, 220, 200, 180, 160, 140, 120, or 100 amino acids). In some embodiments, a protein loop domain may be a globular protein having 800 or less amino acids (e.g., 800, 780, 760, 740, 720, 700, 680, 660, 640, 620, 600, 580, 560, 540, 520, 500, 480, 460, 440, 420, 400, 380, 360, 340, 320, 300, 280, 260, 240, 220, 200, 180, 160, 140, 120, or 100 amino acids). A protein loop domain can have a secondary or tertiary structure with the N- and C-termini of the structure separated by less than 5 Å (eg, a distance of less than 4 Å, 3 Å, 2 Å, or 1 Å).In some embodiments, when a protein loop domain is inserted between a first and a second polypeptide of a TfR construct such that the C-terminus of a first polypeptide is fused to the N-terminus of the protein loop domain and the N-terminus of a second polypeptide is fused to the C-terminus of the protein loop domain, the proximity of the N-terminus and C-terminus of the protein loop domain brings the first and second polypeptides into close proximity with each other, which allows amino acids of the first polypeptide to interact with amino acids of the second polypeptide, e.g., via hydrogen bonds, and enables the TfR construct to form a secondary structure, e.g., a beta sheet.
[0286] Signal peptide The TfR construct can further include a signal peptide, such as a signal peptide that results in secretion of the construct when expressed in a cell (e.g., a eukaryotic cell such as a mammalian cell). Any signal peptide known in the art (e.g., TIFF0007577447000036.tif5128) can also be used in combination with the TfR constructs described herein. The signal peptide can be attached to the N-terminus or C-terminus of the construct, as appropriate.
[0287] Purified peptides The TfR construct may include one or more purification peptides that facilitate purification and isolation of the TfR construct, for example, from a whole cell lysate mixture. In some embodiments, the purification peptide is bound to another moiety that has a specific affinity for the purification peptide. In some embodiments, such a moiety that specifically binds to the purification peptide is bound to a solid support, such as a matrix, resin, or agarose beads. Examples of purification peptides that can be fused to the TfR construct include, but are not limited to, histidine peptides, Avi tags, FLAG peptides, myc peptides, and hemagglutinin (HA) peptides. The histidine peptides (HHHHHH (SEQ ID NO:459) or HHHHHHHHHH (SEQ ID NO:460)) bind to nickel-functionalized agarose affinity columns with micromolar affinity. The Avi tag (GLNDIFEAQKIEWHE (SEQ ID NO:461)) can be biotinylated by the enzyme BirA. The biotinylated Avi tag can then bind to streptavidin and purification can occur. In some embodiments, the FLAG peptide has the sequence DYKDDDDK (SEQ ID NO:462). In some embodiments, the myc peptide has the sequence EQKLISEEDL (SEQ ID NO:463). In some embodiments, the HA peptide has the sequence YPYDVPDYA (SEQ ID NO:464).
[0288] Cleavage peptide A cleavage peptide refers to an amino acid sequence that can be recognized and cleaved by a specific protease. For example, by placing the cleavage peptide between the purification peptide and the remainder of the TfR construct, the purification peptide can be removed by cleaving the cleavage peptide after the TfR construct is expressed and purified. When a protease is in proximity to the cleavage peptide, the protease recognizes and cleaves the cleavage peptide (i.e., by hydrolysis of the peptide backbone). Examples of protease and cleavage peptide pairs include, but are not limited to, ubiquitin-like specific protease 1 (Ulp1) and its cleavage sequence, Smt3. TIFF0007577447000037.tif12157, tobacco etch virus nuclear inclusion A (TEV) protease and its cleavage sequence ENLYFQS (SEQ ID NO: 466), and nonstructural protein 3 protease domain of Hepatitis C virus (NS3 HCV) and its cleavage sequence DEMEECSQ (SEQ ID NO: 467).
[0289] X. Nucleic Acids, Vectors, and Host Cells The modified BBB receptor binding polypeptides and TfR constructs described herein are usually prepared using recombinant methods.Thus, in some aspects, the invention provides an isolated nucleic acid comprising a nucleic acid sequence encoding any of the polypeptides comprising any of the modified Fc polypeptides or TfR constructs described herein, and a host cell into which the nucleic acid encoding the polypeptide is introduced, and / or which is used to replicate the nucleic acid encoding the polypeptide and / or express the polypeptide or TfR construct.In some embodiments, the host cell is a eukaryotic cell, such as a human cell.
[0290] In another aspect, a polynucleotide is provided that comprises a nucleotide sequence that encodes the polypeptide or TfR construct described herein.The polynucleotide may be single-stranded or double-stranded.In some embodiments, the polynucleotide is DNA.In certain embodiments, the polynucleotide is cDNA.In some embodiments, the polynucleotide is RNA.
[0291] In some embodiments, the polynucleotide is comprised within a nucleic acid construct. In some embodiments, the construct is a replicable vector. In some embodiments, the vector is selected from a plasmid, a viral vector, a phagemid, a yeast chromosomal vector, and a non-episomal mammalian vector.
[0292] In some embodiments, the polynucleotide is operably linked to one or more regulatory nucleotide sequences in an expression construct. In one set of embodiments, the nucleic acid expression construct is adapted for use as a surface expression library. In some embodiments, the library is adapted for surface expression in yeast. In some embodiments, the library is adapted for surface expression in phage. In another set of embodiments, the nucleic acid expression construct is adapted for expression of a polypeptide or TfR construct in a system that allows for isolation of the polypeptide or TfR construct in milligram or gram quantities. In some embodiments, the system is a mammalian cell expression system. In some embodiments, the system is a yeast cell expression system.
[0293] Expression vehicles for producing recombinant polypeptides include plasmids and other vectors. For example, suitable vectors include the following types of plasmids: pBR322-derived plasmids, pEMBL-derived plasmids, pEX-derived plasmids, pBTac-derived plasmids, and pUC-derived plasmids for expression in prokaryotes such as E. coli. pcDNAI / amp, pcDNAI / neo, pRc / CMV, pSV2gpt, pSV2neo, pSV2-dhfr, pTk2, pRSVneo, pMSG, pSVT7, pko-neo, and pHyg-derived vectors are examples of mammalian expression vectors suitable for transfection of eukaryotes. Alternatively, derivatives of viruses such as bovine papilloma virus (BPV-1) or Epstein-Barr virus (pHEBo, pREP-derived, and p205) can be used for transient expression of polypeptides in eukaryotes. In some embodiments, it may be desirable to express recombinant polypeptides using a baculovirus expression system. Such baculovirus expression systems include pVL-derived vectors (such as pVL1392, pVL1393, and pVL941), pAcUW-derived vectors (such as pAcUW1), and pBlueBac-derived vectors. Additional expression systems include adenovirus, adeno-associated virus, and other viral expression systems.
[0294] The vector can be transformed into any suitable host cell. In some embodiments, the host cell, such as a bacterial or yeast cell, can be adapted for use as a surface expression library. In some cells, the vector is expressed in the host cell to express relatively large amounts of the polypeptide or TfR construct. Such host cells include mammalian cells, yeast cells, insect cells, and prokaryotic cells. In some embodiments, the cell is a mammalian cell, such as a Chinese hamster ovary (CHO) cell, a baby hamster kidney (BHK) cell, an NS0 cell, a Y0 cell, a HEK293 cell, a COS cell, a Vero cell, or a Hela cell.
[0295] Host cells transfected with an expression vector encoding a transferrin receptor binding polypeptide or a TfR construct can be cultured under appropriate conditions to result in expression of the polypeptide or TfR construct. The polypeptide or TfR construct can be secreted and isolated from the mixture of cells and the medium containing the polypeptide or TfR construct. Alternatively, the polypeptide or TfR construct can be retained in the cytoplasm or in a membrane fraction, and the cells harvested, lysed, and the polypeptide or TfR construct isolated by any desired method.
[0296] XI. Treatment method The BBB receptor binding polypeptide according to the present invention can be used therapeutically in many indications.In some embodiments, the BBB receptor binding polypeptide is used to deliver therapeutic agents to target cell types that express BBB receptors.In typical embodiments, the BBB receptor binding polypeptide can be used to transport therapeutic components across endothelium, such as the blood-brain barrier, so that they can be taken up by the brain.
[0297] In some embodiments, the BBB receptor binding polypeptides of the invention can be used to treat neurological disorders, such as disorders of the brain or central nervous system (CNS), for example by conjugating and delivering a therapeutic agent, such as a disease of the brain or central nervous system (CNS). Exemplary disorders include Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementia, vascular dementia, dementia with Lewy bodies, Pick's disease, primary age-related tauopathy, or progressive supranuclear palsy. In some embodiments, the disease may be a tauopathy, a prion disease (such as bovine spongiform encephalopathy, scrapie, Creutzfeldt-Jakob disease, kuru, Gerstmann-Straussler-Scheinker disease, chronic wasting disease, and fatal familial insomnia), a bulbar palsy, a motor neuron disease, or a nervous system heterogeneous degenerative disease (such as Canavan disease, Huntington's disease, neuronal ceroid lipofuscinosis, Alexander disease, Tourette's syndrome, Menkes kinky hair syndrome, Cockayne syndrome, Hallervorden-Spatz syndrome, Lafora disease, Rett syndrome, hepatolenticular degeneration, Lesch-Nyhan syndrome, Friedreich's ataxia, spinal muscular atrophy, and Unverricht-Lundborg syndrome). In certain embodiments, the disease is a primary cancer of the CNS. In some embodiments, the disease is a metastatic cancer that has metastasized to the brain. In some embodiments, the disease is stroke or multiple sclerosis. In some embodiments, the patient may be asymptomatic but have markers associated with brain or CNS disease. In some embodiments, there is provided a use of a BBB receptor binding polypeptide of the invention in the manufacture of a medicament for treating a neurological disease.
[0298] In some embodiments, the method further comprises administering one or more additional therapeutic agents to the subject.For example, in some embodiments for treating brain or central nervous system disease, the method can comprise administering to the subject a neuroprotective agent, such as an anticholinergic agent, a dopaminergic agent, a glutamatergic agent, a histone deacetylase (HDAC) inhibitor, a cannabinoid, a caspase inhibitor, melatonin, an anti-inflammatory agent, a hormone (e.g., estrogen or progesterone), or a vitamin.In some embodiments, the method can comprise administering to the subject a drug (e.g., an antidepressant, a dopamine agonist, or an antipsychotic) for use in treating cognitive or behavioral symptoms of neurological disease.
[0299] The BBB receptor-binding polypeptides of the present invention are administered to a subject in a therapeutically effective amount or dose. Exemplary doses may range from about 0.01 mg / kg to about 500 mg / kg, or from about 0.1 mg / kg to about 200 mg / kg, or from about 1 mg / kg to about 100 mg / kg, or from about 10 mg / kg to about 50 mg / kg daily. However, the dose may vary depending on several factors, including the route of administration selected, the formulation of the composition, the patient's response, the severity of the condition, the subject's weight, and the prescribing physician's judgment. The dose may be increased or decreased over time, depending on the needs of the individual patient. In some embodiments, the patient is administered a low dose initially, which is then increased to an effective dose that is tolerable to the patient. The determination of an effective amount is well within the capabilities of one of ordinary skill in the art.
[0300] In different embodiments, the BBB receptor binding polypeptides of the invention are administered parenterally. In some embodiments, the polypeptides are administered intravenously. Intravenous administration can be by infusion, for example, over a period of about 10-30 minutes, or over a period of at least 1 hour, 2 hours, or 3 hours. In some embodiments, the polypeptides are administered as an intravenous bolus. A combination of infusion and bolus administration can also be used.
[0301] In some parenteral embodiments, the BBB receptor binding polypeptide is administered intraperitoneally, subcutaneously, intradermally, or intramuscularly. In some embodiments, the polypeptide is administered intradermally or intramuscularly. In some embodiments, the polypeptide is administered intrathecally, for example, by epidural administration, or intracerebroventricularly.
[0302] In other embodiments, the transferrin receptor binding polypeptide can be administered orally, pulmonary, nasally, ocularly, or topically. Pulmonary administration can also be used in combination with an aerosolizing agent, for example, using an inhaler or nebulizer.
[0303] VIII. Pharmaceutical Compositions and Kits In another aspect, pharmaceutical compositions and kits are provided which comprise a BBB receptor binding polypeptide according to the invention.
[0304] Pharmaceutical Compositions Guidance for preparing formulations for use in the present invention can be found in any number of pharmaceutical and formulation handbooks well known to those of skill in the art.
[0305] In some embodiments, pharmaceutical compositions comprise a transferrin receptor binding polypeptide as described herein and further comprise one or more pharma- ceutically acceptable carriers and / or excipients. Pharmaceutically acceptable carriers include any solvent, dispersion medium, or coating that is physiologically compatible and preferably does not interfere with or otherwise inhibit the activity of the active agent. A variety of pharma- ceutically acceptable excipients are well known.
[0306] In some embodiments, the carrier is suitable for intravenous, intrathecal, intracerebroventricular, intramuscular, oral, intraperitoneal, transdermal, topical, or subcutaneous administration. Pharmaceutically acceptable carriers can include one or more physiologically acceptable compounds, such as, for example, stabilizing the composition or increasing or decreasing the absorption of the polypeptide. Physiologically acceptable compounds can include, for example, carbohydrates such as glucose, sucrose, or dextran, antioxidants such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins, compositions that reduce the clearance or hydrolysis of the active agent, or excipients or other stabilizers and / or buffers. Other pharmaceutically acceptable carriers and their formulations are also available in the art.
[0307] The pharmaceutical compositions described herein can be manufactured in a manner well known to those skilled in the art, for example, by conventional mixing, dissolving, granulating, dragee-making, emulsifying, encapsulating, entrapping, or lyophilizing processes. The following methods and excipients are illustrative only and are not intended to be limiting in any way.
[0308] For oral administration, the BBB receptor-binding polypeptides can be formulated by combining with pharma- ceutically acceptable carriers well known in the art. Such carriers allow the compounds to be formulated as tablets, pills, dragees, capsules, emulsions, lipophilic and hydrophilic suspensions, liquids, gels, syrups, slurries, suspensions, and the like, to be taken orally by the patient to be treated. Oral pharmaceutical preparations can be obtained by mixing the polypeptides with solid excipients, optionally grinding the resulting mixture, adding suitable auxiliaries as necessary, and then processing the granular mixture to obtain tablets or dragee cores. Suitable excipients include, for example, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations, such as corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth gum, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and / or polyvinylpyrrolidone. If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
[0309] As disclosed above, the BBB receptor binding polypeptides described herein can be formulated for parenteral administration by injection, for example, by bolus injection or continuous infusion. For injection, the polypeptide can be formulated by dissolving, suspending, or emulsifying in an aqueous or non-aqueous solvent, such as vegetable oil or other similar oils, synthetic fatty acid glycerides, esters of higher fatty acids or propylene glycol, optionally with conventional additives such as solubilizers, isotonicity agents, suspending agents, emulsifying agents, stabilizing agents, and preservatives. In some embodiments, the polypeptide can be formulated in an aqueous solution, preferably in a physiologically compatible buffer such as Hank's solution, Ringer's solution, or physiological saline buffer. The formulation for injection can be provided in unit dosage form, for example, in ampoules with added preservatives, or in multi-dose containers. The composition can take the form of a suspension, solution, or emulsion in an oily or aqueous solvent, and can include formulating agents such as suspending agents, stabilizing agents, and / or dispersing agents.
[0310] In some embodiments, the BBB receptor binding polypeptide is prepared for delivery as a sustained, controlled, extended, timed, or delayed release formulation, for example, in a semipermeable matrix of solid hydrophobic polymers containing the active agent. Various types of sustained release materials have been established and are well known to those skilled in the art. Long-term release formulations include film-coated tablets, multiparticulate or pellet systems, matrix technology using hydrophilic or lipophilic materials, and wax-based tablets containing pore-forming excipients. Sustained release delivery systems can release compounds over hours or days, for example, 4, 6, 8, 10, 12, 16, 20, 24 hours or more, depending on their design. Typically, sustained release formulations can be prepared using naturally occurring or synthetic polymers, for example, polymeric vinylpyrrolidone such as polyvinylpyrrolidone; carboxyvinyl hydrophilic polymers; hydrophobic and / or hydrophilic hydrocolloids such as methylcellulose, ethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose; and carboxypolymethylene.
[0311] Generally, pharmaceutical compositions to be used for in vivo administration are sterile. Sterilization can be accomplished by methods well known in the art, such as, for example, heat sterilization, steam sterilization, sterile filtration, or irradiation.
[0312] The dosage and desired drug concentration of the pharmaceutical composition of the present invention may vary depending on the particular application envisaged. The determination of the appropriate dosage and route of administration is well within the skill of one of ordinary skill in the art. Suitable dosages are also discussed in Section VII above.
[0313] kit In some embodiments, a kit is provided that includes a BBB receptor binding polypeptide as described herein. In some embodiments, the kit is used for the prevention or treatment of a neurological disease, such as a disease of the brain or central nervous system (CNS).
[0314] In some embodiments, the kit further comprises one or more additional therapeutic agents. For example, in some embodiments, the kit comprises a BBB receptor binding polypeptide as described herein and further comprises one or more additional therapeutic agents for use in treating a neurological disorder. In some embodiments, the kit further comprises instructions including instructions (i.e., protocols) for carrying out the methods described herein (e.g., instructions for using the kit to administer a composition across the blood-brain barrier). The instructions typically include, but are not limited to, written or printed material. Any medium capable of storing such instructions and communicating them to an end user is contemplated herein. Such media include, but are not limited to, electronic storage media (e.g., magnetic disks, tapes, cartridges, chips), and optical media (e.g., CD-ROMs). Such media may include an address of an internet site providing such instructions. EXAMPLES
[0315] XIII. Examples The present invention will be described in more detail by specific examples. The following examples are presented for illustrative purposes only and are not intended to limit the present invention in any way. Those skilled in the art will readily recognize a variety of non-critical parameters that can be changed or modified to produce substantially the same results. Although efforts have been made to ensure accuracy with respect to the values used (e.g., amounts, temperature, etc.), some experimental error and deviation can exist. The practice of the present invention employs, unless otherwise indicated, conventional methods of protein chemistry, biochemistry, recombinant DNA technology, and pharmacology, within the skill of the art. Such techniques are fully explained in the literature. Moreover, it should be apparent to those skilled in the art that the methods of manipulation applied to a particular library can also be applied to other libraries described herein.
[0316] The production of BBB receptor binding polypeptides is described using TfR as an example. The methods described herein can also be performed using alternative BBB receptors as targets.
[0317] Example 1. Generation of TfR targets DNA encoding the transferrin receptor (TfR) extracellular domain (ECD) (residues 121-760 of human (SEQ ID NO:235) or cynomolgus monkey (SEQ ID NO:300) TfR) was cloned into a mammalian expression vector with C-terminal cleavable His and Avi tags. This plasmid was transfected into HEK293 cells and expressed. The extracellular domain was purified from the harvested supernatant using Ni-NTA chromatography, followed by size-exclusion chromatography to remove aggregated proteins. Yields were approximately 5 mg per L of culture. Protein was stored in 10 mM K3PO4 (pH 6.7), 100 mM KCl, 100 mM NaCl, and 20% glycerol and frozen at -20°C.
[0318] DNA encoding the permuted TfR apical domain (SEQ ID NO:301) (residues 326-379 and 194-296 of human or cynomolgus TfR) was cloned into a pET28 vector with an N-terminal His tag for purification and an Avi tag for in vivo biotinylation. This plasmid was co-transformed with a BirA expression vector into BL21(DE3) cells. Cells were grown to log phase in LB medium at 37°C and then induced with 1 mM isopropyl 1-thio-β-D-galactopyranoside (IPTG) and incubated overnight at 18°C. Cells were lysed and the soluble fraction was affinity purified over a Ni-NTA column followed by size exclusion chromatography to remove aggregated proteins. Yields were approximately 10 mg per L of culture. Proteins were stored in 50 mM HEPES (pH 7.5), 150 mM NaCl, and 1 mM DTT and frozen at -20°C.
[0319] The purified ECD of TfR was biotinylated using the EZ-link sulfo-NHS-LC-Biotin kit (obtained from Thermo Scientific). A 5-fold molar excess of biotin was used in the reaction. Excess biotin was removed by extensive dialysis against PBS.
[0320] The ECD and apical domains of TfR with Avi tags were biotinylated using BirA-500 (BirA biotin-protein ligase standard reaction kit sold by Avidity, LLC). After the reaction, the labeled protein was further purified by size-exclusion chromatography to remove excess BirA enzyme. The final material was stored in 10 mM K3PO4 (pH 6.7), 100 mM KCl, 100 mM NaCl, and 20% glycerol and frozen at -20°C.
[0321] Example 2. Design and Characterization of Engineered Transferrin Receptor Binding Polypeptides This example describes the design, production, and characterization of the polypeptides herein. For purposes of this example, and for purposes of comparing amino acids that are the same in clone sequences, a "conservative" mutation is considered to occur in all of the identified clones (not a conservative amino acid substitution), whereas a "semi-conservative" mutation is one that occurs in more than 50% of the clones.
[0322] Unless otherwise specified, amino acid residue positions in this section are numbered based on SEQ ID NO:1, which is a human IgG1 wild-type Fc region with three residues PCP from the hinge region at the amino terminus.
[0323] Design of Polypeptide Fc Domain Libraries New molecular recognition means were incorporated into the polypeptide Fc region by selecting specific solvent-exposed surface patches for modification, constructing a surface display library in which the amino acid composition of the selected patches was varied by randomization, and then screening the surface-displayed sequence variants for the desired functionality using standard expression display techniques. As used herein, the term "randomization" includes partial randomization and sequence variation with a defined nucleotide or amino acid mix ratio. Typical surface-exposed patches selected for randomization are approximately 600-1500 Å in size. 2 and is composed of approximately 7 to 15 amino acids.
[0324] Clone Register Each of the following registers was designed and constructed according to the methods described herein. As used herein, the term "register" refers to a series of surface-exposed amino acid residues that form a continuous surface that can be altered (e.g., by introducing mutations into a peptide-encoding gene sequence that result in substitutions, insertions, and / or deletions of amino acids at the listed positions within the register).
[0325] CH2 Register A2 - Set (iii) The CH2A2 register (Table 1) included amino acid positions 47, 49, 56, 58, 59, 60, 61, 62, and 63, numbered based on the amino acid sequence of the Fc region of human IgG1 set forth in SEQ ID NO:1. The CH2A2 register was designed to form a surface along the β-sheet, an adjacent kink, and a subsequent loop. The CH2A2 register is effectively removed from the FcγR and FcRn binding sites.
[0326] CH2 Register C - Set (iv) The CH2C register (Table 2) included amino acid positions 39, 40, 41, 42, 43, 44, 68, 70, 71, and 72, numbered based on the amino acid sequence of the human IgG1 Fc region set forth in SEQ ID NO:1. The CH2C register utilizes solvent-exposed residues close to the FcγR binding site of the CH2 region along a series of loops near the hinge.
[0327] CH2 Register D - Set (v) The CH2D register (Table 3) included amino acid positions 41, 42, 43, 44, 45, 65, 66, 66, 69, and 73, numbered based on the amino acid sequence of the human IgG1 Fc region set forth in SEQ ID NO:1. The CH2D register is similar to the CH2C register, using solvent-exposed residues close to the FcγR binding site along a series of loops at the top of the CH2 region. The CH2C and CH2D registers primarily share one loop and differ in the second loop used for binding.
[0328] CH2 Resistor E3 - Set(vi) The CH2E3 register (Table 4) included amino acid positions 45, 47, 49, 95, 97, 99, 102, 103, and 104, numbered based on the amino acid sequence of the Fc region of human IgG1 set forth in SEQ ID NO: 1. Each position in the CH2E3 register is also near the FcγR binding site, but in addition to using some of the loop residues, it also uses solvent-exposed residues on the β-sheet adjacent to the loop near the FcγR binding site.
[0329] CH3 Register B - Set (ii) The CH3B register (Table 5) included amino acid positions 118, 119, 120, 122, 210, 211, 212, and 213, numbered based on the amino acid sequence of the human IgG1 Fc region set forth in SEQ ID NO:1. The CH3B register is mostly composed of solvent-exposed residues on two parallel β-sheets and some less structured residues near the C-terminus of the CH3 region. The CH3B register is distant from the FcγR and FcRn binding sites.
[0330] CH3 Register C - Set (i) The CH3C register (Table 6) included amino acid positions 157, 159, 160, 161, 162, 163, 186, 189, and 194, as numbered based on the amino acid sequence of the Fc region of human IgG1 set forth in SEQ ID NO: 1. Each position in the CH3C register includes solvent-exposed residues of two loops that are distant from the FcγR and FcRn binding sites, thereby forming a continuous surface.
[0331] Construction of phage display libraries Template DNA encoding the wild-type human Fc sequence (SEQ ID NO:1) was synthesized and engineered into a phagemid vector that contained an ompA or pelB leader sequence, an Fc insert fused to c-Myc and 6xHis epitope tags, and an amber stop codon followed by the M13 coat protein pIII.
[0332] Primers were made containing an "NNK" triplet codon at the corresponding positions for randomization, where N is any DNA base (i.e., A, C, G, or T) and K is G or T. Alternatively, primers for "soft" randomization were used, with a mix of bases at each randomization position, with 70% matching the wild-type base and 10% matching each of the other three bases. Libraries were made by PCR amplification of Fc region fragments corresponding to each region of randomization, then assembled with end primers containing SfiI restriction sites, digested with SfiI, and ligated into a phagemid vector. Alternatively, primers were used for Kunkel mutagenesis. Methods for Kunkel mutagenesis will be known to those skilled in the art. The ligated Kunkel products were transformed into electrocompetent E. coli cells of strain TG1 (obtained from Lucigen®). The recovered E. coli cells were infected with M13K07 helper phage and grown overnight. The library phages were then precipitated with 5% PEG / NaCl, resuspended in PBS containing 15% glycerol, and frozen until use. Typical library sizes were approximately 10 transformants. 9 ~about 10 11 The Fc dimers were displayed on the phage by pairing of pIII-fused Fc with soluble Fc that was not bound to pIII (the latter generated due to an amber stop codon before pIII).
[0333] Preparation of yeast display libraries Template DNA encoding wild-type human Fc sequences was synthesized and inserted into yeast display vectors. For the CH2 and CH3 libraries, Fc polypeptides were displayed on the Aga2p cell wall protein. Both vectors contained a pre-pro leader peptide with a Kex2 cleavage sequence and a c-Myc epitope tag fused to the end of Fc.
[0334] Yeast display libraries were assembled using methods similar to those described for the phage libraries, except that the fragments were amplified using primers with homologous ends to the vector. The linearized vector and assembled library inserts were introduced into freshly prepared electrocompetent yeast (i.e., strain EBY100) by electroporation. Electroporation techniques will be familiar to those skilled in the art. After recovery in selective SD-CAA medium, yeast were grown to confluence and split twice before protein expression was induced by transfer to SG-CAA medium. Typical library sizes were approximately 10 transformants. 7 ~about 10 9 Fc dimers were formed by pairing of adjacently displayed Fc monomers.
[0335] General methods for phage selection The phage method was adapted from Phage Display: A Laboratory Manual (Barbas, 2001). Further protocol details are available from this reference.
[0336] Plate sorting method Human TfR targets were coated onto MaxiSorp® microtiter plates (typically 200 μL of 1-10 μg / mL in PBS) overnight at 4°C. All binding was performed at room temperature unless otherwise noted. Phage libraries were added to each well and incubated overnight for binding. Microtiter wells were washed extensively with PBS containing 0.05% Tween® 20 (PBST) and bound phages were eluted by incubating each well with acid (typically 500 mM KCl or 50 mM HCl containing 100 mM glycine, pH 2.7) for 30 minutes. Eluted phages were neutralized with 1 M Tris (pH 8) and amplified using TG1 cells and M13 / KO7 helper phage and grown overnight at 37°C in 2YT medium containing 50 μg / mL carbenicillin and 50 μg / mL kanamycin. Enrichment was assessed by comparing the titers of phage eluted from wells containing target to those recovered from wells containing no target, and selection stringency was then increased by shortening the binding incubation time and increasing the wash time and number.
[0337] Bead sorting method Human TfR targets were biotinylated via free amines using NHS-PEG4-biotin (obtained from Pierce™). A 3-5 fold molar excess of biotin reagent was used in PBS for the biotinylation reaction. The reaction was stopped with Tris and then extensively dialyzed into PBS. Biotinylated targets were immobilized on streptavidin-coated magnetic beads (i.e., M280 streptavidin beads obtained from Thermo Fisher). The phage display library was incubated with the target-coated beads for 1 hour at room temperature. After this, unbound phages were removed and the beads were washed with PBST. Bound phages were eluted by incubation with 50 mM HCl containing 500 mM KCl (or 0.1 M glycine, pH 2.7) for 30 minutes, then neutralized and grown as described above for plate sorting.
[0338] After 3-5 rounds of panning, single clones were screened by expressing soluble Fc on phage or in the periplasm of E. coli. Such expression methods will be well known to those skilled in the art. Individual phage supernatants or periplasmic extracts were exposed to ELISA plates coated with target or negative control and blocked, and then detected with HRP-conjugated goat anti-Fc (Jackson Immunoresearch) for periplasmic extracts or anti-M13 (GE Healthcare) for phage, followed by development with TMB reagent (Thermo Fisher). Wells with OD450 values greater than about 5 times background were considered positive clones and sequenced, and some clones were then expressed as soluble Fc fragments or fused to Fab fragments.
[0339] General method of yeast selection Bead sorting (magnetic cell sorting (MACS)) method MACS and FACS selections were performed as described in Ackerman, et al. 2009 Biotechnol. Prog. 25(3), 774. Streptavidin magnetic beads (e.g., M-280 streptavidin beads from ThermoFisher) were labeled with biotinylated targets and incubated with yeast (usually 5-10x library diversity). Unbound yeast were removed, beads were washed, and bound yeast were grown in selection medium and induced for subsequent rounds of selection.
[0340] Fluorescence-activated cell sorting (FACS) Yeast were labeled with anti-c-Myc antibody to monitor expression and biotinylated target (at varying concentrations depending on the sorting round). In some experiments, the target was premixed with streptavidin-Alexa Fluor® 647 to increase the avidity of the interaction. In other experiments, the biotinylated target was detected after binding and washed with streptavidin-Alexa Fluor® 647. Bound singlets of yeast were sorted using a FACS Aria III cell sorter. Sorted yeast were grown in selective medium and then induced for subsequent rounds of selection.
[0341] After obtaining an enriched yeast population, the yeast were plated on SD-CAA agar plates and single colonies were grown, induced for expression, and labeled as described above to determine propensity to bind targets. Positive single clones were then sequenced for target binding, and some clones were expressed as soluble Fc fragments or fused to Fab fragments.
[0342] General screening methods Screening by ELISA Clones were selected from the panning output and grown in individual wells of 96-well deep-well plates. Each clone was either induced for periplasmic expression with autoinduction medium (obtained from EMD Millipore) or infected with helper phage for phage display of individual Fc variants on phage. Cultures were grown overnight and centrifuged to pellet the E. coli. Phage-containing supernatants were used directly for phage ELISA. For periplasmic expression, pellets were resuspended in 20% sucrose and then diluted 4:1 with water and shaken for 1 h at 4°C. Plates were centrifuged to pellet solids and supernatants were used for ELISA.
[0343] ELISA plates were coated with the target (usually at 0.5 mg / ml overnight) and then blocked with 1% BSA before adding phage or periplasmic extracts. After 1 hour of incubation and washing away unbound proteins, HRP-conjugated secondary antibodies (i.e., anti-Fc or anti-M13 for soluble Fc or phage-displayed Fc, respectively) were added and incubated for 30 minutes. Each plate was washed again before being developed with TMB reagent and quenched with 2N sulfuric acid. Absorbance at 450 nm was quantified using a plate reader (BioTek®) and binding curves were plotted using Prism software when applicable. Absorbance signals of tested clones were compared to negative controls (phage or periplasmic extract lacking Fc). In some assays, soluble holo-transferrin or other competitors are added during the binding step, usually in large molar excess (greater than 10-fold excess).
[0344] Flow cytometry screening Fc variant polypeptides (expressed on phage, in periplasmic extracts, or as soluble fusions with Fab fragments) were added to cells in 96-well V-bottom plates (approximately 100,000 cells per well in PBS+1% BSA (PBSA)) and incubated for 1 hour at 4°C. After this, each plate was centrifuged, the medium removed and the cells washed once with PBSA. The cells were resuspended in PBSA containing a secondary antibody (typically goat anti-human IgG-Alexa Fluor® 647 (from Thermo Fisher)). After 30 minutes, the plates were centrifuged, the medium removed and the cells washed 1-2 times with PBSA before the plates were read on a flow cytometer (i.e., a FACSCanto™ II flow cytometer). Median fluorescence was calculated for each condition using FlowJo software and binding curves were plotted using Prism software.
[0345] Generation and characterization of CH2A2 clones Selection with the CH2A2 library against the transferrin receptor (TfR) Phage and yeast libraries against CH2A2 were panned against TfR and sorted as described above. Clones that bound to human and / or cynomolgus monkey (cyno) TfR were identified after four rounds of phage panning in an ELISA assay as described above in the section entitled "Screening by ELISA". Sequences from representative clones fell into two groups: group 1, which contained 15 unique sequences (i.e., SEQ ID NO: 47-61), and group 2, which contained one unique sequence (i.e., SEQ ID NO: 62). Group 1 sequences had a conserved Glu-Trp motif at positions 60-61. No consensus was found at any other position, but Arg was frequently found at position 58, and Trp or Tyr was frequently found at position 59.
[0346] Characterization of CH2A2 clones Individual CH2A2 mutants were expressed on the surface of phage and assayed for binding to human TfR, cynomolgus monkey TfR, or an irrelevant control by ELISA. Expression of Fc was confirmed by ELISA against anti-Myc antibody 9E10, which binds to a C-terminal c-Myc epitope tag. Data for four representative clones shown in Figure 1(A)-(D) showed that all of these clones were well expressed and bound to human TfR, whereas none bound to the irrelevant control. Three clones in group 1 also bound to cynomolgus monkey TfR, whereas one clone in group 2 (i.e., clone 2A2.16) was specific for human TfR.
[0347] In the second assay, the concentration of phage was kept constant (i.e., approximately EC 50), and different concentrations of soluble competitor (holo-transferrin or human TfR) were added. Figures 2(A) and (B) show that binding was not significantly affected by the addition of holo-transferrin at concentrations up to 5 μM. In contrast, soluble human TfR competed for binding to surface-adsorbed human TfR, indicating a specific interaction.
[0348] The CH2A2 variants are expressed as Fc fusions with anti-BACE1 Fab fragments by cloning into expression vectors containing anti-BACE1 variable region sequences. After expression in 293 or CHO cells, the resulting CH2A2-Fab fusions were purified by Protein A and size exclusion chromatography and then assayed for binding using ELISA, surface plasmon resonance (SPR; i.e., using a Biacore™ instrument), biolayer interferometry (i.e., using the Octet® RED system), cell binding (e.g., flow cytometry), and other methods described herein. Additionally, the resulting polypeptide-Fab fusions were characterized for stability by thermal melting, freeze-thawing, and heat-accelerated denaturation.
[0349] Further manipulation of CH2A2 clones Two secondary libraries were constructed to increase the binding affinity of the initial hits to human and cynomolgus TfR. The first library was made based on the clones of group 1. The conserved EW motifs at positions 60 and 61 were kept unchanged, and the semi-conserved R at position 58 was mutated using soft randomization. The other library positions (i.e., positions 47, 49, 56, 59, 62, and 63) were mutated by saturation mutagenesis. The second library was constructed based on the clones of group 2. This library was made by soft randomization of the first CH2A2 library positions, but using clone 2A2.16 (SEQ ID NO:62) as template (instead of wild type Fc (SEQ ID NO:1)). Both libraries were constructed for phage and yeast display using the methods described above.
[0350] We then screened the library using the methods described above and identified several clones that bound to human TfR by ELISA (Table 1).
[0351] Generation and characterization of CH2C clones Selection with CH2C library against transferrin receptor (TfR) Phage and yeast libraries against CH2C were panned against TfR and sorted as described above. Clones that bound to human and / or cynomolgus monkey (cyno) TfR were identified after four rounds of phage panning (i.e., clones in groups 1 and 4) in an ELISA assay as described above in the section entitled "Screening by ELISA," and additional clones were identified after four or five rounds of yeast sorting (i.e., clones in groups 2 and 3) by yeast binding assay as described above in the section entitled "General Methodology for Yeast Selection." The sequences of representative clones fell into four groups: group 1 (i.e., SEQ ID NOs:63-78), which contained 16 unique sequences; group 2 (i.e., SEQ ID NOs:79-82), which contained four unique sequences; group 3 (i.e., SEQ ID NOs:83-84), which contained two unique sequences; and group 4 (i.e., SEQ ID NO:85), which contained one unique sequence. Group 1 sequences had a semi-conservative Pro at position 39, a semi-conservative Pro at position 42, a conservative Pro at position 43, a semi-conservative Trp at position 44, a semi-conservative Glu at position 68, and a conservative Tyr at position 70, with little specific trend at other library positions. Group 2 sequences had a conservative Met at position 39, a semi-conservative L at position 40, a conservative Pro at position 42, a conservative Val at position 43, a semi-conservative Pro at position 44, a semi-conservative Thr at position 68, a conservative His at position 70, and a conservative Pro at position 72. The two group 3 sequences differed only at position 68, where either Val or Leu was present. Group 4 consisted of one clone (i.e., CH2C.23) with the sequence shown in SEQ ID NO:85.
[0352] Characterization of CH2C clones The CH2C variants were expressed as Fc fusions with Fab fragments by cloning into expression vectors containing anti-BACE1 benchmark variable region sequences. After expression in 293 or CHO cells, the resulting polypeptide-Fab fusions were purified by Protein A and size exclusion chromatography before being assayed for binding to human or cynomolgus TfR. As shown in Figure 3(A), clone CH2C.23 from group 4 competed with holo-transferrin. Clones belonging to sequence group 1 are shown in Figure 3(B) in binding titrations against human and cynomolgus TfR. Representative clones from the other sequence groups were tested on phage for binding in the presence or absence of holo-Tf (see Figure 3(C)), and clone CH2C.7 was tested for binding to human TfR in the presence of holo-transferrin by biolayer interferometry (i.e., using the Octet® RED system, see Figure 3(D)). Most clones showed some cross-reactivity to the cynomolgus TfR, and with the exception of clone CH2C.23, none of the clones tested competed with holo-Tf.
[0353] Further manipulation of CH2C clones Further engineering methods similar to those described above for CH2A2 for further library design and screening are used to increase the affinity of the CH2C clones.
[0354] Generation and characterization of CH3B clones Selection with the CH3B library against the transferrin receptor (TfR) Phage and yeast libraries against CH3B were panned against TfR and sorted as described above. Clones that bound to human and / or cynomolgus TfR were identified after four rounds of phage panning in an ELISA assay as described above in the section entitled "Screening by ELISA" and additional clones were identified after four or five rounds of yeast sorting by yeast binding assay as described above in the section entitled "General Methods for Yeast Selection". All 17 clones identified from both phage and enzyme (i.e., SEQ ID NOs:30-46) had related sequences, i.e., a semi-conservative Phe at position 118, a semi-conservative negatively charged Asp or Glu at position 119, a semi-conservative Thr at position 122, a conservative G at position 210, a conservative Phe at position 211, a semi-conservative His at position 212, and a conservative Asp at position 213. Several clones contained the T123I mutation, a position that was not intentionally mutated in the library design and was likely introduced by recombination or PCR error.
[0355] Characterization of CH3B clones Two representative clones, CH3B.11 (SEQ ID NO:40) and CH3B.12 (SEQ ID NO:41), were expressed on the surface of phage and tested for binding to human and cynomolgus TfR in the presence or absence of holo-Tf. Neither clone was affected by the addition of holo-Tf (Figure 4(A)). Additionally, CH3B variants were expressed as fusions with Fab fragments by cloning into an expression vector containing anti-BACE1 variable region sequences. After expression in 293 or CHO cells, the resulting polypeptide-Fab fusions were purified by Protein A and size exclusion chromatography and then assayed for binding to human or cynomolgus TfR (Figure 4(B)). All showed specific binding to both orthologues.
[0356] Further manipulation of CH3B clones Further library design and screening: Further engineering methods similar to those described above for CH2A2 were used to increase the affinity of the CH3B clone. In particular, several consecutive patches of 4-7 residues near the paratope were selected for further diversification as shown in Figure 5 (the dark surface represents the register of the original library, and the light patches represent the newly mutated positions). Clone CH3B.12 (SEQ ID NO:41) was used as a starting point. The residues selected for saturation (i.e., NNK) mutagenesis were as follows: CH3B patch 1 (SEQ ID NO:101): amino acid positions 127, 128, 129, 131, 132, 133, and 134; CH3B patch 2 (SEQ ID NO:102): amino acid positions 121, 206, 207, and 209; CH3B patch 3 (SEQ ID NO:103): amino acid positions 125, 214, 217, 218, 219, and 220; CH3B patch 4 (SEQ ID NO:104): amino acid positions 115, 117, 143, 174, and 176; and CH3B patch 5 (SEQ ID NO:105): amino acid positions 155, 157, 158, 193, 194, and 195.
[0357] Each library was constructed using PCR mutagenesis and assembled into yeast and phage as described above in the sections entitled "Construction of a phage display library" and "Construction of a yeast display library." The libraries were screened using the methods described above, and several clones that bound to human TfR by ELISA were identified (Table 5).
[0358] Generation and characterization of CH2D clones Selection with the CH2D library against the transferrin receptor (TfR) The phage library against CH2D was panned against TfR as described above. Clones that bound to human and / or cynomolgus TfR in an ELISA assay were identified as described above in the section entitled "Screening by ELISA". Five unique clones were identified and classified into two sequence groups, each consisting of two and three sequences (Table 3). Sequence group 1 (i.e., clones CH2D.1 (SEQ ID NO:86) and CH2D.2 (SEQ ID NO:87)) had a conserved VPPXM (SEQ ID NO:111) motif at positions 40-45, a SLTS (SEQ ID NO:112) motif at positions 64-67, and a V at position 73. The mutation at position 40 was not included in the design and was likely due to PCR error or recombination. Sequence group 2 (i.e., clones CH2D.3 (SEQ ID NO:88), CH2D.4 (SEQ ID NO:89), and CH2D.5 (SEQ ID NO:90)) had a conservative D at position 41, a semi-conservative D at position 42, a conservative W at position 43, a semi-conservative E at position 44, a conservative aromatic (W or Y) at position 45, a conservative PW motif at positions 64-65, and a conservative W at position 73.
[0359] Characterization and further engineering of CH2D clones Additionally, CH2D mutants were expressed as fusions with Fab fragments by cloning into expression vectors containing anti-BACE1 variable region sequences. After expression in 293 or CHO cells, the resulting polypeptide-Fab fusions were purified by Protein A and size exclusion chromatography and then assayed for binding to cynomolgus and human TfR in the presence or absence of holo-Tf using the methods described herein above.
[0360] Generation and characterization of CH2E3 clones Selection with the CH2E3 library against the transferrin receptor (TfR) The phage library against CH2E3 was panned against TfR as described above. Clones that bound to human and / or cynomolgus TfR in an ELISA assay were identified as described above in the section entitled "Screening by ELISA". Three sequence groups were identified from the five sequences, with two of these groups consisting of only one unique sequence each (Table 4). Sequence group 2 had three unique sequences (i.e., clones CH2E3.2 (SEQ ID NO:92), CH2E3.3 (SEQ ID NO:93), and CH2E3.4 (SEQ ID NO:94)) with a semi-conservative Val at position 45, a conservative Gly at position 47, a conservative Arg at position 49, a conservative Arg at position 95, conservative Ser at positions 97 and 99, a conservative Trp at position 103, and either Arg or Lys at position 104.
[0361] Characterization and further manipulation of CH2E3 clones CH2E3 variants were expressed as fusions with Fab fragments by cloning into expression vectors containing anti-BACE1 benchmark variable region sequences. After expression in 293 or CHO cells, the resulting polypeptide-Fab fusions were purified by Protein A and size exclusion chromatography and then assayed for binding to cynomolgus and human TfR in the presence or absence of holo-Tf using the binding methods described herein above.
[0362] Generation and characterization of CH3C clones Selection with CH3C library against transferrin receptor (TfR) A yeast library against CH3C was panned against TfR and sorted as described above. Population enrichment FACS plots of the first three sorting rounds are shown in FIG. 6. After two additional rounds of sorting, one clone was sequenced and four unique sequences were identified (i.e., clones CH3C.1 (SEQ ID NO:4), CH3C.2 (SEQ ID NO:5), CH3C.3 (SEQ ID NO:6), and CH3C.4 (SEQ ID NO:7)). These sequences had a conserved Trp at position 161 and all had an aromatic residue (i.e., Trp, Tyr, or His) at position 194. High diversity was observed at other positions.
[0363] Characterization of first generation CH3C clones Four clones selected from the CH3C library were expressed as Fc fusions with Fab fragments in CHO or 293 cells, purified by Protein A and size exclusion chromatography, and then screened for binding to cynomolgus and human TfR in the presence or absence of holo-Tf by ELISA. As shown in Figure 7, each clone bound to human TfR, and binding was unaffected by the addition of excess (5 μM) holo-Tf. However, each clone did not bind significantly to cynomolgus TfR. Each clone was also tested for binding to 293F cells, which endogenously express the human TfR. Figure 8 shows that although each clone bound to 293F cells, overall binding was significantly weaker than the high affinity positive control.
[0364] We next tested whether clone CH3C.3 was internalized into TfR-expressing cells. Adherent HEK293 cells were grown in 96-well plates to approximately 80% confluence, the medium was removed, and the following were added at 1 μM: CH3C.3 anti-TfR benchmark positive control antibody (Ab204), anti-BACE1 benchmark negative control antibody (Ab107), and human IgG isotype control (obtained from Jackson Immunoresearch). Cells were incubated for 30 minutes at 37° C. and 8% CO2, then washed, permeabilized with 0.1% Triton™ X-100, and stained with anti-human IgG-Alexa Fluor® 488 secondary antibody. After further washing, cells were imaged under a high-content fluorescence microscope (i.e., Opera Phenix™ system) and the number of puncta per cell was quantified as shown in FIG. 9. At 1 μM, clone CH3C.3 showed a trend towards internalization similar to the anti-TfR positive control, whereas the negative control showed no internalization.
[0365] Secondary manipulation of CH3C clones Further libraries were generated in an attempt to improve the affinity of the initial CH3C hits for human TfR and introduce binding to cynomolgus monkey TfR. Using a soft randomization approach, DNA oligos were generated to introduce soft mutagenesis based on each of the first four hits. Each soft randomized register was shuffled by PCR amplification by constructing the first part of the register (WESXGXXXXXYK; SEQ ID NO:113) and the second part of the register (TVXKXXWQQGXV; SEQ ID NO:114) with separate fragments (e.g., the first part of the register from clone CH3C.1 was mixed with the second part of the register from clones CH3C.1, CH3C.2, CH3C.3, and CH3C.4, etc.). All fragments were mixed and then introduced into yeast for surface expression and selection.
[0366] The selection scheme is shown in Figure 10. After one round of MACS and three rounds of FACS, individual clones were sequenced (clones CH3C.17 (SEQ ID NO:8), CH3C.18 (SEQ ID NO:9), CH3C.21 (SEQ ID NO:10), CH3C.25 (SEQ ID NO:11), CH3C.34 (SEQ ID NO:12), CH3C.35 (SEQ ID NO:13), CH3C.44 (SEQ ID NO:14), and CH3C.51 (SEQ ID NO:15)). The selected clones fell into two major sequence groups. Clones in group 1 (i.e., clones CH3C.18, CH3C.21, CH3C.25, and CH3C.34) had a semi-conservative Leu at position 157, a Leu or His at position 159, a conserved and semi-conserved Val at positions 160 and 162, respectively, and a semi-conserved PTW motif at positions 186, 189, and 194, respectively. Clones in group 2 had a conserved Tyr at position 157, the motif TXWSX (SEQ ID NO:470) at positions 159-163, and the conserved motif S / TEF at positions 186, 189, and 194, respectively. Clones CH3C.18 and CH3.35 were used in further experiments as representative members of the respective sequence groups. Clone CH3C.51 was noted as having a first part of its register from group 1 and a second part of its register from group 2.
[0367] Binding property analysis of CH3C clones from the soft mutagenesis library Each clone from the soft mutagenesis library was reformatted as an Fc-Fab fusion polypeptide and expressed and purified as described above. As shown in Figure 12, these mutants had improved ELISA binding to the human TfR compared to the top clone (CH3C.3) from the initial library selection, and also did not compete with holo-Tf. The ECs shown in Table 7 below. 50 Values were not significantly affected beyond experimental error by the presence or absence of holo-Tf.
[0368] Table 7. EC of ELISA binding of CH3C mutants to TfR in the presence or absence of holo-Tf. 50 Value (nM) TIFF0007577447000038.tif64128
[0369] Of note, clone CH3C.35 bound to human TfR generally as well as the high affinity anti-TfR control antibody Ab204. As shown in FIG. 13, each of the clones selected from the soft randomized library also had improved cell binding to 293F cells. In a similar cell binding assay, these clones were tested for binding to CHO-K1 cells stably expressing high levels of human or cynomolgus TfR on their surface. Each of the clones selected from the soft randomized library bound to cells expressing human TfR (FIG. 14(A)) to the same extent as cynomolgus TfR (FIG. 14(B)), but did not bind to parental CHO-K1 cells (FIG. 14(C)). Their size and binding EC 50 Values were significantly lower for the cynomolgus monkey TfR compared to the human TfR. The data are summarized in Table 8 below.
[0370] Table 8. EC binding of CH3C clones to cells 50 and maximum MFI (median fluorescence intensity) value TIFF0007577447000039.tif73168
[0371] Epitope mapping To test whether the engineered CH3C Fc region binds to the apical domain of TfR, the TfR apical domain (SEQ ID NO: 107 and 108 for human and cynomolgus monkey, respectively) was expressed on the surface of phage. To properly fold and display the apical domain, one of the loops needs to be shortened and the sequence needs to be circularly rearranged (the sequences expressed on the phage are identified as SEQ ID NO: 109 and 110 for human and cynomolgus monkey, respectively). Clones CH3C.18 and CH3C.35 were coated onto ELISA plates and the phage ELISA protocol described above was followed. Briefly, after washing and blocking with 1% PBSA, each dilution of phage display was added and incubated for 1 hour at room temperature. Each plate was then washed, anti-M13-HRP was added, and after further washing, each plate was developed with TMB substrate and quenched with 2N H2SO4. In this assay, both CH3C.18 and CH3C.35 bound to the apical domain.
[0372] Because binding to the cynomolgus TfR is known to be significantly weaker than binding to the human TfR, we hypothesized that one or more amino acid differences between the cynomolgus and human apical domains were likely responsible for the difference in binding. Therefore, we introduced a series of six point mutations into the apical domain of the human TfR, replacing human residues with the corresponding cynomolgus residues. These mutants were displayed on phage and the phage concentration was increased to OD 268, and binding to CH3C.18 and CH3C.35 was tested by phage ELISA titration (Figure 16(B) and (C)). Capture with anti-Myc antibody 9E10 showed that the presentation levels of all mutants were similar (Figure 16(A)). Binding to human TfR mutants clearly showed a strong effect of the R208G mutation, suggesting that this residue is a critical part of the epitope and is negatively affected at this position by the cynomolgus residue. Introducing the G208R mutation into the phage-displayed cynomolgus apical domain showed that this mutation significantly improved binding to the cynomolgus apical domain (Figure 16(D) and (E)). These results indicate that each CH3C clone bound to the apical domain of TfR and that position 208 was important for binding, whereas positions 247, 292, 364, 370, and 372 were significantly less important.
[0373] Paratope Mapping To understand which residues in the Fc domain are most important for binding to the TfR, we generated a series of clones of mutants CH3C.18 and CH3C.35 in which one position in the TfR binding register of each mutant was reverted to wild type. The resulting mutants were recombinantly expressed as CH3C Fc-Fab fusions and tested for binding to human or cynomolgus TfR (Figure 17). In CH3C.35, positions 161 and 194 were absolutely critical for binding, and reverting either of these to wild type completely abolished binding to the human TfR. Surprisingly, reverting position 163 to wild type significantly increased binding to the cynomolgus TfR, while having little effect on human binding. In contrast, reverting residue 163 to wild type had little effect in CH3C.18, whereas reverting positions 189 and 194 in this mutant completely abolished binding to the human TfR. In both mutants, binding to the cynomolgus TfR was abolished in most cases, whereas other single reversion mutations had a small (negative) effect on binding to the human TfR.
[0374] Further engineering to improve binding to cynomolgus monkey TfR Additional libraries were prepared to further increase the affinity of CH3C mutants for the cynomolgus TfR. These libraries had a theoretical diversity of approximately 10 7 The libraries were designed to have fewer clones than the total number of types, allowing for the entire diversity space to be encompassed using yeast surface display. The designs of these libraries are shown in Figure 18. Four library designs were used, and all libraries were generated using degenerate oligos at NNK or other degenerate codon positions and amplified by overlap PCR as described above.
[0375] The first library was based on the consensus of CH3C.35-like sequences (Figure 18(A)), where positions 157-161 were kept constant as YGTEW (SEQ ID NO:115), while positions 162, 163, 186, 189, and 194 were mutated using saturation mutagenesis.
[0376] The second library was based on the consensus of CH3C.18-like sequences (Figure 18(B)), where position 157 was restricted to Leu and Met, position 159 was restricted to Leu and His, position 160 was held constant as Val, position 161 was restricted to Trp and GIy, position 162 was restricted to Val and Ala, position 163 was fully randomized, position 164 was added to the register and fully randomized, position 186 was soft randomized, position 189 was fully randomized, and position 194 was restricted to aromatic amino acids and Leu.
[0377] In the third library, new randomized positions were added to the library (Figure 18(C)). Two versions were made with CH3C.18 and CH3C.35 as the starting registers, respectively, and then the following additional positions were randomized by saturation mutagenesis: E153, E155, Y164, S188, and Q192.
[0378] The fourth library held certain positions of CH3C.18 constant but mutated other positions with less bias than the consensus library (Figure 18(D)): positions 160, 161, and 186 were fixed, positions 157, 159, 162, 163, and 189 were randomized by saturation mutagenesis, and position 194 was mutated but restricted to aromatic residues and Leu.
[0379] Each library was selected in yeast against cynomolgus TfR for 4-5 rounds as described above, and single clones were sequenced and converted to polypeptide-Fab fusions. The greatest enrichment in binding to cynomolgus TfR was observed from the second library (i.e., a derivative of the CH3.18 parent), although there was also a slight decrease in binding to the human TfR.
[0380] Characterization of binding of CH3C mature clones Binding ELISA was performed with purified CH3C Fc-Fab fusion variants and plate-coated human or cynomolgus TfR as described above. Mutants CH3C3.2-1, CH3C.3.2-5, and CH3C.3.2-19 from the CH3C.18 maturation library showed approximately equivalent EC2s to human and cynomolgus TfR. 50 Whereas the parental clones CH3C.18 and CH3C.35 showed 10-fold higher binding to the human TfR versus the cynomolgus TfR (FIG. 19).
[0381] Next, we tested whether the novel polypeptides were internalized into human and monkey cells. Using the protocol described above in the section entitled "Characterization of First Generation CH3C Clones," we tested internalization in human HEK293 cells and rhesus LLC-MK2 cells. As shown in FIG. 20, CH3C.3.2-5 and CH3C.3.2-19, mutants that bound similarly to human and cynomolgus TfR, showed significantly improved internalization in LLC-MK2 compared to CH3C.35.
[0382] Further manipulation of the CH3C clone In further engineering of the further affinity matured clones CH3C.18 and CH3C.35, additional mutations were added to backbone (i.e., non-register) positions to improve binding via direct interactions, second hydration shell interactions, or structural stabilization. This was achieved by creating “NNK-walk” or “NNK-patch” libraries and selecting from these libraries. In the NNK-walk library, NNK mutations were introduced one by one at residues near the paratope. By looking at the structure of Fc bound to FcgRI (PDB ID: 4W4O), 44 residues near the original library register were identified as candidates for investigation, as shown in Figure 21. In particular, the following residues were targeted for NNK mutagenesis: K21, R28, Q115, R117, E118, Q120, T132, K133, N134, Q135, S137, K143, E153, E155, S156, G158, Y164, K165, T166, D172, S173, D174, S176, K182, L183, T184, V185, K187, S188, Q191, Q192, G193, V195, F196, S197, S199, Q211, S213, S215, L216, S217, P218, G219, and K220. Kunkel mutagenesis was used to generate these 44 single-point NNK libraries, and the products were pooled and electroporated into yeast as described above for the other yeast libraries.
[0383] A small library was generated by combining these mini-libraries (each mutating one position, resulting in 20 mutants), which was selected for positions that yielded higher affinity binding using yeast surface display. Selections were performed as described above using the TfR apical domain protein (Figure 22). After three rounds of sorting, clones from the enriched yeast library were sequenced, identifying several "hot spot" positions where specific point mutations significantly improved binding to the apical domain protein. In CH3C.35, these mutations included E153 (mutated to Trp, Tyr, Leu, or Gln) and S188 (mutated to Glu). The sequences of single and compound mutants of CH3C.35 are set forth in SEQ ID NOs: 21-23, 236-241, and 297-299. In CH3C.18, these mutations included E153 (mutated to Trp, Tyr, or Leu) and K165 (mutated to Gln, Phe, or His). The sequences of the single mutants of CH3C.18 are set forth in SEQ ID NOs:242-247.
[0384] The "NNK patch" approach is similar to that described above for the CH3B library, but each patch is immediately adjacent to the CH3C register. The following libraries were generated using clone CH3C.35 as the starting point: CH3C patch 1: amino acid positions: K21, R28, Y164, K165, and T166. CH3C patch 2: amino acid positions: Q115, R117, E118, Q120, and K143. CH3C patch 3: amino acid positions: T132, K133, N134, Q135, and S137. CH3C patch 4: amino acid positions: E153, E155, S156, and G158. CH3C patch 5: amino acid positions: D172, S173, D174, S176, and K182. CH3C patch 6: amino acid positions: L183, T184, V185, K187, and S188. CH3C patch 7: Amino acid positions: Q191, Q192, G193, V195, and F196. CH3C patch 8: amino acid positions: S197, S199, Q211, S213, and S215; and CH3C patch 9: amino acid positions: L216, S217, P218, G219, and K220. Selections were performed as described above using the TfR apical domain protein, however no clones with improved binding were identified.
[0385] Further maturation of the library to improve the affinity of CH3C.35 To identify combinations of mutations from the NNK walk library but add several more positions around them, a further library was created as described for the yeast library above. In this library, the YxTEWSS and TxxExxxxF motifs were kept constant and the following six positions were fully randomized: E153, K165, K187, S188, S197, and S199. Positions E153 and S188 were included because they were "hot spots" in the NNK walk library. Positions K165, S197, and S199 were included because they constitute part of the core where the binding region may be located, and K187 was selected because it is adjacent to position 188.
[0386] The library was sorted by only the apical domain of the cynomolgus TfR as described above. The enriched pool after five rounds was sequenced and the sequences of the CH3 regions of the unique clones identified are set forth in SEQ ID NOs:248-265.
[0387] Investigation of permitted diversity and hotspots within the original register of CH3C.35.21 The next library was designed to explore the landscape of allowed diversity within the major binding paratope. The approach used was similar to the NNK walk library. A series of single-position saturation mutagenesis libraries were generated on yeast by individually randomizing each of the original register positions (157, 159, 160, 161, 162, 163, 186, 189, and 194), as well as the two hot spots (153 and 188) with NNK codons. Furthermore, each position was individually remutated to the wild-type residue, and these individual clones were displayed on yeast. Figure 23 shows the binding of the parent clone CH3C.35.21 compared to the wild-type revertant and single-position NNK libraries. It was noted that positions 153, 162, 163, and 188 were the only positions that maintained appreciable binding to TfR when remutated to the wild-type residue (remutation of position 186 to wild-type showed largely abolished binding, although some residual binding was observed).
[0388] Single-position NNK libraries were sorted in three rounds against the human TfR apical domain to recover the top 5% of binders, and then at least 16 clones were sequenced from each library. These results, in conjunction with the CH3C.35 clone, indicate which amino acids can be tolerated at each position without significantly compromising binding to the human TfR. A summary is provided below. Position 153: Trp, Leu, or Glu; Position 157: Tyr or Phe; Position 159: Thr only; Position 160: Glu only; Position 161: Trp only; Position 162: Ser, Ala, or Val (it was noted that the wild-type Asn residue appeared to maintain some binding, but not in subsequent library sorts); Position 163: Ser or Asn; Position 186: Thr or Ser; Position 188: Glu or Ser; Position 189: Glu only; and Position 194: Phe only
[0389] The above residues represent paratope diversity that maintains binding to the TfR apical domain when substituted, either singly or in combination, into clone CH3C.35. Clones with mutations at these positions are shown in Table 9, and the sequences of the CH3 domains of these clones are set forth in SEQ ID NOs:237-241, 264, and 266-296.
[0390] Monovalent Polypeptide Fab Fusions Generation of monovalent TfR-binding polypeptide-Fab fusions Although Fc domains naturally form homodimers, selective heterodimerization of two Fc fragments can be achieved by a series of asymmetric mutations known as "knobs-in-holes" in which one Fc unit has a knob mutation of T139W (corresponding to position 366 using the EU numbering scheme) and the other Fc unit has hole mutations of T139S, L141A, and Y180V (corresponding to positions 366, 368, and 407, respectively, using the EU numbering scheme). In some embodiments, modified CH3 domains of the invention contain Trp at position 139. In some embodiments, modified CH3 domains of the invention contain Ser at position 139, Ala at position 141, and Val at position 180. Heterodimeric TfR-binding polypeptides were expressed in 293 or CHO cells by transient co-transfection of two plasmids (i.e., knob-Fc and hole-Fc), while polypeptide-Fab fusions were expressed by transient co-transfection of three plasmids (i.e., knob-Fc-Fab heavy chain, hole-Fc-Fab heavy chain, and common light chain). Purification of secreted heterodimeric polypeptides or polypeptide-Fab fusions was performed in the same manner as for homodimers (i.e., two-column purification using Protein A followed by size-exclusion chromatography, followed by concentration and buffer exchange as required). Mass spectrometry or hydrophobic interaction chromatography was used to determine the amount of heterodimer formed relative to homodimers (e.g., knob-knob or hole-hole paired Fc). In typical preparations, more than 95% and often more than 98% of the polypeptides were heterodimers. For clarity, all monovalent TfR binders (Fc homodimers) generated in this manner are designated "ZZ.monovalent," where ZZ is the name of the polypeptide and ".monovalent" indicates monovalent TfR binding. Unless otherwise noted, in heterodimeric polypeptides and polypeptide-Fab fusions, mutations that confer TfR binding included "knob" mutations, whereas Fc regions that do not bind TfR were used with "hole" regions.In some cases, these constructs also contained additional mutations that altered the properties of the Fc, such as L7A / L8A, M25Y / S27T / T29E, N207S, or N207S / M201L for altered FcγR or FcRn binding, respectively.
[0391] Binding Characterization of CH3C.monoFc Polypeptide Binding of monovalent CH3C polypeptides was measured by ELISA using a modification of the method described above. Streptavidin was coated overnight at 1 μg / mL in PBS onto 96-well ELISA plates. After washing, the plates were blocked with 1% BSA in PBS, and then biotinylated human or cynomolgus TfR was added at 1 μg / mL and incubated for 30 minutes. After further washing, the polypeptides were added to each plate in serial dilutions and incubated for 1 hour. Each plate was washed, and secondary antibody (i.e., anti-κ-HRP, 1:5000) was added for 30 minutes, and the plates were washed again. Each plate was developed with TMB substrate and quenched with 2N H2SO4 before reading absorbance at 450 nm on a BioTek® plate reader. The results are shown in FIG. 24, which shows a direct comparison of the standard (i.e., bivalent TfR binding) and the monovalent TfR-binding polypeptides. Ab204 is a high affinity anti-TfR control antibody.
[0392] Binding to 293F cells, which endogenously express the human TfR, and to CHO-K1 cells stably transfected with either the human TfR or the cynomolgus TfR, was further tested (FIG. 25).
[0393] In general, significantly reduced binding to human TfR was observed for the monovalent polypeptides compared to the bivalent polypeptides, and binding of the monovalent polypeptides to cynomolgus monkeys was too weak to be detected in these assays.
[0394] We next tested whether the monovalent version of the CH3C polypeptide could be internalized into HEK293 cells expressing the human TfR. We used the method described above for the internalization assay. As shown in Figure 26, which compares the bivalent and monovalent polypeptides, the monovalent peptide was also able to be internalized, but the overall signal was weaker than the corresponding bivalent version, likely due to loss of binding affinity / avidity.
[0395] Binding kinetics of CH3C polypeptides measured by biolayer interferometry. Binding kinetics were measured for several monovalent and bivalent CH3C polypeptide variants fused to anti-BACE1 Fab and compared to their bivalent counterparts using biolayer interferometry (i.e., using the Octet® RED system). TfR was captured on a streptavidin sensor, followed by binding and washing away of the CH3C polypeptide. The sensorgrams were fitted to a 1:1 binding model, revealing that the K of the bivalent polypeptide was 0.01–0.02, and 0.01–0.02. D The (app) values indicated strong binding to the TfR dimer. The results are shown in Table 10 and Figures 27 and 28.
[0396] Table 10. Kinetics of CH3C polypeptides with Octet® RED TIFF0007577447000040.tif71128 Not detected = not measured due to binding signal too low.
[0397] Polypeptides converted to a monovalent format have significantly weaker K D Clones CH3C.3.2-1, CH3C.3.2-5, and CH3C.3.2-19, which were shown above to have similar binding to human and cynomolgus monkey TfR by ELISA, had very similar K D (app) values were also obtained. Attempts were made to test monovalent forms of these polypeptides, but binding in this assay was too weak to allow calculation of kinetic parameters.
[0398] Example 3. Characterization of the binding of further CH3C mutants using Biacore™ The affinity of clonal variants of the recombinant TfR apical domain was measured by surface plasmon resonance using a Biacore™ T200 instrument. A Biacore™ Series S CM5 sensor chip was immobilized with anti-human Fab (human Fab capture kit from GE Healthcare). 5 μg / mL of polypeptide-Fab fusion was captured on each flow cell for 1 min, and serial 3-fold dilutions of human or cynomolgus apical domain were injected at room temperature at a flow rate of 30 μL / min. Each sample was analyzed with 45 s of binding and 3 min of dissociation. After each injection, the chip was regenerated with 10 mM glycine-HCl (pH 2.1). Binding responses were corrected by subtracting the RU from a flow cell in which irrelevant IgG was captured at a similar density. Steady-state affinities were obtained by fitting the equilibrium responses to concentration using Biacore™ T200 Evaluation Software v3.1.
[0399] To determine the affinity of clonal variants of recombinant TfR extracellular domain (ECD), Biacore™ Series S CM5 sensor chips were immobilized with streptavidin. Biotinylated human or cynomolgus TfR ECD was captured on each flow cell for 1 min and serial 3-fold dilutions of each clonal variant were injected at room temperature at a flow rate of 30 μL / min. Each sample was analyzed with 45 s of binding and 3 min of dissociation. Binding responses were corrected by subtracting the RU from a flow cell without TfR ECD at similar density. Steady-state affinities were obtained by fitting the equilibrium responses against concentration using Biacore™ T200 Evaluation Software v3.1.
[0400] The binding affinities are summarized in Table 11. The affinities were obtained by steady state fitting.
[0401] Table 11. Binding affinities of further CH3C mutants TIFF0007577447000041.tif103146
[0402] Example 4 Binding properties of CH3C mutants to FcRn FcRn binding assays were performed using a ForteBio® Octet® RED384 instrument using a ForteBio® streptavidin biosensor. Biotinylated recombinant BACE1 was diluted to a concentration of 10 μg / mL in kinetic buffer (obtained from ForteBio®) and captured on each biosensor for 1 min. A baseline was then established for 1 min in kinetic buffer. 10 μg / mL of polypeptide-Fab fusions (containing anti-BACE1 Fab arms) were bound to the sensor chip in the presence or absence of 1 μM ECD of human TfR. Binding of recombinant human FcRn (pH 5.5) to the immobilized polypeptide-Fab fusions was analyzed using a 3 min binding and 3 min separation.
[0403] The sensorgrams obtained from these experiments (Figure 29) show that each polypeptide-Fab fusion mutant binds to FcRn at acidic pH (pH 5.5) and that binding to TfR did not significantly inhibit binding to FcRn.
[0404] Example 5 Pharmacokinetic / Pharmacodynamic Characterization of CH3C Mutants This example describes the pharmacokinetic / pharmacodynamic (PK / PD) characterization of the CH3C mutant polypeptide of the present invention in mouse plasma and brain tissue.
[0405] Pharmacokinetics of CH3C in wild-type mouse plasma Since the polypeptide-Fab fusions bind only to the human TfR and not to the mouse TfR, the pharmacokinetics (PK) of several CH3C mutants were tested in wild-type mice to demonstrate in vivo stability in a model that does not have TfR-mediated clearance. The experimental design is shown in Table 12 below. 6-8 week old C57B16 mice were intravenously administered and exsanguinated in situ by submandibular exsanguination at the time points indicated in Table 12. Blood was collected into EDTA plasma tubes and centrifuged at 14,000 rpm for 5 minutes, after which plasma was isolated for subsequent analysis.
[0406] Table 12: PK study design TIFF0007577447000042.tif107155
[0407] Ab122 was used as an anti-RSV control with normal PK in mice. Ab153 was used as an anti-BACE1 control with normal PK in mice. In this experiment, the Fab arm of Ab153 was fused to each modified Fc polypeptide.
[0408] Polypeptide concentrations in mouse plasma were quantified using a generic human IgG assay (MSD® Human IgG Kit #K150JLD-4) according to the manufacturer's instructions. Briefly, pre-coated plates were blocked with MSD® Blocker A for 30 minutes. Plasma samples were diluted 1:2500 using a Hamilton® NIMBUS liquid handling device and added in duplicate to the blocked plates. Dose solutions were also analyzed on the same plate to confirm proper dose. A standard curve of 0.78-200 ng / mL IgG was fitted using a 4-parameter logistic regression. Figure 30 and Table 13 show the results of the analysis of these data. All of the CH3C polypeptide variants had clearance and half-life values comparable to standard Ab122, except for CH3C.3.2-5, which had a significantly faster clearance and shorter half-life. Interestingly, this variant was a point mutation of CH3C.3.2-19(N163D), the latter of which had a normal PK profile.
[0409] Table 13. PK parameters of CH3C polypeptide-Fab fusions TIFF0007577447000043.tif48160
[0410] Further PK experiments in wild-type mice A second PK study was performed in wild type mice according to the experimental design in Table 14 below (all polypeptide-Fab fusions were fused to Ab153 Fab).
[0411] (Table 14) TIFF0007577447000044.tif47160
[0412] Mice and samples were treated as described in the previous experiment and the data are shown in Table 15.
[0413] Table 15. Clearance values of CH3C.35 polypeptide-Fab fusions TIFF0007577447000045.tif49160
[0414] As evidenced by the clearance values, these polypeptide-Fab fusions showed similar clearance in wild type mice compared to the standard control antibody.
[0415] PK / PD evaluation of monovalent CH3C.35.N163 in brain tissue of wild-type mice Transgenic mice expressing the human Tfrc apical domain within the mouse Tfrc gene were generated using CRISPR / Cas9 technology, and the resulting chimeric TfR was expressed in vivo under the control of the endogenous promoter.
[0416] Chimeric huTfR アピカルHeterozygous mice (n=4 / group) were administered either Ab153 or monovalent CH3C.35.N163 at 42 mg / kg intravenously, and wild-type mice (n=3) were administered 50 mg / kg intravenously with control human IgG1. Ab153 was used as a control with normal PK in mice. All mice were perfused with PBS 24 hours after dosing. Prior to perfusion, blood was collected by cardiac puncture into EDTA plasma tubes and centrifuged at 14,000 rpm for 5 minutes. Plasma was then isolated for subsequent PK and PD analysis. Post-perfusion brains were removed and brain hemispheres were separated and homogenized in 10 times the tissue weight in PBS, 1% NP-40 (for PK) or 5M GuHCl (for PD).
[0417] Figure 31 shows the results of a brain PK experiment. Uptake was greater in the monovalent CH3C.35.N163 group than in the Ab153 and control human IgG1 groups.
[0418] hTfR アピカル+ / + PKPD in brain and plasma of polypeptide-Fab fusions in mice: CH3C.35.21 and CH3C.35.N153 As shown in the experimental design in Table 16, homozygous hTfR アピカル+ / + Mice were injected intravenously with 50 mg / kg of either the anti-BACE1 antibody Ab153, the anti-TfR / BACE1 bispecific antibody Ab116, CH3C.35.21.monovalent fused to the Fab of Ab153, or CH3C.35.N153.monovalent fused to the Fab of Ab153. In this experiment, all Fcs carried the LALAPG mutation to eliminate effector function.
[0419] Table 16. Experimental design for single point brain and plasma PKPD experiments TIFF0007577447000046.tif41160
[0420] After 24 hours, blood was collected by cardiac puncture and mice were perfused with PBS. Brain tissue was homogenized in lysis buffer containing 1% NP-40 in PBS at 10 times the tissue weight. Blood was collected in EDTA tubes to prevent clotting and centrifuged at 14,000 rpm for 7 minutes to isolate plasma. Polypeptide concentrations in mouse plasma and brain lysates were quantified using a generic human IgG assay (MSD Human IgG Kit #K150JLD) according to the manufacturer's instructions. Briefly, pre-coated plates were blocked with MSD Blocker A for 30 minutes. Plasma samples were diluted 1:10,000 using a Hamilton Nimbus liquid handling device and added in duplicate to the blocked plates. Brain samples were homogenized in 1% NP40 lysis buffer and lysates were diluted 1:10 for PK analysis. Dosing solutions were also analyzed on the same plate to confirm proper doses. A standard curve ranging from 0.78 to 200 ng / mL IgG was fitted using four-parameter logistic regression.
[0421] The plasma concentrations of TfR-binding polypeptides after 24 hours were lower than those of anti-BACE1, which may be due to the peripherally expressed hTfR. アピカル This may be due to clearance of this antibody via binding to CH3C35.N153. (Figure 32(A)). In the brain, a significant increase in the concentration of anti-TfR / BACE1 was observed compared to anti-BACE1 (Figure 32(B)). The greatest increase was observed with CH3C35.21. monovalent, but brain uptake was also significantly improved with CH3C35.N153. bivalent compared to anti-BACE. This significant accumulation of engineered TfR-binding polypeptides is due to TfR-mediated transcytosis at the BBB, thus demonstrating the utility of engineered TfR-binding in the Fc region.
[0422] BACE1 inhibition of cleavage of the amyloid precursor protein APP was used as a pharmacodynamic indicator of antibody activity in plasma and brain. Brain tissue was homogenized in 10 times the tissue weight in 5M guanidine-HCl and then diluted 1:10 in 0.25% casein buffer in PBS. Mouse Aβ40 concentrations in plasma and brain lysates were measured using a sandwich ELISA. 384-well MaxiSorp plates were coated overnight with a polyclonal capture antibody specific for the C-terminus of the Aβ40 peptide (Millipore#ABN240). Guanidine brain lysates diluted in casein were further diluted 1:2 on the ELISA plate and biotinylated M3.2 was added simultaneously as a detection antibody. Plasma was analyzed at a dilution of 1:5. Each sample was incubated overnight at 4°C before the addition of streptavidin-HRP followed by TMB substrate. A standard curve ranging from 0.78 to 50 pg / mL of msAβ40 was fitted using four-parameter logistic regression.
[0423] The presenc...
Claims
1. A TfR polypeptide construct comprising, from N-terminus to C-terminus: (A) (a) a first polypeptide comprising a C-terminal fragment of the TfR apical domain; and (b) a second polypeptide comprising an N-terminal fragment of the TfR apical domain; wherein said first polypeptide and said second polypeptide are fused in tandem; or (B) (a) a first polypeptide comprising a C-terminal fragment of the TfR apical domain; (b) a linker, wherein the linker is 1-10 amino acids in length or comprises a protein loop domain; and (c) a second polypeptide comprising an N-terminal fragment of the TfR apical domain; wherein the first polypeptide, the linker, and the second polypeptide are fused in tandem; and wherein the first polypeptide of (A) or (B) comprises a sequence having at least 90% sequence identity to the sequence of TISRAAEKLFGNMEGDCPSDWKTDSTCRMVTSE (SEQ ID NO: 427); and The second polypeptide of (A) or (B) comprises a sequence having at least 90% sequence identity to the sequence of DKNGRLVYLVENPGGYVAYSKAATVTGKLVHANFGTKKDFEDLYTPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQT (SEQ ID NO: 428).
2. (a) the last amino acid of the first polypeptide is fused to the first amino acid of the second polypeptide; and / or (b) the C-terminal fragment of the TfR apical domain comprises 35-55 amino acids, and / or the N-terminal fragment of the TfR apical domain comprises 85-120 amino acids, and / or (c) the first polypeptide comprises the sequence of SEQ ID NO: 427; and / or (d) the second polypeptide comprises the sequence of SEQ ID NO: 428; and / or (e) the TfR apical domain comprises the sequence of SEQ ID NO: 107 or 108; The TfR construct of claim 1.
3. The TfR construct of claim 1 or 2, which binds to an arenavirus.
4. The TfR construct of any one of claims 1 to 3, comprising: (A) (a) a first polypeptide comprising a sequence having at least 95% sequence identity to the sequence of SEQ ID NO: 427; and (b) the second polypeptide comprising a sequence having at least 95% sequence identity to the sequence of SEQ ID NO: 428; or (B) (a) the first polypeptide comprising a sequence having at least 95% sequence identity to the sequence of SEQ ID NO: 427; (b) the linker, and (c) the second polypeptide comprising a sequence having at least 95% sequence identity to the sequence of SEQ ID NO: 428; or (C) (a) the first polypeptide comprising the sequence of SEQ ID NO: 427; (b) the second polypeptide comprising the sequence of SEQ ID NO: 428; or (D) (a) the first polypeptide comprising the sequence of SEQ ID NO: 427; (b) the linker, and (c) the second polypeptide comprising the sequence of SEQ ID NO:
428.
5. (a) the first polypeptide further comprises at its C-terminus a sequence having at least 90% sequence identity to the sequence of SKNVKLTVSNVLKEIKILNIFGVIK (SEQ ID NO: 429), or a fragment thereof having any of the sequences of SEQ ID NOs: 430 to 433; (b) the second polypeptide further comprises at its C-terminus a sequence having at least 90% sequence identity to the sequence of KFPIVNAELSFFGHAHLGTGDPYTP (SEQ ID NO: 434), or a fragment thereof having any of the sequences of SEQ ID NOs: 435 to 438; (c) the first polypeptide further comprises at its N-terminus a sequence having at least 90% sequence identity to the sequence of GFPSFNHTQFPPSRSSGLPNIPVQ (SEQ ID NO: 439), or a fragment thereof having any of the sequences of SEQ ID NOs: 440 to 443; (d) the second polypeptide further comprises, at its N-terminus, a sequence having at least 90% sequence identity to the sequence of SKVWRDQHFVKIQVKDSAQNSVIIV (SEQ ID NO: 444), or a fragment thereof having any of the sequences of SEQ ID NOs: 445 to 448; (e) the first polypeptide comprises a sequence having at least 90% sequence identity to the sequence of SSGLPNIPVQTISRAAAEKLFGNMEGDCPSDWKTDSTCRMVTSESKNVKLTVSN (SEQ ID NO: 449); and / or (f) the second polypeptide comprises a sequence having at least 90% sequence identity to the sequence of DSAQNSVIIVDKNGRLVYLVENPGGYVAYSKAATVTGKLVHANFGTKKDFEDLYTPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVNAELS (SEQ ID NO: 450); A TfR construct according to any one of claims 1 to 4.
6. (a) a first polypeptide having the sequence of SEQ ID NO: 449 and a second polypeptide having the sequence of SEQ ID NO: 450, wherein the C-terminus of the first polypeptide is fused to the N-terminus of the second polypeptide; or (b) a first polypeptide having a sequence of SSGLPNIPVQTISRAAAEKLFGNMEGDCPSDWKTDSTCKMVTSENKSVKLTVSN (SEQ ID NO: 451) and a second polypeptide having a sequence of DSAQNSVIIVDKNGGLVYLVENPGGYVAYSKAATVTGKLVHANFGTKKDFEDLDSPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVKADLS (SEQ ID NO: 452), wherein the C-terminus of the first polypeptide is fused to the N-terminus of the second polypeptide; A TfR construct according to any one of claims 1 to 5.
7. (i) the linker is G, GG, GGG, or GGGG (SEQ ID NO: 453); or (ii) the distance between the N-terminus and C-terminus of the loop domain of the protein is less than 5 Å; A TfR construct according to any one of claims 1 to 6.
8. (a) further comprising a purified peptide; (b) further comprising a truncation peptide; and / or (c) being soluble; A TfR construct according to any one of claims 1 to 7.
9. (i) the purified peptide is fused to the N-terminus or C-terminus of the TfR construct; and / or (ii) the truncation peptide is fused to the N-terminus or C-terminus of the TfR construct; The TfR construct of claim 8.
10. The TfR construct of claim 1 , comprising an amino acid sequence having at least 90% identity to any one of SEQ ID NOs: 109, 110, 301, 468, and 469.
11. The TfR construct of claim 10, comprising any one of the amino acid sequences of SEQ ID NOs: 109, 110, 301, 468, and 469.
12. An isolated polynucleotide comprising a nucleotide sequence encoding the TfR construct of any one of claims 1 to 11.
13. A vector comprising the polynucleotide of claim 12.
14. A host cell comprising the polynucleotide of claim 12 or the vector of claim 13.
15. 1. A method for identifying a substance that binds to the apical domain of TfR, comprising: (a) contacting the TfR construct of any one of claims 1 to 11 with said substance; (b) determining whether the agent binds to the TfR construct; Including, The method.
16. (i) the substance is a polypeptide or a protein; (ii) the agent is a modified Fc polypeptide or a modified Fc polypeptide dimer; (iii) the substance is an antibody, and / or (iv) the determining step (b) is carried out by ELISA or surface plasmon resonance; The method of claim 15.
17. 12. A method for producing the TfR construct of any one of claims 1 to 11, comprising expressing a gene comprising a first polynucleotide and a second polynucleotide fused in tandem, wherein the first polynucleotide encodes the C-terminal fragment of the TfR apical domain and the second polynucleotide encodes the N-terminal fragment of the TfR apical domain.
18. (a)(i) the first polynucleotide and the second polynucleotide are fused in tandem such that, upon expression, the first amino acid of the N-terminal fragment of the TfR apical domain is linked in primary sequence to the last amino acid of the C-terminal fragment of the TfR apical domain; or (ii) the gene further comprises a linker polynucleotide encoding a protein linker, such that, upon expression, the first amino acid of the N-terminal fragment of the TfR apical domain is linked in primary sequence to the last amino acid of the linker, and the first amino acid of the linker is linked in primary sequence to the last amino acid of the C-terminal fragment of the TfR apical domain; or (b)(i) the gene encodes the first polynucleotide and the second polynucleotide in tandem such that, upon expression, the expressed protein is in the form of a circular structure; or (ii) the gene encodes the first polynucleotide, the linker polynucleotide, and the second polynucleotide in tandem such that, upon expression, the expressed protein is in the form of a circular structure; and / or (c) purifying the expressed protein to obtain the TfR construct.
20. The method of claim 17.
19. A TfR construct produced according to the method of claim 17 or 18.
